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Abstract 
Clostridium difficile is the leading cause of antibiotic associated diarrhoea 
worldwide. Infection typically follows treatment with broad spectrum antibiotics 
which disrupt the protective microbiota. The mechanisms of infection are being 
slowly unravelled and it is now known that the microbiota plays an important 
role in mediating colonisation resistance to C. difficile. C. difficile is spread by 
spores which once ingested germinate, a process stimulated by primary bile 
acids (BAs), particularly taurocholate (TC). The aim of the work presented was 
to further extend our understanding of the functional role BAs play in 
germination, colonisation resistance and disease severity. A final aim was to 
examine how the production of para-cresol, a bacteriostatic compound produced 
by C. difficile, impacts upon acute and relapsing infections. 
To examine the role of the microbiota in C. difficile pathogenesis, three mouse 
models of infection were used, in which disease severity is dependent on the 
combination of antibiotics administered prior to C. difficile challenge. In the 
first model, administration of an antibiotic cocktail (ABC) followed by 
clindamycin induced more severe disease. In contrast, mice treated with 
clindamycin only became colonised, whilst those given the ABC alone were only 
transiently infected. Colonisation resistance was found to be associated with the 
absence of bacteria involved in bile metabolism.  This is because unmodified bile 
acids (BAs) act as germinants for C. difficile, stimulation germination and 
bacterial outgrowth. Loss of bile salt hydrolase (BSH) producing bacteria did not 
correlate with increased severity of disease. Further analysis of the microbiome 
data suggests that severity may be linked to loss of bacteria associated with 
mucus layer integrity.   
BAs are toxic molecules that can damage both bacterial membranes and their 
DNA. Limiting exposure to these compounds is essential for C. difficile to survive 
in vivo. Investigation of the genetic response to the TC post germination was 
investigated using RNA seq. This resulted in the identification of several genes, 
including efflux pumps that may be important in mediating C. difficile bile 
resistance. It is likely genes involved in bile resistance are important in enabling 
successful colonisation of C. difficile. 
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Finally the production of para-cresol in acute and relapsing infection was 
examined. Strains that were unable to generate para-cresol caused greater 
severity in the mouse model of disease. Extensive in vitro and in vivo 
experiments showed slightly increased toxin production in the non para-cresol 
producing R20291_hpdA::CT strain, providing one potential explanation for this 
unusual phenotype.  
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1 Introduction 
 Clostridium difficile  1.1
C. difficile is a Gram positive, obligate anaerobe which is capable of 
producing endospores.  First isolated from a healthy infant’s stool in 1935 
(Hall & O’Toole, 1935) it is a disease largely of the modern antibiotic era, first 
being identified as the cause of clindamycin associated pseudomembranous 
colitis (PMC) in the early 1970’s (Bartlett et al., 1977). C. difficile is now 
recognised as the leading cause of antibiotic associated diarrhoea (AAD) 
worldwide causing an estimated 10-15% of cases of AAD and 95% of PMC 
(Bartlett, 1994). C. difficile disease is typically associated with the elderly 
(those over 65) (Rea et al., 2012) and immunocompromised individuals. It is 
frequently seen in patients who have been treated with a number of 
predisposing antibiotics, which, include clindamycin, the cephalosporins and 
penicillin (Bartlett, 2002). Infection with C. difficile is associated with a wide 
range of symptoms from mild, self-resolving diarrhoea, to severe relapsing 
infection that can proceed to PMC, toxic mega colon (TMC) and sometimes 
death. It is thought that between 3-7% of the healthy adult population carry 
C. difficile as part of their normal flora (Pires et al., 2016; Kato et al., 2001) 
and in infants carriage rates are much higher (up to 70%) although this 
carriage is typically asymptomatic (Jangi & Lamont, 2010). 
C. difficile is a complicated disease and can often cause relapsing and 
difficult to treat infections. This is estimated to occur in between 30-60% of 
patients (Viswanathan et al., 2010) with the likelihood of relapse increasing 
with each successive episode (Khoruts & Sadowsky, 2011) which most likely 
reflects a persistent and ongoing disruption of the microbiota (Chang et al., 
2008). These patients are difficult to treat leading to poor quality of life. It is 
for these patients that new treatments for this infection need to be sought, as 
for many, traditional antibiotic therapy is no longer effective. This has 
resulted in a move towards bacterial therapies such as faecal microbial 
transplantation (FMT) and defined bacterial therapies, which will be discussed 
in detail in sections 1.5.1 and 1.5.2. The financial cost associated with C. 
difficile infection is also enormous with the USA estimated to have spent in 
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excess of $4.8 billion on treatment in 2008 alone (Dubberke & Olsen, 2012), 
whilst costs in Europe have been calculated to be approximately £8000 per 
patient (Wiegand et al., 2012). Although improvements in antibiotic 
stewardship have resulted in the number of cases in the UK falling steadily 
since 2009 (Carter, 2013), cases are still challenging to treat. For this reason, 
greater understanding of the disease itself and improvement of treatment is 
essential. Although, many recent advances have been linked to increased 
knowledge of the role of the microbiota, a clearer understanding of the 
bacterial functions that influence C. difficile germination, colonisation and 
persistence are required.  
1.1.1 Emergence of a hyper-virulent ribotype 
In the early 2000s, the epidemiology of C. difficile underwent a dramatic 
change with a sudden increase in the rates of infection reported in the USA, 
Canada and the UK. The outbreaks were found to all be associated with the 
spread of a newly emergent clone referred to as NAP1/REA/027,  which will 
be referred to as the 027 type for the remainder of this thesis (Warny et al., 
2005). The spread of this hyper-virulent epidemic clone was associated with 
higher levels of mortality and increased incidence of PMC and TMC. During 
this time, several severe outbreaks occurred culminating in the death of 25 
patients at The Stoke Mandeville hospital in the UK (Katikireddi, 2005). 
Another outbreak across Quebec in Canada during 2003-2005 was estimated to 
have killed between 1440-2000 people (Pepin et al., 2004; Eggertson 2005; 
Eggertson 2006). In addition to the high death rates, surviving patients 
infected with this strain suffered higher rates of antibiotic failure and relapse 
of disease (Marsh et al., 2012).  
1.1.2 The role of toxin production in C. difficile disease 
 The pathogenicity locus and regulation of toxin production 1.1.2.1
Most of the clinical symptoms of C. difficile disease are associated with 
production of two toxins that result in epithelial damage and inflammation. 
These toxins, known as toxin A (TcdA) and toxin B (TcdB) are encoded on a 
19.6kb pathogenicity locus (PaLoc), which is only found in pathogenic strains 
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of C. difficile. This locus consists of 5 genes that control toxin production, 
regulation and release (Figure 1.1). 
 
Figure 1.1 The structure of the PaLoc in C. difficile. Adapted from Voth & Ballard (2005) 
The 19.6kb pathogenicity locus from C. difficile contains 5 genes. The tcdB and tcdA genes 
encode for toxins. The PaLoc contains two regulators with tcdR acting as a positive regulator 
and tcdC acting as a negative regulator. Toxin release is thought to be mediated by tcdE a 
putative holin. 
Toxins are most highly expressed during the stationary phase of growth 
(Dupuy & Sonenshein 1998), with a transcriptional study showing high levels of 
expression of tcdR, tcdA, tcdB and tcdE during this phase. In contrast only low 
levels of tcdC were expressed during this phase with tcdC expressed 
predominantly during exponential phase. This suggests a role of TcdC as a 
negative regulator of toxin production (Hundsberger et al., 1997). 
Investigation of the structure of TcdC suggests this repression may be 
achieved through its action as an anti-sigma factor enabling it to interfere 
with positive regulation that is mediated by tcdR. TcdR is a σ factor of RNA 
polymerase (RNAP) that enables the expression of both toxins genes by 
directing the RNAP to the toxin promoter regions (Mani & Dupuy, 2001).  
Repression of toxin production by TcdC is thought to be achieved through its 
ability to prevent the TcdR containing RNAP from recognising the toxin gene 
promoters, preventing binding (Matamouros et al., 2007).  
Early analysis of the hyper-virulent 027 strains reported that mutations in 
tcdC were associated with the production of higher levels of toxin in vivo 
(Dupuy et al., 2008). This was supported by a study that created mutants in 
the tcdC gene and found that this resulted in increased toxin production and 
virulence in the hamster model of infection (Carter et al., 2011). However, 
subsequent studies have reported no difference in toxin production. A 
landmark study by Cartman et al., (2012) replicated the tcdC mutations 
associated with hyper virulence in R20291 in a non-hyper virulent 630 strain. 
They also reversed the Δ117 frameshift in R20291 that is thought to be 
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associated with increased toxin production. It was found that these changes 
had no impact on toxin production in either strain suggesting that these 
mutations may not be responsible for increased toxin production. 
 The influence of CodY on toxin production 1.1.2.2
Wider control of toxin production is complicated. It is in part influenced by 
CodY, a global gene regulator that is involved in several important processes 
including toxin production and sporulation (Nawrocki el al., 2016). A study 
that constructed a codY null strain found that lack of CodY activity resulted in 
the >4-fold overexpression of 146 genes and the under expression of a further 
19. This included genes involved sporulation, toxin production, amino acid 
biosynthesis, fermentation pathways and surface proteins (Dineen et al., 
2010). Another study by Dineen et al., (2007) found that inactivation of CodY 
resulted in increased expression of 5 genes within the pathogenicity locus 
including tcdR, tcdB, tcdE, tcdA and tcdC. It was also demonstrated that 
there was strong interaction between CodY and tcdR. This suggests that the 
majority of the CodY repression of toxin production is mediated through this 
interaction. It has also been shown that this repression is increased in the 
presence of branched chain amino acids and GTP, potentially highlighting a 
link between toxin production and nutrient limitation. This fits with earlier 
observations that toxins are predominately expressed in the stationary phase 
(1.1.2.1). 
 Toxin action and receptor mediated endocytosis 1.1.2.3
For toxins to become active they must first be internalised within the cell. 
Both tcdA and tcdB contain 3 distinct domains that are involved in different 
processes. These domains are a glucosyl transferase domain (GDT), a cysteine 
protease domain (CPD) and a combined repetitive oligo-peptide repeat (CROP) 
(Figure 1.2). Each domain has a distinct role in toxin internalisation, 
activation and action. The CROP region is responsible for the binding of the 
toxin to the colonic epithelial cells with TcdA binding to carbohydrates and 
TcdB to poliovirus receptor-like 3. Receptor mediated endocytosis then occurs 
during which the toxin is internalised into the cell in acidified endosomes. The 
environment within the endosome allows the CROP domain to embed into the 
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endosomes membrane. After the toxin has embedded the CPD and GTD 
domains are transferred into the cytosol. Once within the cytosol inositol 
hexakisphosphate (IP6) triggers the cleavage of the CPD releasing the GTD 
(Figure 1.2). The GTD can then inactivate both Rho and Rac GTPases. 
Inactivation of these molecules leads to the disruption of tight junctions, 
actin rearrangement and apoptosis. Cell damage and death results in an influx 
of immune cells to the site and if inflammation is not controlled it can lead to 
severe inflammatory bowel disease typified by PMC. Inflammation is mediated 
by the release of inflammatory promoting cytokines such as IL-1, TNF-α and 
IL-8 which result neutrophil influx and destruction of the epithelial cell lining 
(Shen 2012; Warny et al., 2000; Savidge et al., 2003). 
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Figure 1.2 Toxin structure, internalisation and action. Adapted from (Abt, McKenney, & 
Pamer, 2016) 
After binding to epithelial cells toxins are internalised into acidified endosomes. The CROP 
domain is embedded into the membrane of the endosome allowing the CPD and GTD to enter 
the cytosol where the toxin is then activated thought the cleavage of the CPD domain. The GTD 
then inactivates Rho and Rac GTPases resulting in the loss of tight junctions resulting in fluid 
efflux and cell death. Additionally, increases in the inflammatory cytokines IL-1, IL-8 and TNF-α 
result in an influx of immune cells to the site which can lead to inflammation.   
Initial studies using purified toxins indicated that TcdA was solely responsible 
for the majority of disease symptoms, with hamsters and mice succumbing to 
disease when given purified TcdA alone (Lyerly et al., 1985). However 
subsequent experiments using strains in which the individual toxin genes have 
been rendered inactive have now shown that typically both toxins are 
required to cause disease. Initially, work carried out by Lyras et al., (2009), in 
which mutants in each toxin gene were used to infect hamsters, showed that 
TcdB not TcdA was essential for virulence. However a later study that also 
created mutants in each toxin gene found that mutation of either toxin was 
not sufficient to render the strain avirulent. However hamsters infected with 
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a strain producing TcdA only took longer to develop symptoms of disease than 
those only producing TcdB (Kuehne et al., 2010). An additional study by the 
same group confirmed these findings and again found that although both 
toxins cause disease TcdB is required for severe disease (Kuehne et al., 2014). 
Interestingly clinical isolates are frequently identified that are TcdA negative 
but TcdB positive, (Samra et al., 2002; Pituch et al., 2001; Alfa et al., 2000; 
Limaye et al., 2000) whereas TcdA only strains have never been isolated from 
humans (Di Bella et al., 2016). This lack of TcdA only producing strains 
suggests that TcdB is essential for disease in humans. 
In addition to TcdA and TcdB some isolates can also produce C. difficile 
binary toxin (CDT). Production of CDT has been associated with an increased 
risk of mortality within 30 days of infection (Gerding et al., 2014). However, 
the role of CDT in disease is unclear with CDT production alone not sufficient 
to cause disease in hamsters (Geric et al., 2006). A recent study found that 
CDT may increase virulence by inducing host inflammation via a Toll like 
receptor mediated pathway which in turn results in the suppression of the 
immune response (Cowardin et al., 2016). The recent isolation of a strain 
expressing CDT alone from a patient suffering from severe diarrhoea (who 
tested negative for other intestinal pathogens), suggests that these strain may 
be able to cause disease in humans (Androga et al., 2015). Further work to 
fully understand the role of CDT is required and its relative importance in 
disease is still not well understood.  
 C. difficile spore germination and outgrowth 1.2
The etiological agent of C. difficile is the spore. These are formed under 
conditions of stress, such as oxygen exposure and nutrient limitation. Spores 
are highly resistant to environmental insults such as heat, desiccation and 
antibiotic exposure, allowing C. difficile to persist in the environment, 
facilitating transfer to new hosts. To cause disease spores must germinate to 
form vegetative cells that subsequently produce toxins. In C. difficile, spore 
germination is triggered by a combination of BAs and glycine. This has been 
confirmed experimentally in vitro (Sorg & Sonenshein, 2008) and indirectly in 
vivo with caecal extracts from antibiotic treated mice less able to induce 
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spore germination after incubation with cholestyramine, a BA binding resin 
(Giel et al., 2010). A recent study sought to determine the sites of spore 
germination and outgrowth in vivo. To do this they took ex-vivo extracts from 
the small intestine, caecum and colon of mice before and after antibiotic 
treatment. They found that the mouse small intestine continually promotes C. 
difficile spore germination, even without antibiotic treatment due to the 
presence of primary BAs. However, they found that outgrowth in the large 
intestine was only possible after antibiotic treatment and that this was due to 
decreases in the abundance of secondary BAs (Theriot et al., 2015). It is 
therefore likely that germination is triggered early in the GI tract and that 
outgrowth in the caecum and colon only occurs when the level of secondary 
BAs decreases. 
1.2.1 C. difficile spore formation 
 Genetic regulation of sporulation 1.2.1.1
C. difficile forms metabolically dormant spores under conditions of stress and 
nutrient limitation, although the precise signals are unknown. Spore formation 
is essential to aid transmission of C. difficile and to enable it to persist in the 
environment. The structure of the spore enables them to be highly resistance 
to a range of environmental insults including heating, desiccation, radiation 
and chemical stresses. As with toxin production the global regulator CodY is 
involved in sporulation with activation of sporulation genes associated with 
nutrient limitation (Nawrocki et al., 2016). Genetic control of sporulation is 
controlled by the master regulator Spo0A, with inactivation of this gene 
completely removing the ability of C. difficile to form spores.  
Activation of Spo0A is achieved through phosphorylation by sensor histidine 
kinases. After phosphorylation Spo0A induces the expression of σH, which then 
forms a positive feedback loop with Spo0A. Downstream from Spo0A are 4 
compartment specific alternative sigma factors, σF, σE, σG and σK In the 
forespore (FS) σF activates SpoIIR, a signalling protein that can then activate 
σE in the mother cell (MC) and σG in the FS. After activation σE can then 
activate σK in the MC. These transcription factors then initiate the production 
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of specific genes involved in formation of the spore (Fimlaid et al., 2013; 
Paredes-Sabja et al., 2014; Pereira et al., 2013). 
 Clostridium difficile spore structure 1.2.1.2
The structure of the spore is what enables C. difficile to exhibit high levels of 
resistance to multiple stresses. The formation of the spore begins with the 
formation of a septum in the MC resulting in the formation of two unequal 
sized compartments. The FS is then engulfed by the MC and the several layers 
of the spore-coat assembled. The spore is a complex structure with several 
layers that help to confer resistance to environmental stresses and to protect 
the DNA, RNA and enzymes held within the spore core. Around this core is an 
inner membrane and a germ cell wall. These layers have low permeability 
thus preventing water and other small molecules from entering the spore 
core. This maintains the low water content of the spore is and protects from 
DNA damaging molecules. A thick peptidoglycan layer is then surrounded by 
an outer membrane which in turn is covered with the spore-coat. This consists 
of many unique proteins that help to mediate C. difficile spore resistance 
properties. The final layer is the exosporium which is also involved in aiding 
resistance of the spore.  After formation of these layers the MC lyses and the 
spore is released into the environment where it can persist and disseminate. 
Under exposure to the right stimulus C. difficile can undergo germination to 
form a vegetative cell (Paredes-Sabja et al., 2014). 
1.2.2 Bile acids and glycine trigger spore germination 
To cause active disease C. difficile spores must germinate to form vegetative 
cells that can then produce toxin. In C. difficile the most potent inducer of 
spore germination is the conjugated BA taurocholate (TC), which is only found 
in the GI tract of mammals and other vertebrates. Exposure of C. difficile 
spores to TC and glycine results in a rapid and irreversible induction of 
germination pathways (Figure 1.3). 
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Figure 1.3 Simplified schematic of C. difficile spore germination, vegetative outgrowth 
and toxin production 
The sensing of TC and glycine by the spore results in a rapid induction of germination and 
progression to vegetative outgrowth and toxin production (red circles). This is a two stage 
process with dipicolinic acid (DPA) release followed by cortex degradation. 
Induction of spore germination is followed by rapid efflux of calcium and DPA 
(ca-DPA) followed by cortex hydrolysis. Vegetative outgrowth is followed by 
toxin production. Understanding the complex process of germination is 
essential to improve understanding of disease progression and may help to 
identify therapeutic targets of this disease. 
 Genetic regulation of germination 1.2.2.1
To cause disease spores must first germinate to form vegetative cells. 
However, in comparison to Bacillus subtilis in which the different steps in 
germination are well defined, knowledge of the C. difficile germination 
pathway remains undeveloped. Initial progress was hampered by the failure to 
find any homologs to known germinant receptors (encoded by the ger operon) 
that regulate initiation of germination in Bacillus species. Knowledge of C. 
difficile spore germination is improving as a consequence of the increased 
availability of genetic tools that allow manipulation of the organism, including 
mutagenesis of individual genes (Heap et al., 2010), and the creation of 
transposon mutant libraries (Dembek et al., 2015; Cartman & Minton 2010). 
Additionally, the availability of multiple genome sequences has enabled easier 
study of this and other biological processes in C. difficile.  
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Figure 1.4 Schematic of current understanding of C. difficile spore germination adapted 
from Olguín-Araneda et al., (2015) 
The sensing of TC by CspC results in the rapid induction of spore germination. The protease 
CspB activates SleC which then activates spore cortex hydrolysis. The bacterium can then 
rehydrate and outgrow.  
Spore germination in C. difficile is a two-step process, the first step, release 
of DPA triggers the second step of cortex break down (Figure 1.4). 
Germination is initiated through activation of the germinant receptor cspC, by 
TC. Mutants in cspC that are unable to respond to TC have severely 
attenuated germination rates in vitro. This mutant can still cause fatal 
infection in hamsters, although only 50% of animals succumb to infection 
compared to 100% of those infected with the WT. This suggests that either C. 
difficile is able to germinate spontaneously in vivo or that other germinants 
exist that can be sensed using an alternative pathway (Francis et al., 2013). 
Activation of CspC leads to the loss of calcium and DPA, initiating the second 
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stage of germination, cortex hydrolysis. Hydrolysis is controlled by a single 
cortex hydrolase, SleC, which is essential for the transition to vegetative 
growth (Burns et al., 2010). To be functional SleC must first be activated by 
the Csp family of proteases. In C. difficile this has been associated with the 
production of CspBA, a fusion of the active protease CspB to the inactive CspA 
(Francis et al., 2015)  Interestingly, although mutation of CspB results in 
decreased germination efficiency, it does not eradicate this process. This 
suggests that SleC may be activated by as yet undefined proteases (Adams et 
al., 2013). Additionally, it would appear that CspA has a role in controlling 
the levels of CspC in the mature spore (Kevorkian et al., 2016) with a 
nonsense mutation in the cspA region of cspBA gene resulting  in severely 
decreased levels of germination (Francis et al., 2013). 
 Diverse responses to TC as a germinant 1.2.2.2
Although TC is known to induce spore germination, numerous studies have 
revealed that responses to TC vary considerably between isolates of C. 
difficile (Heeg et al., 2012; Carlson et al., 2015; Moore et al., 2013). The 
implication of this is unclear, with  higher rates of germination linked to both 
increased (Moore et al., 2013) and decreased disease severity (Carlson et al., 
2015). Such variation in germination response has also been reported for other 
Clostridia including Clostridium perfringens, in which similar disparity 
between germination rates and disease and non-disease causing strains has 
been described (Akhtar et al., 2009). Whilst the mechanisms by which TC 
induces germination have been well studied, little is known about the role of 
glycine in the process. Spores cannot geminate in the presence of TC alone, 
and glycine has been identified as an essential co-germinant (Sorg & 
Sonenshein, 2008). Kinetic analysis of germination suggests that glycine 
binding follows TC recognition, through an as yet unidentified receptor 
(Ramirez et al., 2010).  
 
 
Chapter 1- Introduction 
32 
 
 Other factors affecting germination 1.2.2.3
1.2.2.3.1 Bile acids 
Although TC and glycine are the most potent combination of germinants, 
several other compounds have been identified that influence C. difficile spore 
germination. These include other cholate derived BAs, such as cholic acid 
(CA), deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA). The role of 
these compounds is complicated. For instance, CA is often reported as a 
germinant of C. difficile, and yet it has been frequently reported as unable to 
induce germination even after 6 hours of exposure (Ramirez et al., 2010; 
Wheeldon et al., 2008; Sorg & Sonenshein 2008). However CA has been shown 
to  enhance colony formation on an agar plates (Sorg & Sonenshein, 2008). In 
contrast, CDCA has been reported as a competitive inhibitor of TC mediated 
germination with a higher affinity for the germinant receptor than TC (Sorg & 
Sonenshein, 2009). This has led to the development of potential treatments 
based around this compound, which will be discussed in section 1.5.3.1. 
Similarly DCA has been shown to inhibit vegetative growth of C. difficile (Sorg 
& Sonenshein, 2008). Interestingly, a subset of BAs only produced by mice, 
muricholic acids (MA), inhibit spore germination and growth of C. difficile 
(Francis et al., 2013). The production of these BAs may provide an 
explanation as to why infections of mice with C. difficile have been classically 
difficult to achieve.  
1.2.2.3.2 Amino acids 
In addition to glycine, several other amino acids have been shown to act as 
co-germinants of C. difficile. These include histidine, aspartic acid, arginine, 
serine and valine. Although these amino acids in isolation were unable to 
induce efficient germination, if used in combination with TC and glycine, 
these amino acids resulted in increased germination efficiency. This suggests 
that nutrient sensing may play a role in  this process (Wheeldon et al., 2011).  
Whilst efficient C. difficile spore germination has been linked to TC and 
glycine, they are not essential, as C. difficile is able to germinate in rich 
media alone (Heeg et al., 2012). This suggests that control of germination is 
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somewhat ‘leaky’ with initiation of germination possible in the absence of 
specific germinants. However, it is likely that in vivo, where competition is 
greater and nutrients are scarce, that this pathway is more tightly controlled. 
 BA production and function in the host 1.3
Although BAs play a role in triggering C. difficile spore germination, their 
main role in the host is to facilitate lipid absorption in the colon. BAs are 
cholesterol derivatives produced by liver hepatocytes. Their main function is 
to enable easy absorption of lipids and lipid soluble vitamins through the 
formation of micelles. BAs have also been found to interact with a number of 
host nuclear receptors including the farnesoid X receptor (FXR), pregnane X 
receptor (PXF) and the vitamin D receptor (VDR) (Zhou & Hylemon 2014; De 
Aguiar Vallim et al., 2013) but these interactions fall outside of the remit of 
this thesis. Bile itself contains approximately 0.8% BAs with the rest consisting 
of water (97%), cholesterol, lipids, bilirubin and phosphatidylcholine.  
There are two main BAs produced in the human body, CA and CDCA. Both CA 
and CDCA can be produced by the neutral pathway whereas the acidic 
pathway only produces CDCA. In addition to CA and DCA, rodents produce an 
additional group of murine specific MA (Botham & Boyd, 1983). The majority 
of BAs are produced by the neutral pathway. In this pathway cholesterol is 
converted to 7α-hydroxycholesterol by the enzyme cholesterol 7α-hydroxylase 
(CYP7A1). Conversion of 7α-hydroxycholesterol to CA is dependent on 
hydroxylation by sterol 12-alpha-hydroxylase (CYP8B1) followed by oxidation 
of cholesterol side chain by sterol 27-hydroxylase (CYP27A1). Oxidation alone 
of 7α-hydroxycholesterol by CYP27A1 results in the formation of CDCA. In the 
acidic pathway CYP27A1 converts cholesterol to 27-hydroxycholesterol which 
can then be converted into CDCA through hydroxylation by oxysterol 7α-
hydroxylase (CYP7B1) (Figure 1.5) (De Aguiar Vallim et al., 2013). 
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Figure 1.5 Simplified schematic of production of conjugated primary BA from cholesterol 
BAs are produced from cholesterol by the acidic and neutral pathways. The neutral pathway 
can result in the formation of both CA and CDCA whereas the acidic pathway only forms CDCA. 
Both CA and CDCA are then conjugated to either glycine or taurine before they are secreted 
into the gall bladder. 
Approximately 95% of BAs are conjugated to either glycine or taurine. 
Conjugated bile acids are transported from the liver to the gall bladder where 
they are stored before their release into the duodenum after food 
consumption (Ridlon et al., 2006; Ridlon et al., 2016). Diet can impact upon 
the proportion of glycine to taurine conjugates, with people consuming a 
western diet having bile with a higher ratio of taurine to glycine conjugates 
(Hardison 1978). Such increases in taurine conjugation have been linked to 
elevated inflammation and expansion of pathobionts in mice (Devkota et al., 
2012). The type of conjugation can also be affected by other factors, 
including antibiotic treatment and the absence/disruption of the microbiota, 
which can increase the proportion of taurine conjugates and decrease BA 
diversity (Swann et al., 2011).  
BAs act as detergents due to their amphipathic nature, harbouring both 
hydrophobic and hydrophilic regions. This structure enables the formation of 
micelles around lipids, allowing uptake of lipids and lipid soluble vitamins 
Chapter 1- Introduction 
35 
 
(Figure 1.6). Modification of BAs by intestinal bacteria is important as it alters 
their amphipathic structure decreasing their ability to form micelles and 
influences absorption. 
 
Figure 1.6 Micelle formation around lipids and lipid soluble vitamins by BAs 
The amphipathic nature of BAs allows for the formation of micelles around lipids, facilitating 
their absorption. 
To facilitate the efficient absorption of lipids there are high concentrations of 
BAs in the duodenum, jejunum and proximal ileum. The majority of BAs are 
reabsorbed in the colon and recycled through the body via enterohepatic 
circulation (EHC), an efficient process which happens multiple times 
throughout the day (Figure 1.7). 
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Figure 1.7 Enterohepatic circulation of BAs through the gastrointestinal (GI) tract 
Enterohepatic circulation of BAs is the process by which BAs are reabsorbed allowing them to 
be recycled multiple times. As BAs move through the GI tract they are modified by members of 
the microbiota to form secondary BAs. The majority of BAs are reabsorbed and returned to the 
liver with only 5% are lost in faeces. 
Deconjugated BAs and glycine CBAs can be passively reabsorbed, although 
there is also some active transport of BAs in the distal ileum. This process is 
very efficient with only small quantities (approx. 800mg) of BAs entering the 
colon each day (Ridlon et al., 2006). These BAs are open to modification by 
members of the microbiota, the process of which will be discussed in section 
1.3.2. 
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1.3.1 Bile acids impact the structure of the microbiota 
As described in the previous sections, BAs play an important role in a number 
of important physiological processes. These include the capacity to alter the 
structure of the microbiota due to their toxicity. High levels of bile in the 
small intestine help to supress bacterial overgrowth, mostly through non-
specific damage to the bacterial membrane (Merritt & Donaldson, 2009). In 
addition, some direct modification of BAs by resident bacteria increases their 
bactericidal activity, resulting in the inhibition of growth of a wide range of 
bacteria (Floch et al., 1972).  In a study by Islam et al., (2011) it was found 
that the feeding of CA to mice led to changes in the structure of the caecal 
microbiota, including dominance by several Clostridial species. A similar study 
by Ridlon et al., (2013) also observed that, mice fed 1% CA as part of their 
diet, showed an increase in the number of DCA producing bacteria. These 
studies suggest that BAs are important for shaping the environment in the GI 
tract by creating selective pressures that hinder growth of different bacteria 
species. As the host produces no equivalent enzymes to those generated by 
the microbiota, it is clear that bacteria are playing a key role in the diversity 
and population structure of each individual’s microbiota.  
1.3.2 Modification of Bile acids by intestinal bacteria 
Many of the bacteria present within the GI tract possess enzymes that are 
involved in the modification of BAs. The conversion of conjugated BAs to 
secondary BAs is a complex, multistep enzymatic process (Figure 1.8). The 
gateway reaction involves the removal of the conjugated amino acid. This 
reaction is facilitated by the production of bile salt hydrolases (BSH) enzymes, 
which cleave the terminal taurine or glycine. 
 Bile salt hydrolases  1.3.2.1
BSH are part of the N-terminal nucleophilic hydrolase superfamily of enzymes 
and are produced by many bacterial species in the gut. The majority of BSH 
producers belonging to Gram positive species such as Clostridium, 
Bacteroides, Lactobacillus and Enterococcus (Begley et al., 2005). BSH are 
typically intracellular enzymes, the expression of which linked to bacterial 
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growth (De Smet et al., 1995). The exact purpose of BSH activity to individual 
bacteria is not well understood with multiple theories explored in the 
literature. Three main ideas remain in circulation. The first suggests that 
these bacteria are able utilise the amino acid, cleaved by the action of the 
BSH, as a carbon source giving them an advantage over other bacteria within 
the gut. Some bacterial species have been shown to utilise the amino acid 
that is freed by deconjugation (Begley et al., 2005). Both glycine and taurine 
can be further modified to ammonia and carbon dioxide, which may then be 
used in the formation of other metabolites (Patel et al., 2010). A study by Van 
Eldere et al., (1996) showed that some strains can utilise the free taurine as 
an electron acceptor.  
It has also been proposed that BSH activity increases tolerance to BAs and 
therefore aids in vivo survival. A large number of bacteria have been found to 
have increased bile resistance due to BSH production (Gueimonde et al., 
2009; De Smet et al., 1995; Grill et al., 2000; Bi et al., 2016). However the 
link between BSH activity and bile tolerance is disputed, with multiple studies 
finding no link between BSH activity and bile tolerance (Moser & Savage, 
2001; Usman & Hosono, 1999). It could be that BSH do play some role in bile 
tolerance, but that in some bacteria this is part of a complex response to BAs 
meaning that BSH function is not the primary determinant of bile resistance 
(Fang et al., 2009). However expression of a BSH is an attractive trait for 
probiotic bacteria (Patel et al., 2010; Kumar et al., 2012). In the pathogen 
Listeria monocytogenes, BSH production is considered a virulence factor as it 
is enables the bacteria to effectively colonise the GI tract, with mutation of 
this gene reducing colonisation of this pathogen (Dussurget et al., 2002). A 
final potential role of BSH production is the incorporation of the modified BA 
into the membrane of the bacteria which may help the bacteria to adapt to 
environmental stressors and aid in vivo survival (Taranto et al., 2003).   
 7α-dehydroxylation of deconjugated BAs 1.3.2.2
Following deconjugation of the amino acid side chain, the BA is susceptible to 
further modifications. In the context of C. difficile infection the most 
important is 7α-dehydroxylation of the BA, which results in the formation of 
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DCA, which inhibits C. difficile outgrowth. The advantage of 7α-
dehydroxylation to the bacteria that facilitate this process is unknown, 
although it may provide additional electron acceptors for anaerobic 
respiration (Mallonee & Hylemon, 1996). The production of DCA may also help 
to limit competition from other members of the microbiota including C. 
difficile. 7α-dehydroxylation completes the conversion from primary to 
secondary BA and is carried out as part of a multi-step reaction controlled by 
the BA inducible operon (BAI). Currently, only members of the Clostridia and 
Eubacteriaceae have been identified as able to carry out this process. This 
includes C. scindens, Clostridium hylemonae, Clostridium sordellii, 
Clostridium hiranonis and various unclassified Eubacteria (Ridlon et al., 
2016).  A simplified pathway of bacterial bile metabolism is shown in Figure 
1.8. 
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Figure 1.8 A simplified diagram of bacterial enzymes involved in bile modification and the impact of this on the efficiency of C. difficile spore germination 
Conjugated BAs are first modified by BSH which cleave the amino acid from the BA opening it up to further modification. In the context of C. difficile infection the most 
important secondary modification is 7α-dehydroxylation resulting in the formation of secondary BAs. As BAs are modified from conjugated to secondary their ability to 
induce C. difficile spore germination decreases. 
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7α-dehydroxylation of BAs is incredibly complex, requiring up to 10 different 
proteins individually encoded on the BAI. Whilst several bacteria encode this 
operon there is significant diversity observed between individual species (Ridlon 
et al., 2016). The BAI from C. scindens is shown in Figure 1.9. The operon itself, 
encodes genes involved in its own regulation, BA uptake and modification 
including genes involved in the formation of either DCA or lithochoilc acid (LCA).   
In addition, the specialised BA transporter only binds CA or CDCA and not CBAs, 
meaning deconjugation by BSH is an essential prerequisite of 7α-dehydroxylation 
(Batta et al., 1990; Van Eldere et al., 1996).  
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Figure 1.9 The BAI operon from C. scindens 
Figure showing the structure and function of the genes within the BAI operon in C. scindens. 
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This operon encoding this specialised function is possessed by a very small subset 
of bacteria (Stellwag & Hylemon 1978; Ferrari & Beretta 1977; Wells et al., 
2000). This process however, is highly efficient with the majority of BAs present 
in the healthy human colon being converted to their secondary form. Ultimately, 
the presence of these bacteria and activity of the enzymes determine the levels 
of secondary BAs present within the BA pool. This is important as these BAs are 
more toxic to cells and have been associated with increased incidence of colon 
cancer (Barrasa et al., 2013; McGarr et al., 2003). As western diets are known to 
influence the prevalence of bacteria associated with bile breakdown, this may 
help to explain the apparent recent increase in the frequency of this disease. 
1.3.3 Bacterial bile acid resistance and virulence 
 BA induce resistance mechanisms in enteric bacteria and 1.3.3.1
pathogens 
All bacterial species that inhabit the GI tract come into contact with conjugated 
and free BAs. Damage associated with exposure is frequently linked to 
modification of membranes although BAs can also damage DNA, RNA and 
proteins. For this reason bacteria have evolved multiple mechanisms in order to 
deal with this toxicity and to utilise these molecules. Mechanisms for this 
include production of enzymes involved in the modification of CBAs and BAs 
(1.3.2), upregulation of efflux pumps, induction of DNA repair mechanism and 
modifications to the outer membrane (Begley et al., 2005).  
One of the best-characterised mechanisms for resistance is the increased 
expression of efflux pumps, which allow rapid efflux of BA before damage can 
occur. Modification of efflux pump regulation and production  following bile 
exposure has been demonstrated in a huge range of commensal and pathogenic 
bacteria including Salmonella typhimurium, Escherichia coli, Campylobacter 
jejuni, Pseudomonas aeruginosa and Vibrio cholerae  (Prouty et al., 2004; Okoli 
et al., 2007; Gunn 2000). The most studied example in this context are the 
acrAB genes expressed by E. coli. Homologs of these genes are found in a large 
range of enteric bacteria including S. typhimurium and Bifidobacterium longum 
(Baucheron et al., 2014; Gueimonde et al., 2009). Upregulation of efflux pumps 
has been shown to increase resistance to antibiotics and other stressors such as 
solvents and detergents (Prouty et al., 2004). Efflux pumps involved in bile 
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resistance have now been identified in a multitude of Gram positive and Gram 
negative bacteria and seem to be incredibly important factor influencing bile 
resistance (Gunn, 2000). In addition to increased efflux of BAs, Salmonella 
enterica has been shown to remodel its peptidoglycan layer in response to 
exposure to sub lethal concentrations of DCA (Hernández et al., 2015) and to 
alter lipopolysaccharide transport which also helps to increase bile resistance 
(Hernández et al., 2012) 
 Modulation of virulence by BA 1.3.3.2
A number of bacterial species have been found to modify expression of genes as 
a consequence of exposure to a variety of BAs. This includes genes involved in 
BA resistance as described in section 1.3.3.1, but also genes involved in 
regulating virulence. Amongst these are genes associated with a number of 
virulence-associated traits including motility, biofilm formation and epithelial 
cell invasion. The regulation of virulence genes in response to bile has been 
shown in an array of pathogens including, E. coli (Hamner et al., 2013), 
Salmonella typhimurium (Prouty et al., 2004), Shigella flexneri (Pope et al., 
1995), Vibrio cholera (Krukonis & DiRita, 2003) and L. monocytogenes (Dussurget 
et al., 2002) Interestingly responses to bile vary between different bacterial 
species, mostly likely due to differences in pathogenesis. 
As the concentration and ratio of particular BAs varies considerably along the 
length of the GI tract it is possible that bacteria have adapted regulation and 
expression of virulence traits to ensure expression at the most appropriate 
location within the gut. This seems to be the case for S. typhimurium and E. coli 
which both downregulate several virulence genes in the presence of BAs. In E. 
coli O157:H7, incubation with BAs (an undefined mixture consisting mostly of 
glycocholate and TC) results in the significant downregulation of 41 genes from 
the locus of enterocyte effacement (LEE), which includes genes involved in 
attachment to epithelial cells, and upregulation of genes for iron scavenging and 
metabolism (Hamner et al., 2013). In S. typhimurium the presence of bile has 
been shown in multiple studies to result in reduced expression of both SPI-1 and 
SPI-2 genes resulting in decreased invasion of epithelial cells (Prouty, Brodsky, 
Manos, et al., 2004; Prouty & Gunn 2000; Hernández et al., 2012). As 
concentrations of BAs are high in the lumen, but decrease with proximity to the 
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epithelial surface, regulation of these genes by BAs could halt expression of 
genes for invasion until they are required. Interestingly S. flexneri shows the 
opposite control of adherence and invasion to S. typhimurium with increased 
invasion in the presence of DCA (Pope et al., 1995). A later study by Olive et al., 
(2007) found that DCA directly interacts with IpaD protein at the tip of the 
needle complex of the type III secretion system. This interaction causes a 
conformational change that facilitates binding of IpaB resulting in increased 
capability to invade epithelial cells.  
In addition to changes associated with invasion, BAs have also been shown to 
influence genes involved in motility and biofilm formation. Exposure to BAs 
results increased levels of swarming motility and decreased toxin production in 
V. cholerae (Gupta & Chowdhury, 1997). This same increase in motility was also 
found by Krukonis & DiRita (2003) and was thought to be due to increased 
flagella formation. Increased motility enabled the bacteria to penetrate the 
mucus layer more effectively and access the underlying epithelial cells. It has 
also been found that different BAs have different effects on biofilm formation in 
V. cholera with a crude bile mix found to increase biofilm formation through 
increased production of polysaccharides (Hung et al., 2006). Interestingly 
exposure to TC was also found to stimulate biofilm dispersal in V. cholera 
suggesting that different BAs have different impacts upon the same organism 
(Hay & Zhu, 2015). DCA has also been found to increase biofilm formation in C. 
jejuni, by stimulating production of flagella resulting in increased adherence 
(Svensson et al., 2014).  
Considering that C. difficile also encounters this environment during infection 
and the fact that BAs, particularly TC, play such a pivotal role in germination 
and outgrowth (Sorg & Sonenshein, 2008, 2009), it is not surprising that this area 
has been subject to recent significant scientific interest. It is likely that further 
attention will be paid to this area as currently nothing is known about how BAs 
influence genes involved in bile resistance in C. difficile (Sistrunk et al., 2016). 
This interest also stems from our increased understanding of the composition 
and functional activity of the gut microbiome which is known to be influential in 
C. difficile infection.  
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 The human gut microbiota 1.4
1.4.1 The structure and function of the human gut microbiota 
The human gut is colonised following birth by a huge number of bacteria, viruses 
and fungi. Bacteria are the most studied of these symbionts and in the GI tract 
there are 10 times as many bacterial cells as there are human cells (Luckey, 
1972). Bacteria in this location encode an astonishing 150 times more unique 
genes than the human genome and provide many important functions that 
support human health (Qin et al., 2010). The gut is thought to harbour 500-1000 
species with large variation between individuals. Interestingly, the metabolic 
potential of the microbiome shows greater conservation, probably reflecting the 
high level of functional redundancy between bacterial species (Figure 1.10). 
 
 
Figure 1.10 Structure and function of the Human gut microbiome from Huttenhower et al., 
(2013) 
A) The bacterial phyla present in stool samples from healthy human subjects. There is large 
variation between subjects with different proportions of bacterial phyla present in each sample. B) 
Investigation of metabolic pathways present within human stool samples. The metabolic activity of 
the microbiota is much more highly conserved compared to the species present. 
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The abundance of bacteria and the species present within specific body sites 
varies along the length of the GI tract. The density of bacteria increases 
throughout the GI tract, with the colon being the most densely populated site 
with an estimated 1011 CFU/ml. The typical bacteria associated with the 
different sites in the GI tract are shown in Figure 1.11.  
 
Figure 1.11 The distribution and identification of microorganisms along the GI tract. 
Adapted from Tiihonen et al., 2010 
This figure highlights the abundance and distribution of the bacterial species in several locations 
along the GI tract. 
There is additional variation even within a specific location, with the luminal 
bacteria differing from those found intimately associated with the mucosa 
(Ouwehand et al., 2004; Swidsinski et al., 2002; Zoetendal et al., 2002). 
The microbes in our gut play a number of important roles in health, 
development of local immune responses and disease. Much information has been 
gleaned from studies performed on germ free (GF) animals. In these animals’ the 
structural integrity and linked immune system remain undeveloped (Bauer et al., 
2006). Additionally, such animals require higher calorie intake and suffer from 
vitamin deficiencies, however they also live longer and are more resistant to 
developing kidney stones (Wilks, 2007), thus demonstrating the complex 
relationship that exists between the host and their commensal bacteria.  
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A major area of interest is the potential role of the microbiota in influencing 
autoimmune diseases and infection, with disruption being increasingly linked to 
irritable bowel syndrome (IBS) (Dupont, 2014), Crohn's disease (Dicksved et al., 
2008) and obesity (Ley et al., 2005; DiBaise et al., 2012). For infectious disease, 
one of the most important functions of the microbiota is its role in colonisation 
resistance and protection from colonisation with pathogenic bacteria. This 
concept was first described in 1962 when it was defined as ‘antibiotic associated 
susceptibility’ and was linked to the increased vulnerability of mice to 
Salmonella infection following streptomycin treatment (Bohnhoff & Miller, 
1962). Antibiotic use remains one of the major factors influencing microbial 
diversity within the microbiome and it is their use that can be linked, in the 
majority of cases, to disruption of colonisation resistance.   
1.4.2 The microbiome and the immune system 
The proximity of many of these bacteria and their metabolic by-products to the 
epithelium of the GI tract means that the immune system must be perfectly 
balanced to ensure elimination of potential pathogens whilst limiting the 
response to commensals. Homeostasis of this system is crucial, with over-
activation of host defences and/or mucosal defects linked with a range of 
inflammatory diseases. One mechanism by which this balance is achieved is the 
physical separation achieved through the continual production and secretion of 
mucus by goblet cells. Cross linking of mucin results in the formation of a two 
layered structure. A tightly cross-linked and adherent inner mucus layer and a 
more loosely linked outer layer. Bacteria are unable to penetrate the inner 
layer, decreasing contact between luminal bacteria and epithelial cells. The 
outer mucus layer is colonised by commensal bacteria, with the thickness of this 
layer increasing with progress through the GI tract, as the bacterial load 
increases (Johansson et al., 2011). Mucus production is stimulated by several 
bacterial factors including peptidoglycan and lipopolysaccharides, which have 
been shown to ameliorate reduced mucus production in GF mice (Petersson et 
al., 2011). The mucus layer is not just a physical barrier but contains several 
immune molecules that help to prevent contact of luminal bacteria with the 
epithelia. This includes secretory IgA, Reg-IIIγ and antimicrobial peptides (AMPs) 
which help to keep the inner mucus layer free of bacteria (Maynard et al., 
2012). Homeostasis of this system is important with dysregulation of mucin 
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production linked to inflammatory disorders like colitis (Van der Sluis et al., 
2006; Heazlewood et al., 2008). Furthermore, development of host immunity 
appears to be triggered by species specific microbes, with GF mice only able to 
develop normal immune responses if transplanted with organisms from the 
mature mouse gut (Chung et al., 2012). 
1.4.3 The aging microbiota 
One of the main risk factors associated with C. difficile susceptibility is ageing, 
with the majority of cases seen in patients aged 65 or above (Rea et al., 2012). 
It is now recognised that the composition of the microbiota changes as people 
age with significant alterations seen in individuals living in healthcare facilities 
(Claesson et al., 2012; McDonald et al., 2016). Whilst most of these studies 
showed a large amount of variation in the changes associated with aging, the 
overall impression is a decrease in stability and diversity within the microbiome 
of the elderly (Tiihonen et al., 2010; Claesson et al., 2012; Claesson et al., 
2011). These changes may reflect changes to the complexity of diet, which can 
be restricted by poor dental health and problems with digestion. Elderly people 
are also likely to be taking prescription medications with 75% of over 65s taking 
at least one drug (Chrischilles et al., 1992). Several of these medications, 
including proton pump inhibitors (PPIs), antibiotics (as discussed in section 1.4.4) 
and laxatives have been found to influence the microbiota (Tiihonen et al., 
2010). Large scale changes in the composition of the microbiota can influence 
the production and concentration of short chain fatty acids (SCFA) with 
decreased levels of butyrate and increased concentrations of phenol and 
branched fatty acids observed. This change in profile represents a shift to 
putrefaction rather than saccharolytic fermentation (Woodmansey 2007; 
Woodmansey et al., 2004). Alteration of the SCFA profile can also favour 
decreases in barrier function (Suzuki et al., 2007) and modulation of immune 
response (Meijer et al., 2010). As a consequence such changes may contribute to 
the increased rates of C. difficile infection observed in this age group.  
1.4.4 Impact of antibiotic treatment on the microbiota  
The number of prescriptions written for antibiotics each year in England is 
estimated to be in the region of 34 million with antibiotic exposure identified as 
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the biggest risk factor for developing C. difficile infection (Furuya-Kanamori et 
al., 2015). Antibiotics, particularly those with broad spectrum activity, have a 
huge impact on the structure and function of the bacteria in the microbiota and 
there is increasing evidence that taking antibiotics in the early years of life can 
result in profound and long lasting changes to the structure of the microbiota 
(Yassour et al., 2016; Jernberg et al., 2007). In particular their use alters the 
diversity of the microbiota known as dysbiosis. Persistent dysbiosis has been 
shown to be intrinsically linked to both acute and relapsing C. difficile infection 
and therapies that restore this lost diversity have been found to be highly 
effective. 
1.4.5 The microbiota in C. difficile infection 
The structure of the microbiota associated with C. difficile infection has now 
been studied extensively in both mouse and man. Infection is typically 
associated with disproportional blooms of Enterobacteriaceae, Enterococcus and 
Proteobacteria such as E. coli (Reeves et al., 2011; Fuentes et al., 2014; 
Schubert et al., 2015). Such large changes in population structure have been 
linked to significant changes in the gut metabolome. A study by Antunes et al., 
(2011) found 87% of the metabolites within the gut were altered following 
antibiotic treatment. Key changes included reduction in a number of short chain 
fatty acids (SCFAs) including butyrate, altered BA modifications (1.4.5.2) and 
presence of certain sugar alcohols and amino acids (Theriot et al., 2014). These 
changes, favour C. difficile colonisation, germination and outgrowth particularly 
through the production of primary BAs and succinate (Ferreyra et al., 2014; 
Curtis et al., 2014). Such changes can persist for many weeks after antibiotic 
treatment potentially leaving the host susceptible to C. difficile infection over 
long periods of time (Theriot et al., 2014).  
 Influence of gut dysbiosis in chronic relapsing infection 1.4.5.1
As discussed, large proportion of patients who contract C. difficile suffer from 
repeated, relapsing infection, either as a consequence of reinfection by a new 
strain, or, relapse of existing disease. Relapse as a consequence of recurrence 
accounts for between 64-87% of such cases, making it more common than 
reinfection (Figueroa et al., 2012; Johnson et al., 1989; Alonso et al., 2001; Dé 
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et al., 2000). The reason for repeated relapse is unclear, however a study by 
Chang et al., (2008) found that patients who were suffering from relapsing 
disease had limited diversity within the structure of the microbiota. Additionally 
it has been found that patients suffering from long term dysbiosis have 
significantly increased numbers of  Parabacteroides, Enterobacteriaceae, 
Veillonella and Streptococcus with these patients found to be at higher risk of 
infection (Khanna et al., 2016). This would suggest that C. difficile is able to 
persist in environments in which the diversity is limited. 
At present it is unclear in what form C. difficile persists within the gut or 
whether the organism is able to manipulate the local environment to maintain 
the modified niche to perpetuate its persistence. However it has been 
hypothesised that production of para-cresol, a bacteriostatic compound, may 
assist the capacity to persist (Dawson et al., 2011; Dawson et al., 2008; Selmer 
& Andrei, 2001). C. difficile is among the few bacterial species that is able to 
produce para-cresol (Elsden et al., 1976; Hafiz & Oakley, 1976) with strains of C. 
difficile associated with high rates of relapse able to produce and tolerate 
higher quantities of this compound (Dawson et al., 2008; Dawson et al., 2011). 
The capacity of bacteria to produce compounds that limit the growth of other 
species is well documented. Typical examples include bacteriocin production, 
nutrient limitation and production of toxic compounds.  
In S. typhimurium production of a bacteriocin called colicin Ib (ColIb) allows the 
bacteria to outcompete closely related Enterobacteriaceae but only in an 
inflamed gut (Petkova Nedialkova et al., 2014). Similarly bacteriocin production 
by Enterococcus faecalis enables it to outcompete other non-bacteriocin 
producing E. faecalis strains in a mouse model (Kommineni et al., 2015). More 
general mechanisms of niche maintenance involve the production of inhibitory 
molecules and metabolites. These often involve the production of a compound 
to which the producer is highly tolerant to but which can damage other bacteria. 
An example of this is the production of DCA by C. scindens as described in 
section 1.3.2.2. DCA is toxic to many other bacterial species including C. 
difficile so production of this compound may help C. scindens to maintain its 
niche within the gut by creating an environment in which it can flourish. It may 
Chapter 1- Introduction  
 
52 
 
be that para-cresol production by C. difficile represents a similar mechanism of 
niche maintenance but this requires further investigation. 
 Antibiotic impact on bacterial bile metabolism  1.4.5.2
Multiple antibiotics have been associated with changes in BA metabolism 
including streptomycin (Antunes et al., 2011), cefoperazone (Theriot et al., 
2014; Theriot et al., 2015), clindamycin (Andréasson et al., 1988; Theriot et al., 
2015) and vancomycin (Theriot & Young 2014; Theriot et al., 2015). Clindamycin 
is commonly used to render animals susceptible to C. difficile before infection 
(Sun et al., 2011; Chen et al., 2008; Reeves et al., 2011; Bartlett et al., 1977; 
Larson & Borriello 1990). As clindamycin is circulated within bile and is present 
in high concentrations in bile (Leigh, 1981) it is likely that high levels of the 
antibiotic will be present in areas populated by bacteria involved in bile 
metabolism. The loss of members of the microbiome that are able to modify 
taurine conjugated BAs results in the formation of an environment in which C. 
difficile is able to germinate, grow and produce toxins resulting in disease 
(Figure 1.12). 
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Figure 1.12 The impact of antibiotic exposure on the microbiota, bile metabolism and C. 
difficile infection 
Antibiotic exposure can disrupt the intestinal microflora, resulting in a decrease in species able to 
modify primary bile salts (taurocholate) to secondary bile salts (deoxycholate) which creates an 
environment that promotes C. difficile germination and outgrowth. 
 Current and developing treatments 1.5
Due to the complicated nature of C. difficile infection, treatment can prove 
challenging. The significant rates of relapse and recurrence suggest that current 
treatment of acute disease is not effective and exploration of alternatives is 
required (1.1). Currently the recommended treatment is with vancomycin or 
metronidazole, however, failure rates are high and with reports of high rates of 
relapse (Vardakas et al., 2012) and reduced susceptibility to these treatments 
(Baines et al., 2008). It has also been found that exposure to these antibiotics 
increases susceptibility to a range of hospital pathogens including C. difficile 
(Lewis et al., 2015; Wafa et al., 2008) As decreased microbial diversity has been 
linked to infection, restoration and protection of this niche has now become the 
focus of a huge number of emerging therapeutics. This includes development of 
narrow spectrum antibiotics such as fidaxomicin which has been shown to be as 
effective as vancomycin (Johnson & Wilcox, 2012) but with lower rates of 
relapse (Drekonja et al., 2012). There have also been efforts to utilise C. 
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difficile specific bacteriophage therapy (Nale et al., 2016) and the use and 
delivery of BA analogues (1.5.3.1). All these approaches aim to target C. difficile 
whilst protecting the microbiota from further damage. An alternative approach 
is the direct replacement of the microbiota either through FMT or targeted 
bacteriotherapy. At present, FMT is still reserved for use in only the most 
difficult to treat cases, but with the increasing rate of treatment failure the 
need for change is apparent. 
1.5.1 Faecal microbial transplantation 
FMT was first performed on patients with PMC in 1958 at the University of 
Colorado, Veterans Administration Hospital. In this small study, four patients 
were treated with faecal retention enemas. This treatment was found to be 
highly effective and the treating physicians observed that if a more precise 
preparation of microorganisms could be identified and delivered in capsules, 
that this would be a “more aesthetic and more effective” treatment. Since this 
there have been intermittent reports of this non-standard type of treatment for 
C. difficile. Today, the effectiveness of this approach has been widely reported 
in the literature with hundreds of patients being treated. The first official 
clinical trial conducted to compare the efficacy of FMT to traditional antibiotic 
therapy reported a 90% cure rate after two FMT infusions compared to 31% for 
traditional treatment with vancomycin. The trial was so successful that it was 
ended prematurely to allow those being treated with vancomycin to be given the 
more effective FMT (van Nood et al., 2013). Meta-analysis of multiple studies 
report success rates for FMT of between 89.7-91.2% and recurrence rates of 5.5% 
(Li et al., 2015; Kassam et al., 2013). These rates suggest that FMT is much more 
effective than traditional antibiotic therapy, with the use of fresh versus frozen 
stool seemingly having no impact on efficacy (Hamilton et al., 2013; Youngster 
et al., 2014). Efforts to understand how this treatment works have been helped 
by our increasing knowledge of the composition of the ‘healthy’ human gut 
microbiota as discussed in section 1.4. Interestingly, assessment of microbial 
population structure of patients before and after FMT, have shown that the 
composition of the recipients gut microbiota shifts to one that resembles that of 
the donor (Weingarden et al., 2014). In some studies, this change persists for 
years (Broecker et al., 2016) with significant increases in bacterial diversity. 
Overall these changes include significant increases in Bacteroidetes and 
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Firmicutes with concurrent decreases in the proportion of Proteobacteria (van 
Nood et al., 2013; Khoruts et al., 2010; Hamilton et al., 2013; Shankar et al., 
2014; Weingarden et al., 2015; Seekatz et al., 2014)  
Unsurprisingly, given the importance of BAs in C. difficile germination and 
outgrowth, it has been found that changes in BA composition are associated with 
infection in both mice (Theriot et al., 2014) and humans (Allegretti et al., 2016). 
It has now been shown that FMT is able to restore normal BA metabolism in 
these patients providing one explanation to the mechanism of C. difficile control 
(Weingarden et al., 2014; Weingarden et al., 2016).  
However, several issues around the widespread implementation of FMT exist.  
These include the possibility of transmitting pathogens and obvious problems 
with the aesthetics of this approach. For this reason there has been a move 
towards the creation of treatments that are easier to administer and tolerate, 
such as delivery within an oral capsule (Youngster et al., 2014). Additionally the 
long-term consequences of such large scale modifications to the human 
microbiome remain unknown. Short term side effects such as bloating and 
diarrhoea have been reported but it is too soon to know if there are any long 
term implications (Li et al., 2015). Many of the FMT procedures that take place 
in the USA utilise pre-screened faecal matter provided by not for profit stool 
banks such as Openbiome and AdvancingBio. It is likely in the future that there 
will be a shift towards the use of more defined bacteriotherapy increasing the 
need for a good understanding of how these therapies work. For this reason, 
much work has focused on producing a defined, safe and evidence based 
bacteriotherapy that can be embraced by both patients and regulatory agencies. 
1.5.2 Defined bacteriotherapy for treatment of C. difficile 
The development of an effective treatment based on a defined combination of 
bacteria has been on-going for many years. One benefit of these synthetic 
mixtures is the potential to validate the safety and effectiveness of each 
formulation. This is more difficult for FMT as, although each donation is 
screened for potential pathogens, it is difficult to ensure that all risk is 
removed. Amongst the first reported successes was the use of a human derived 
strain Lactobacillus GG that was used to successfully treat 6 patients (Gorbach 
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et al., 1987).  Two years later a combination of 10 bacteria that suppressed the 
growth of C. difficile in vitro, was successfully used to treat a further 6 patients 
with recovery associated with restoration of Bacteroides to the gut (Tvede & 
Rask-Madsen, 1989). More recently a combination of 6 bacteria, isolated from a 
healthy mouse, was able to suppress infection as effectively as an infusion of 
unmodified donor faeces. Interestingly, other combinations of bacteria were 
unable to suppress infection, suggesting it is the functional capacity of the 
combination that is important for protection. However, it is important to note 
that many of the species used were species that were specific to the murine gut, 
potentially limiting direct application to humans subjects (Lawley et al., 2012). 
Another synthetic mix developed by Petrof et al., (2013) graphically termed 
‘RePOOPulate’ consists of 33 bacterial species isolated from a human faecal 
sample. These can be delivered at known abundances, are pathogen free and 
contain bacteria that have been screened for the presence of antibiotic 
resistance genes. RePOOPulate has been used to successfully treat 2 patients 
who had previously failed to respond to antibiotic therapy. A recent study from 
the same group suggests that the combination is effective as it both restores 
diversity and protects against inflammation caused by TcdA (Martz et al., 2016). 
Clinical studies using such defined mixtures of bacteria are currently underway 
to treat C. difficile infection (Khanna et al., 2016; Dubberke et al., 2014).  
1.5.3 Targeting bile metabolism to treat C. difficile 
As BAs play an important role in modulating spore germination and vegetative 
outgrowth of C. difficile, there are numerous studies that attempt to utilise BAs 
as treatment for C. difficile.  
 Chenodeoxycholate and bile acid analogues as competitive inhibitor 1.5.3.1
of germination 
CDCA is a competitive inhibitor of C. difficile germination and has been 
proposed as a potential therapeutic agent (Sorg & Sonenshein, 2009). Analogues 
of this compound have been found to act as even more efficient inhibitors of 
spore germination and were also shown to resist modification by 7α-
dehydroxylation (Sorg & Sonenshein, 2010). Although able to inhibit C. difficile 
germination in vitro, these compounds have not been tested in vivo. An 
alternative treatment using a TC analogue, CamSA (cholate meta-sulfonic 
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benzene derivative) (Howerton et al., 2011), was shown to be able to protect 
mice in a dose dependent manner by inhibiting spore germination (Howerton et 
al., 2013). Although this proved successful in pre-clinical studies, there have 
been no subsequent reports of its use in the clinical setting. 
 A move towards functionality 1.5.3.2
A recent and ground breaking study by Buffie et al., (2014) found that the use of 
a single species of bacteria, C. scindens, was able to increase resistance to C. 
difficile infection in mice. They proposed that this was achieved through the 
production of DCA, which can inhibit the outgrowth of C. difficile. Mice that 
were treated with C. scindens had a lower mortality rate and lower toxin titres 
in their faeces. Full protection was only achieved when C. scindens was 
administered in conjunction with 3 other bacterial species. This suggests that 
although the production of secondary BAs is important there must also be other 
factors that impact colonisation and outgrowth.  
 Animal models of C. difficile infection 1.6
Much of our knowledge of C. difficile infection has been gleaned from the use of 
animal models. Multiple animal models of infection have been described in the 
literature to study various aspects of infection such as colonisation, transmission 
and virulence. These include the Syrian Golden hamster, several inbred species 
of mice, gnotobiotic piglets, rats, rabbits, guinea pigs, prairie dogs, rhesus 
monkeys, quails and zebrafish embryos (Hutton et al., 2014; Best et al., 2015). 
The most commonly used of these models are the hamster and mouse models of 
infection and these will be discussed in detail in this section. 
1.6.1 Syrian Golden hamster model for acute infection 
The Syrian Golden hamster has been considered the ‘gold standard’ model of 
this infection as animals develop many symptoms that parallel those seen in 
clinical disease. Animals are administered clindamycin 5 days prior to infection 
to disrupt the microflora and to render them susceptible to infection (Buckley et 
al., 2011). After infection animals are monitored for signs of disease and culled 
when they become moribund (Figure 1.13). 
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Figure 1.13 Typical infection timeline for hamster experiments 
Animals are given a single dose of clindamycin before infection with C. difficile. After infection 
animals are monitored closely for signs of disease and culled when they become moribund as 
determined by a temperature drop to below 35 ̊C. 
Following infection with toxigenic strains of C. difficile animals rapidly develop 
symptoms including diarrhoea (wet tail), lethargy, hunching and quickly become 
moribund. The histology of the caecal and colonic tissues mirrors inflammation 
and tissue haemorrhage seen in human disease. As a consequence this model has 
been used to shed light on several aspects of the infection including virulence, 
colonisation, transmission and the role of toxins in disease. In addition, this 
model has been used to determine the efficacy of several prototypical vaccines 
and therapies (O’Brien et al., 2005; Kink & Williams 1998; Kokkotou et al., 
2008). However, the rapidly fatal infection C. difficile causes in hamsters does 
not reflect the infection outcome of C. difficile in the majority of human cases. 
For this reason the development of models that display a wider range of disease 
outcomes that more closely reflect those seen in humans were required. An 
additional problem is a lack of suitable immunological tools that allow 
evaluation of the host response to this infection. The recent development of 
several mouse models of infection is helping to expand our overall knowledge of 
C. difficile host pathogen interactions.  
1.6.2 Mouse models of infection 
The use of mouse models to investigate C. difficile pathogenesis is increasing 
with several different mouse models being developed in recent years. These 
models utilise either conventional mice or GF mice with a humanised microbiota 
(Collins et al., 2015) with conventional mice used most commonly. Untreated 
mice are resistant to infection and, as with humans, susceptibility to infection 
must be induced through disruption of the microbiota. In recent years a huge 
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number of mouse models have been developed in which different antibiotic pre-
treatments lead to different disease susceptibilities. These models typically use 
one antibiotic or a combination of antibiotics to disrupt colonisation resistance. 
This includes models that utilise a single dose of clindamycin (Buffie et al., 
2012), delivery of cefoperazone in the drinking water (Theriot et al., 2011) and 
use of a cocktail of antibiotics followed by a single dose of clindamycin (Chen et 
al., 2008). Use of these models has allowed the study of longer term infection, 
relapsing infection and more severe disease, much of which would not have been 
possible in the hamster model of infection (Figure 1.14). 
 
Figure 1.14 The most commonly used mouse models of infection 
The 3 most common mouse models of infection are shown in the diagram above. One model uses 
delivery of cefoperazone in the drinking water for 10 days to sensitise mice to infection. Another 
uses a single dose of clindamycin. A variation of this model uses an antibiotic cocktail prior to 
clindamycin treatment and which results in increased disease severity. 
All of these treatments render mice susceptible to infection but interestingly 
they result in differing infection outcomes. One model that has been used 
frequently is one that uses an antibiotic cocktail (ABC) of 5 antibiotics in 
conjugation with clindamycin treatment to induce susceptibility to more severe 
disease (Chen et al., 2008). Mice treated with this regime display symptoms that 
more closely resembles infection in man as animals do not uniformly succumb to 
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infection but follow a range of disease outcomes from diarrhoea to significant 
weight loss (Collins et al., 2015; Reeves et al., 2011). In contrast use of 
clindamycin alone results in colonisation of animals but with minimal weight loss 
and severity. Use of these different antibiotic regimes allows for investigation of 
different disease states, increasing the usefulness of these models even further. 
One of the main advantages of the mouse model is that the animals do not 
appear as sensitive to the action of TcdA and TcdB. This means that studies of 
temporal changes in the composition of the microbiota during antibiotic 
treatment, infection and relapse can be determined.  
 Aims of this study 1.7
As the structure of the microbiota and BAs plays an essential role in modulating 
C. difficile infection the initial aim of this work was to;  
1. Understand the population structure of the antibiotic treated gut and its 
influence on susceptibility to C. difficile colonisation and disease 
severity. This was achieved using several mouse models in which the 
extent of antibiotic pre-treatment and disease are linked. 
2. To determine specific role of BAs and BA modifying bacteria on C. 
difficile germination and colonisation resistance.  
3. To establish how increased concentrations of TC can affect both 
germination and subsequent growth of C. difficile. This was achieved 
through the construction of a transposon mutant library and RNA-seq to 
identify those genes whose expression was significantly altered in the 
presence of TC.  
4. To investigate the influence of the bacteriostatic compound para-cresol 
produced by C. difficile in persistence and relapsing infection.  
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2 Materials and Methods 
 Materials 2.1
2.1.1 Enzymes 
All restriction enzymes and Phusion high fidelity DNA polymerase were 
purchased from New England BioLabs Hitchin UK. Thermo Start Reddy Mix® was 
purchased from Thermo Fisher. 
2.1.2 Antibiotics 
 For use in culture media 2.1.2.1
Antibiotics were dissolved, filter sterilised using a 0.2 μm Ministart® syringe 
filter and stored at -20 °C before use. Antibiotics were added to sterilised liquid 
media immediately before use. For inclusion in agar, the media was allowed to 
cool before the addition of the antibiotics. Concentrations of routinely used 
antibiotics are shown in Table 2-1. 
Table 2-1 Antibiotics for in vitro work 
Antibiotic Stock 
concentration 
Working 
concentration 
Diluent 
Chloramphenicol 12.5 mg/ml 12.5 μg/ml Ethanol 
Anhydrotetracycline 500 μg/ml 50-100 ng/ml Ethanol 
Lincomycin 20 mg/ml 20 μg/ml Ethanol 
Erythromycin 5 mg/ml 5 μg/ml Ethanol 
Clindamycin 20 mg/ml 20 μg/ml Sterile deionised 
water (SDW) 
Thiamphenicol 1.5 mg/ml 15 μg/ml Dissolve in acetic 
acid and make up 
volume with SDW 
   
 For in vivo use 2.1.2.2
For in vivo use, antibiotics were dissolved and sterilised using a 0.2 μm 
Ministart® syringe filter. Antibiotics that were delivered in the drinking water 
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were prepared fresh on the day of use. Clindamycin was stored at -20 °C prior to 
use. 
Table 2-2 Antibiotics for in vivo use 
Antibiotic Concentration Method of 
delivery 
Diluent 
Kanamycin 400 mg/L Ab libitum in the 
drinking water as a 
cocktail 
SDW 
Gentamycin 35 mg/L SDW 
Colistin 850000 (U/L) SDW 
Vancomycin 45 mg/L SDW 
Metronidazole 215 mg/L Dissolve in 
acetic acid and 
make up 
volume with 
SDW 
Clindamycin 250 mg/L SDW 
Clindamycin 15 mg/ml 200 µl Oral gavage SDW 
 
 Bacterial strains and vectors 2.2
2.2.1 Storage of bacterial strains 
 Preparation of bacterial glycerol stocks 2.2.1.1
Non-sporulating bacterial strains were stored at -80 °C as glycerol stocks. These 
were prepared from single colonies inoculated and grown to mid-log phase in 
BHI. This culture was then aliquoted into 800 l volumes of culture which were 
mixed with 20 % glycerol, before storage at -20 oC. Stocks of E.coli were 
prepared in an identical manner except colonies were grown to mid log phase in 
LB broth.  
 Preparation of spore stocks of Clostridium difficile for in vivo 2.2.1.2
infections 
C. difficile strains were stored at -80 °C as spores. Spores were subject to the 
following protocol to limit clumping as this is important to ensure accuracy of 
the infectious dose during in vivo experiments. Briefly, 100 ml of BHI broth was 
inoculated with a single colony and grown anaerobically for 7 days at 37 °C after 
which cells were harvested by centrifugation for 10 minutes at 2950 g. The 
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resultant pellet was resuspened and left for 1h in 75 % ethanol and vortexed 
every 10 minutes. The pellet was again collected by centrifugation before being 
treated, at 37 °C, with 10ml of phosphate buffered saline (PBS) containing 1 % 
sarkosyl for 1 hour. Spores were again harvested by centrifugation before 
resuspension in 10 ml PBS containing 0.125 M Tris buffer (pH 8) and 10 mg/ml 
lysozyme before incubation at 37 °C overnight. The following day, samples were 
layered onto 10 ml of 50 % sucrose and centrifuged at 2950 g for 20 minutes. The 
resultant pellet was then resuspened in 10 ml PBS containing 200 mM EDTA, 300 
ng/ml proteinase K and 1 % sarkosyl and incubated at 37 °C for at least 3 hours. 
Samples were layered onto 10 ml of 50 % sucrose and centrifuged as described 
previously. Finally the pellet was washed twice in 10 ml PBS before being 
resuspened in 1-2 ml PBS. The purified spores were then aliquoted into 200 μl 
volumes and stored at -80 °C. 
2.2.2 Isolation of bacteria from mouse faecal samples 
Bacteria were recovered from faecal pellets collected from each animal, for 
aerobic bacteria pellets were placed immediately in Brain Heart Infusion (BHI) 
broth. The samples were homogenised then serially diluted in BHI and plated on 
to BHI, Man Rogosa Sharpe (MRS), Fastidious anaerobic media (FAM), Columbia 
base media (CBM) supplemented with horse blood (5%), Wilkins-Chalgren 
anaerobic (WCA) media and Luria Bertani (LB). To enable recovery of anaerobic 
organisms, pellets were collected in preconditioned BHI and transported in 
anaerobic conditions to ensure maximum recovery of organisms. Bacterial 
growth was recovered from this range of agars following incubation at 37 °C for 
between 24-72 hours. 
2.2.3 Bacterial strains used in this work 
The bacterial strains utilised as part of this work are detailed in Table 2-3. 
Bacteria were stored at -80 °C in 20 % glycerol or as spores. For long term 
storage, plasmids were transformed into E. coli DH5α. 
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Table 2-3; Bacterial species and strains used in this work 
Species Origin Antibiotic resistance 
C. difficile BI-7  Trevor Lawley Clindamycin 
C. difficile R20291 Lisa Dawson Erythromycin 
C. difficile 
R20291_hpdA::CT 
Lisa Dawson Lincomycin 
C. difficile R20291_1754::CT  Lisa Dawson 
 
Lincomycin 
C. difficile R20291  
harbouring pRPF215 
(transposon) 
This work Thiamphenicol 
E. coli CA434 harbouring 
pRPF215 (transposon) 
Rob Fagan Chloramphenicol 
Dermococcus This work - 
Citrobacter This work - 
Escherichia fergusonii 
Shigella sonnei or E.coli 
This work - 
E.fergusonii S. sonnei or 
E.coli 
This work - 
Enterococcus faecium This work - 
Enterococcus casseliflavus This work - 
Enterococcus This work - 
Enterococcus This work - 
Lactobacillus apodemi This work - 
L. apodemi This work - 
Kocuria rhizophila This work - 
K. rhizophila This work - 
Micrococcus luteus This work - 
Enhydrobacter or Moraxella This work - 
Staphylococcus lentus This work - 
Staphylococcus warneri This work - 
S. warneri This work - 
S. warneri This work - 
E.coli DH5α Thermo Fisher Plasmid dependent 
E.coli BL21 Thermo Fisher Plasmid dependent 
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 Molecular methods 2.3
2.3.1 Oligonucleotides  
All oligonucleotides used in this study are listed in Table 2-4. All oligonucleotides 
were purchased from MWG Eurofins. Primers were diluted in DNAse and RNAse 
free water (Thermo Fisher) to a working concentration of 10 mM unless 
otherwise stated.  
Table 2-4 Oligonucleotides used in this study 
Name  Description Sequence 
BSH G1 (F) Degenerate primers for 
amplification of BSH from group 
1 
 
Primers provided by Prof Julian 
Marchesi 
CGTCCAGGCCCGGACNAT
HGARTGGG 
BSH G1 (R) GGTGGCGGAGGTCCAYTG
NGT 
16s rRNA V4 (F) Primers for amplification of the 
V4 region of the 16s rRNA gene. 
The forward primer is 
universal. The reverse primer 
contains a unique 12bp Golay 
barcode (red) to allow 
multiplexing of samples for 
sequencing  
 
 
 
 
Primers provided by Dr Chris 
Quince 
AATGATACGGCGACCACC
GAGATCTACACTATGGTA
ATTGT 
GTGNCAGCMGCCGCGGTA
A 
 
16s rRNA V4 (R) CAAGCAGAAGACGGCATA
CGAGATGTCGAATTTGCG
AGTCAGTCAGCCGGACTA
CHVGGGTWTCTAAT 
 
S12tBSH Production of both the tBSH 
from S12 and the full length 
BSH from S15 
GGGAGAAATTTTGACTAT
GAG 
S15BSH ATGTGTACTGCAGTATCA
TTTAAAAC 
BSH R TTAGTTAGCGTAATTGAAA
TG 
S12CLO F Primers for cloning of tBSH and 
BSH. Forward primers contain 
Sph1 restriction. Reverse 
primer contains a Xba1 site for 
cloning into pnz44. Additional 
S12 contains an ATG site to 
allow expression of S12 BSH 
ATTGCATGCATGTTGGGG
AGAAATTTTGACTATG 
 
S15CLO F ATTGCATGCATGTGTACT
GCAGTATCATTTAAAAC 
BSHCLO R TAAGCATCTAGATTAGTTA
GCGTAATTGAAATGTTG 
hpdA F Check for mutant in hpdA gene 
 
Primers provided by Dr Lisa 
TGTATGAATTTTTGTGCA
GTGGATC 
hpdA R TCGAAATTAGAAACTTGC
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Dawson GTTCAGTAAAC 
MVLA_1 F Primers directed to 7 VNTR 
regions in C. difficile. Pattern 
of PCR products is used for 
typing. 
ATTAATCATATCCTACAGA
ACACGA 
MVLA_1 R TAAAACAAATGATATAAAC
TGAAAAG 
MVLA_2 F GTAGAAGGGGCAAATAAT
GAG 
MVLA_2 R CCTTCTGGCTTCCTTGTAA
TA 
MVLA_3 F AATTTTAAGTTAACGTTTT
TCTACAT 
MVLA_3 R AGCCATTTTTATCAATCCT
TTCTAT 
MVLA_4 F TCTGGGATGTAACTAGCG
ACTTGT 
MVLA_4 R TCTTAGGGAATTTATTGG
AGGAA 
MVLA_5 F AGGAGCTTTATATGGACA
TTCAGGTAG 
MVLA_5 R AATCTCTTTCAAACTCTTC
AATCTCAAT 
MVLA_6 F AACATATTTAGGCATTTTA
GTC 
MVLA_6 R GAGTATTATTTATCATTTG
TGGGTATTA 
MVLA_7 F GGTGCACATGCTGGTCCT
G 
MVLA_7 R AACGCATTAAATTTCACTC
CTCATAC 
 
2.3.2 General PCR protocol  
PCR was performed using Biometra Professional Thermocycler. Reactions were 
carried out in 0.2 ml PCR tubes (Sarstedt). A general PCR protocol and PCR 
reaction mixture used in this study are shown in Table 2-5 and Table 2-6. 
Annealing temperature and cycle number were varied for each primer set and 
this information is detailed in the corresponding sections. For general PCR 
reactions Thermo Start Reddy Mix was used, when PCR products were to be used 
for cloning or for V4 16s sequencing Phusion® High fidelity master mix was 
included to reduce PCR induced errors. 
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Table 2-5 Reaction mixture for PCR reactions 
Component Quantity in 25µl reaction 
1X Master mix 22.5 µl 
Forward primer (10 mM) 1 µl 
Reverse primer (10 mM) 1 µl 
DNA template Variable 
Nuclease free water Up to 25 µl 
MgCl2 (50 mM) Dependent on reaction 
 
Table 2-6 A general PCR protocol used in this study 
Reaction step Temperature (°C) Time 
Initial denaturing  (x1) 95 2 minutes 
Denaturing (x30) 95 30 seconds 
Annealing (x30) Variable 30 seconds 
Amplification (x30) 72 1 minute per Kb 
Amplification (x1) 72 10 minutes 
 
2.3.3 Agarose gel electrophoresis  
PCR products, plasmids and digests were all run on 1% agarose gels in 1xTAE 
buffer containing 10 µl GelRed (10000X) (Cambridge Biosciences) per 100 ml of 
gel. Gels were run at 140 V for 45 minutes. 1 Kb Plus DNA ladder (Thermo Fisher) 
was used to determine the size of DNA fragments. 
2.3.4 Gel extraction and PCR purification 
For gel extraction the band was excised from the gel using a clean scalpel. 
Extraction was carried out using the QIAquick gel extraction kit (Qiagen) as per 
the manufactures instructions. PCR purification was carried out using the 
QIAquick PCR purification kit (Qiagen) as per the manufactures instructions.   
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 DNA extraction, 16s amplification and genome 2.4
sequencing of bacteria  
 Purification of genomic DNA from C. difficile and bacteria isolated 2.4.1.1
from faeces 
A single colony was inoculated into 20 ml of BHI or tryptone soy broth (TSB) and 
grown statically at 37 °C, aerobically or anaerobically, depending on the origin 
of the isolate. Cultures were incubated for 24 hours. DNA was extracted using a 
DNEasy Blood and Tissue kit (Qiagen) as per the manufactures instructions. DNA 
was stored at -80 °C until required. 
 Amplification of 16s rRNA from bacteria 2.4.1.2
To determine the identity of bacteria isolated from the faecal samples PCR was 
used to amplify the V4 region of the 16s rRNA gene. The annealing temperature 
of the reaction was at 44 °C. The expected product size was 350 bp.  
 DNA extraction from faecal samples for microbiome 2.5
analysis 
Faecal samples were collected and stored at 5 °C for a maximum of 12 hours 
before DNA extraction. Extraction was carried out as described in the QIAgen soil 
kit with the addition of a homogenisation step using the Fastprep® machine 
(MpBio) at speed 6 m/s for 40 seconds. DNA was stored at -80 °C until required. 
2.5.1 Amplification of the 16s rRNA gene from faecal DNA 
To amplify the 16s rRNA gene the concentrations of faecal DNA were quantified 
using Nanodrop (Thermo Fisher) and diluted to 2 ng/µl before use. Each 25 µl 
reaction contained 12.5 µl of Phusion high fidelity master mix, 0.87 µl of forward 
primer, 0.87 µl of reverse primer (containing a 12 bp Golay barcode to allow 
multiplexing), 1.25 µl of DMSO, 6.5 µl of nuclease free water and 3 µl of DNA (2 
ng/µl). The PCR reaction was limited to only 20 reaction cycles in order to 
reduce PCR induced error. PCRs were performed in triplicate and pooled. Pooled 
samples were run on a 1 % agarose gel at 125 V for 1 hour and the correct band 
(378 bp) excised and DNA recovered from the gel. Library preparation and 
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sequencing of 16s rRNA gene amplicons was carried out at the Liverpool Centre 
for Genomic Research (LCGR).  
2.5.2 Microbiome analysis 
All code used to carry out microbiome analysis is open source and is available at 
http://userweb.eng.gla.ac.uk/umer.ijaz/.  
 Processing of 16s amplicons 2.5.2.1
After gel extraction the 16s rRNA samples were sent to LCGR where the library 
was assembled and sequenced. After sequencing, the adaptor sequences were 
removed and the samples were demultiplexed using the unique Golay sequences 
associated with each sample (Table 2-4). This was carried out by the LCGR. All 
further analysis was carried out in conjunction with Dr Umer Ijaz.  
As sequencing often produces reads that drop in quality towards the 3 prime end 
it necessary to trim sequences before further analysis. To do this we utilised 
Sickle, a program that examines the quality scores along a read and trims the 
read if the quality drops below the desired level. It also filters reads below a 
certain length. For this analysis sequences were trimmed when the phred score 
dropped below 20. In addition, sequences of 10 bp or less were removed before 
further processing. After quality trimming, paired end reads must be overlapped 
and mismatches and uncalled bases corrected. This was achieved using Pandaseq 
(Masella et al., 2012). Reads required a minimum overlap of 20bp to be used. 
For removal of chimera sequences (a fusion of 2 or more sequences) and 
taxonomic assignment to OTUs Usearch was used (Edgar, 2010). OTUs were 
determined at a 97 % similarity level and assignments were determined using 
RDP classifier (Wang et al., 2007), which gives identity at Phylum, Class, Order, 
Family and Genus level. 
To further analyse the composition of the microbiome beyond merely OTU 
presence and absence it is necessary to construct maximum likelihood 
phylogenetic trees. These allow comparisons of abundance and the relatedness 
of OTUs to be undertaken and are required for the analysis of both alpha and 
beta diversity measures. To do this multiple sequence alignment was carried out 
in MAFFT (Katoh et al., 2002). These alignments were then used to generate 
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maximum likelihood phylogenetic trees using FastTree (Price et al., 2010). Data 
was then imported into R where additional analysis was carried out including 
creation of taxa plots, assessment of alpha and beta diversity and changes in 
OTU abundance. 
 Metabolic prediction using Tax4fun 2.5.2.2
Analysis of the OTUs within microbiota samples is incredibly useful. However its 
main limitation is the lack of functional information. Bioinformatics packages 
that allow for the inference of metabolic potential from this data are now in 
existence. One such package is Tax4Fun. Tax4fun is an open source R package 
that uses the SILVA database and reference genomes to infer the likely 
metabolic potential of OTUs within a 16s dataset (Aßhauer et al., 2015). To use 
Tax4fun it is necessary to create a biom file in QIIME. This was achieved by 
annotating the OTUs using the SILVA database which is compatible with the 
Tax4fun package. The biom file can then be used to extract KEGG information 
for the OTUs identified in the microbiome samples. Further analysis allows the 
changes in abundance of specific enzymes and KEGG pathways to be 
determined. In addition to this it was also possible to determine the importance 
of specific functions in classifying samples into treatment groups using a Random 
Forest Classifiers.  
 Determining the impact of BAs on C. difficile 2.6
germination and outgrowth 
2.6.1 Detection of BSH activity using a plate based assay 
To test bacterial isolates for BSH activity bacteria were plated onto BHI media 
containing 0.5 % TC and incubated for up to 72 hours. BSH activity was 
determined by the presence of a halo of precipitate or by the formation of white 
granular colonies. 
2.6.2 Amplification of BSH genes from microbiome samples  
Primers for amplification of BSH were a kind gift from Professor Julian Marchesi 
(Cardiff University). These were designed using consensus-degenerate hybrid 
oligonucleotide (CODEHOP), which aligns the amino acid sequences of the 
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homologous enzymes from different bacteria and creates degenerate primers 
that are able to amplify all of the variations (Rose et al., 1998). Using this 
method numerous bacterial BSH can be amplified using a single set of primers. 
The PCR reaction was as described in 2.3.2. Reactions contained 1 µl of template 
DNA at 50 ng/µl. The annealing temperature of the reaction was 60 °C with an 
expected product size of 858 bp. 
2.6.3 Amplification of Lactobacillus murinus BSH 
Primers were designed to the BSH sequences recovered from the L. murinus 
genome sequences. Due to sequence homology a universal reverse primer was 
used for both L. murinus strains. In contrast forward primers were specifically 
designed to the individual strains. The annealing temperature of the reaction 
was 50 °C with an expected product size of 978 bp for the BSH+ve strain and 939 
bp for the BSH-ve strain. 
2.6.4 Attempts to clone and express the BSH from Lactobacillus 
murinus 
 Plasmid purification 2.6.4.1
Plasmids were purified from 5 ml of LB culture using a QIAprep spin miniprep kit 
(Qiagen), using the manufacturers protocols. 
 Amplification of Lactobacillus murinus BSH for use in cloning 2.6.4.2
Primers were designed containing restriction sites that were also found in the 
pnz44 plasmid. Forward primers contained the Sph1 restriction site and reverse 
primer Xba1 to allow ligation into pnz44 vector. The annealing temperature of 
the reaction was 50 °C. 
 Restriction digest of pnz44 vector 2.6.4.3
Restriction digests were carried out in 50 µl volume reactions containing 5 µl of 
cutsmart buffer, max of 1 µg of template DNA, 10 units of Sph1 and of 20 units 
of Xba1. DNAse and RNase free water was added to a final volume of 50 µl. 
Restriction digests were carried out in a water bath at 37 °C for 3 hours followed 
by heat inactivation of the restriction enzymes. 
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 Ligation of L. murinus BSH into pnz44 2.6.4.4
Similarly digested vector and PCR fragment were ligated at room temperature 
for 15 minutes. A 20ul ligation reaction contained 400 units of T4 DNA ligase, 2 
µl 10 X reaction buffer and vector and insert at a 3:1 molar ration. The reaction 
mix was made up to 20 µl with nuclease free water. 
 Transformation of BSH containing pnz44  2.6.4.5
5 µl of ligation mixture was added to 50 µl of chemically competent DH5α E. coli 
and incubated on ice for 30 minutes. Cells were heat shocked at 42 °C for 45 
seconds and then incubated on ice for 5 minutes. 300 µl of LB media was added 
and samples incubated at 37 °C with shaking before plating onto LB with the 
appropriate selection antibiotic. 
2.6.5 Germination assays 
 Impact of strains isolated from mouse faeces on C. difficile spore 2.6.5.1
germination 
To determine if strains recovered from the faeces were able to functionally 
modify BA in vitro 10 ml BHI broth was inoculated with a single colony of each 
isolate before incubation for 24 hours or until the culture reached an OD of 
approximately 1. Assays were carried out in triplicate with a minimum of 3 
biological replicates for each sample. BHI was used as a negative control, BHI 
with 0.1 % TC as a positive control of maximum germination and BHI with 0.1 % 
CA to determine the ability of CA to induce germination. To determine if the 
strains were able to deconjugate TC to CA and impact germination 30 µl of each 
overnight culture was added to 3 ml of BHI with 0.1 % TC. The plate was 
incubated for 24 hours either aerobically or anaerobically depending on the 
origins of isolation. Cultures were sterilised using a 0.2 μm Ministart® syringe 
filter (Sartorius) to remove bacteria from the media and adjusted to pH7. The 12 
well plates were incubated anaerobically for a minimum of 2 hours to condition 
the media. A minimum of 1 X 104 spores were added and incubated for a further 
2 hours to allow for germination of spores. Cultures were serially diluted to 10-3 
and plated onto BHI agar containing 0.1 % TC giving total bacteria numbers. The 
remaining sample was heated at 65 °C for 20 minutes in order to kill and 
vegetative cells leaving only non-germinated spores. These spores were also 
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enumerated and from this the percentage of germination was calculated using 
the equation below.  
 
 Impact of BSH expressing E. coli on C. difficile spore germination  2.6.5.2
To clarify the role of BSH activity in inhibition of C. difficile germination E. coli 
clones expressing BSH from the human gut microbiota were utilised (Jones et 
al., 2008). The E. coli harbour BSH genes cloned into the constitutive pnz44 
plasmid. This plasmid is a derivative of pnz8048 where the PnisA promoter has 
been replaced with the constitutive p44 promoter from Lactococcus lactis. 
Carriage of pnz44 confers chloramphenicol resistance (Mcgrath et al., 2001). E. 
coli were grown overnight in LB broth containing chloramphenicol (12.5 ug/mL). 
300 µl of this culture were used to inoculate 30 ml of BHI broth with 0.1 % TC 
and incubated for 24 hours. Cultures were centrifuged at 2950 g for 10 minutes 
and the supernatant filter sterilised using 0.2 μm Ministart® syringe filter. The 
rest of the assay was performed as in section 2.6.5.1. 
2.6.6 The impact of BAs on bacterial growth 
 Germination and outgrowth of C. difficile spores in the presence of 2.6.6.1
different BAs 
To investigate how different BAs influence germination and subsequent 
outgrowth of C. difficile, growth curves of the organism in the presence of 
different BAs were carried out. 100 µl of C. difficile spores were used to 
inoculate flasks containing 10 ml BHI, BHI with 0.1 % TC, BHI with 0.1 % CA or 
BHI with 0.1 % DCA. Cultures were incubated anaerobically at 37 °C. OD600 
measurements were taken every 3 hours for the first 12 hours with a final 
sample taken at 24 hours. 
 Growth of L. murinus in the presence of TC 2.6.6.2
To determine the impact of TC on growth of L. murinus growth curves were 
carried out in MRS broth and MRS broth containing 0.1 % TC. Growth curves were 
set up by inoculating 100 µl of an overnight culture of L. murinus into 10 ml of 
MRS broth or MRS broth containing 0.1 % TC. Cultures were incubated 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑔𝑒𝑟𝑚𝑖𝑛𝑎𝑡𝑖𝑜𝑛 = (𝑉𝑒𝑔𝑒𝑡𝑎𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 ÷ 𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑐𝑒𝑙𝑙𝑠) × 100 
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anaerobically at 37 °C. Samples were taken every 3 hours for 9 hours. Samples 
were serially diluted onto MRS agar and incubated for 24 hours before bacteria 
were enumerated. 
2.6.7 Biofilm assays to determine the impact of TC on biofilm 
abundance and adherence 
 Crystal violet assay to measure biofilm abundance in the presence 2.6.7.1
and absence of TC 
An overnight culture of C. difficile in BHIS-C media was used to seed a 6 well 
plates. Overnight cultures were grown in BHIS-C alone or with the addition of 0.1 
% TC. 200 µl of an overnight culture was inoculated into 1.8 ml of pre-reduced 
BHIS-C media with or without 0.1 % TC, giving a total of 4 different growth 
combinations. Each biofilm was set up in triplicate with wells left uninoculated 
to serve as blanks. Plates were incubated anaerobically at 37 °C for 24 and 48 
hours. After this time plates were removed from the cabinet and the media 
carefully removed using a vacuum pump. Biofilms were washed once with 1ml 
PBS before staining with 500 µl of 1 % crystal violet (CV). Plates were stained for 
30 minutes and then washed twice with PBS to remove residual CV. CV was 
extracted from biofilms with the addition of 500 µl of methanol. Dilutions were 
performed to ensure accuracy of reading the sample at OD 544 nm. To allow 
effective absorbance measurements, 200 µl of the sample was transferred to a 
96 well plate and the OD was determined at 544 nm using the FLOUstar OPTIMA 
plate reader (BMG labtech). The OD of the negative control well was subtracted 
from the samples to give an accurate reflection of biofilm formation. 
 Assays to determine biofilm adherence to an abiotic surface in the 2.6.7.2
presence and absence of TC 
As with the biofilm method described in section (2.6.7.1) overnights were set up 
in BHIS-C alone or with the addition of 0.1 % TC. 1ml of overnight culture was 
used to seed 25 cm3 vented tissue culture flasks containing 9 mls BHIS-C or BHIS-
C 0.1 % TC, again giving a total of 4 growth conditions. Flasks were incubated 
statically and incubated anaerobically for 24 and 48 hours. After this time flasks 
were removed from the cabinet. Flasks were then mechanically disturbed to 
determine if the biofilm was adhered to the base of the flask (Dawson et al., 
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2012). Photos were taken using a Panasonic lumix dms-t60 camera with samples 
placed on a light box. 
 Generation of a transposon mutant library 2.7
 Creation of a random transposon mutant library of C. difficile 2.7.1.1
The vector containing the mariner transposon pRPF215 was stored in E. coli 
CA434 and was a kind gift from Dr Rob Fagan (University of Sheffield). 
Maintenance of the plasmid was mediated by thiamphenicol resistance (Figure 
2.1). 
 
Figure 2.1 Vector map of pRPF215 
The pRPF215 plasmid contains the mariner transposon which contains an ermB cassette to allow 
for selection of bacteria in which the transposons has integrated into the genome. Expression of 
the mariner transposon is under control of a tetracycline inducible promoter. 
Regulation of expression of the mariner transposon is controlled by the addition 
of anhydrotetracycline (AHT). Following expression, this transposon is able to 
insert into any TA site within the chromosome, resulting in the generation a 
library of mutants in which the transposon is inserted randomly. The insertion of 
the transposon containing the ermB gene into the genome renders strains 
lincomycin resistance allowing for easy selection of transposon mutants. A 
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variation of pRPF215 in which a fluorescent LOV domain was linked to the C 
terminal end of the transposon (pYAA023) was also utilised in this project.  
 Conjugation of pRPF215 and pYAA023 from E. coli CA434 into C. 2.7.1.2
difficile R20291 
Donor E. coli CA434 harbouring the pRPF215 or pYAA023 plasmid was streaked 
onto LB agar containing chloramphenicol (12.5 μg/ml). The recipient C. difficile 
strain was inoculated onto Braziers CCEY agar containing erythromycin (5 
μg/ml). Overnight cultures of both the donor E. coli and recipient C. difficile 
strain were grown in antibiotic containing broth, the E. coli in LB and the C. 
difficile in BHI. 1.5 ml of the E. coli was harvested and centrifuged at 2950 g for 
10 minutes. The pellet was washed gently in PBS and carefully resuspened in 200 
µl of C. difficile. The conjugation mixture was spotted onto a non-selective BHI 
plate and incubated anaerobically at 37 °C. After 8 hours the conjugation 
mixture was scrapped from the plate and resuspened in 500 µl of PBS. 100 µl of 
this mixture was spread onto BHI containing cycloserine (250 µg/ml), cefoxitin (8 
µg/ml) and thiamphenicol (15 μg/ml) to facilitate for selection of C. difficile 
containing the plasmid. A well isolated colony was subbed onto fresh selective 
agar. This step was repeated to purify C. difficile containing the transposon 
containing plasmid until no E. coli contamination remained. 
 Generation of a transposon mutant library in C. difficile 2.7.1.3
To generate a transposon mutant library, C. difficile harbouring either pRPF215 
or pYAA023 was streaked onto Braziers with thiamphenicol (15 μg/ml) and used 
to inoculate an overnight culture in BHI. The culture was then used the following 
day to inoculate (1:100) tryptone yeast broth with glucose (TY+G) and grown to 
an OD of 0.4. The culture was diluted to 1:5, 1:25 and 1:125 and plated onto 
Braziers CCEY agar containing AHT to induce the expression of the transposon. 
Plates also contained lincomycin (20 μg/ml) to select for transposon mutants. 
Colonies were scraped from the plate and stored as a pool in BHI with 12.5 % 
glycerol at -80 °C or used for the production of spores. 
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 Selection for C. difficile mutants unable to germinate in the presence 2.7.1.4
of TC 
Spores that were produced from the mutant library were harvested (2.2.1.2) and 
then incubated in BHI containing 10 % TC for 12 hours to induce germination of 
those spores able to respond to TC as a germinant. The sample was subsequently 
heat shocked at 65 °C for 30 minutes to kill any vegetative cells leaving only 
non-germinated spores. The remaining spores were then artificially germinated 
using thioglycollate and lysozyme. Spores were incubated in 2 mM of 
thioglycollate (pH 10) for 50 minutes and plated onto Braziers containing 
lincomycin (20 μg/ml) and 10 mg/ml lysozyme (Kamiya et al., 1989). Colonies 
formed on these plates were considered to be germination mutants. 
 Genome assembly and annotation 2.7.1.5
The code used for this analysis is open source and available at 
http://userweb.eng.gla.ac.uk/umer.ijaz/ 
To identify the location of transposon insertion within the germination deficient 
mutants genome sequencing of strains was carried out. DNA was extracted and 
sequence carried out at GPF on the MiSeq platform. Read 1 and read 2 files were 
downloaded and the following steps carried out in order to assemble the 
genomes. Before genome assembly was carried out the quality scores of the 
reads was checked. Quality of reads was determined by examining the phred 
score associated with each read. Phred scores give a probability that a base pair 
is incorrect. For example, a phred score or 10 gives the probability that 1 in 10 
nucleotides have been misidentified. A phred score of 20 gives a 1 in 100 chance 
and so on. For genome assembly any reads with a phred quality score lower than 
35 were removed. Assembly was carried out using the Spades assembly tool. 
Briefly, this takes the read 1 and read 2 files and assembles them into contigs 
(Bankevich et al., 2012). Contigs less than 1 kb in length were removed before 
annotation. Remaining contigs were annotated using PROKKA (Seemann, 2014). 
This creates a variety of files including a genbank file which can then be mined 
for genes of interest or analysed further. To identify the location of the 
transposon within the genome of the germination mutants the annotated contigs 
were imported into CLC genomics workbench and an internal blast search 
directed to the ermB gene carried out. Once this gene was identified with the 
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contigs the gene that is was present in was determined by carrying out a Blast 
search. 
2.7.2 RNA collection, extraction and sequencing from C. difficile 
To investigate the impact of TC on gene expression RNA-seq was carried out. C. 
difficile R20291 was grown shaking at 37 °C until an optical density (OD) of 0.4 
was reached. To one sample, BHI containing TC was added to give a final 
concentration of 0.1 % TC. To the second sample an equal volume of BHI alone 
was added. This ensured that both samples were treated equivalently. In total, 3 
biological replicates for each growth condition were prepared. Following the 
addition of BHI, or BHI containing TC samples were incubated with shaking at 37 
°C for 1 hour after which 5 mls of culture was removed and added to 9 mls of 
pre-reduced RNAlater (Thermo Fisher) and incubated for 15 minutes. To harvest 
the bacterial cells, samples were centrifuged for 15 minutes at 2950 g at 4 °C 
and the supernatant discarded. 20 units of rRNasin (Promega) was added and 
pellets were stored at -80 °C until RNA extraction. RNA extraction was 
completed using the FastRNA Pro blue kit (MP bio) following the manufacturer’s 
instructions. Total RNA was DNAse treated using Turbo DNA-free kit (Ambion) 
rigorous treatment, with complete removal of DNA was confirmed by failure to 
amplify the 16s rRNA gene from this sample (2.4.1.2). Depletion of ribosomal 
RNA was carried out using Ribo-zero rRNA removal kit (Illumina). Testing of RNA 
quality, cDNA library preparation and sequencing of the cDNA library was carried 
out at the Glasgow Polyomics Facility (GPF). 
2.7.3 RNA seq analysis to identify differentially expressed genes 
after TC exposure 
Analysis of RNA-seq data was carried out in CLC Genomics Workbench version 7. 
A reference genome of C. difficile R20291 was downloaded and tracks created to 
allow alignment of reads to the genome. Differential gene expression was 
evaluated using Deseq2 package (Love et al., 2014). This package investigates 
differential count data, in this case the number of cDNA reads aligned to genes 
in different growth conditions and then compares these. Analysis was carried out 
to the specifications given in the CLC RNA seq analysis tutorials. 
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 In vivo models of infection 2.8
All in vivo experiments were carried out in line with the UK Animals (Scientific 
Procedures Act) 1986. Food and water was provided ad libitum and animals were 
kept at a constant room temperature of 20-22 °C with a 12 hour light/dark 
cycle. All mice used in this study were female C57bl/6 mice aged 6-8 weeks. 
After infection mice were monitored daily for weight loss and changes in 
behaviour. At the end of the experiments mice were humanely sacrificed by the 
schedule one method of cervical dislocation. 
2.8.1 Different antibiotic treatments modulate disease outcome 
Multiple mouse models were used to determine the impact of different 
antibiotic treatments on the microbiota. The first used a single dose of 
clindamycin (150 mg/kg) by oral gavage (200 µl) to induce susceptibility to 
infection. The second used treatment with an antibiotic cocktail (ABC) 
containing a daily dose of kanamycin (40 mg/kg), gentamicin (3.5 mg/kg), 
colistin (4.2 mg/kg), metronidazole (21.5 mg/kg), and vancomycin (4.5 mg/kg) 
(Sigma-Aldrich) ad libitum in the drinking water for 3 days. This is followed by a 
single dose of clindamycin (150 mg/Kg) given by oral gavage 2 days after the 
cessation of the antibiotic cocktail. Use of this model resulted in more severe 
disease. Multiple regimes based around these treatments were used and are 
shown in Figure 2.2. 
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Figure 2.2 Timeline of infection 
The figure above details the mouse models used to determine the impact of different antibiotic 
treatments on colonisation and disease severity. The ABC was administered for 3 days (D-5 to D-
3). Clindamycin was given on D-1 and 10
5
 C. difficile spores on D0. Animals were culled at 4DPI. 
Stars indicate the timing of sampling for microbiome analysis.  
During antibiotic treatment mice were transferred daily into clean sterile. On 
D0, 105 C. difficile spores were administered by oral gavage to each animal. 
Faeces were collected prior to and post infection with C. difficile to monitor 
relative levels of infection (2.9.1). Following cull, toxin levels (2.9.4) and C. 
difficile numbers in the caecum and colon were enumerated (2.9.2). 
 Bile salt extraction for mouse caecal samples 2.8.1.1
To prepare samples for Time of Flight mass spectrometer analysis (TOF-Mass 
spec) of BAs, 1 ml of caecum content, resuspened in PBS, was added to 3 mls of 
methanol to allow for extraction of BAs. This was mixed and centrifuged at 3000 
g for 10 minutes. The supernatant was retained for analysis of BA composition. 
 TOF-MS analysis of bile salts in mouse caecal samples 2.8.1.2
To determine the levels of TC and DCA in the caecum of mice, TOF-Mass 
spectrometry was used. This was carried by Dr Jia Li at Imperial Collage London 
using 6538 UHD Accurate Mass Q-TOF; Agilent Technologies. Parameters and 
methods are described in (Zhang et al., 2016).  
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2.8.2 A mouse model to examine the role of para-cresol 
production in relapsing infection 
The factors effecting relapsing C. difficile infection are not known. In order to 
investigate these factors further a relapsing model of C. difficile infection has 
been developed. This makes use of the observation that treatment of mice with 
clindamycin alone results in persistent colonisation, which although below the 
limit of detection can be induced by further use of clindamycin. This model was 
used specifically to determine the impact of para-cresol production in relapsing 
and acute infection. Mice were given clindamycin ad libitum in the drinking 
water (250 mg/L) for 3 days and then switched to normal drinking water. 2 days 
after cessation of clindamycin mice were administered 105 spores of either C. 
difficile R20291 or R20291_hpdA::CT, which is unable to produce para-cresol. 
Faeces were taken daily to determine the level of colonisation with C. difficile. 
After cessation of shedding, relapse was induced with a single dose of 
clindamycin (150 mg/kg) by oral gavage on D35. Again, mice were monitored and 
faeces collected to determine levels of C. difficile in the faeces (Figure 2.3). 
 
Figure 2.3 Timeline of relapsing infection 
Clindamycin was given in the DW for 3 days (D-5 to D-3). Mice were switched to sterile DW for 2 
days and then administered 10
5
 C. difficile spores at D0. 
A variation of this model was also used to examine acute infection in which 
animals were culled at 2DPI. After cull, toxin levels and C. difficile numbers in 
the caecum and colon were enumerated. 
 Colony PCR for detection of R20291_hpdA::CT from bacterial 2.8.2.1
colonies 
In these experiments all of the strains used are derived from the same parental 
R20291 strain making it not possible to differentiate between these strains with 
MVLA. Therefore it was necessary to ensure that each mouse was infected with 
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the correct strain of C. difficile. After isolation of C. difficile from faeces, 
colonies from each infection group were recovered used directly for 
amplification. Recovered colonies were added to 20 µl of SDW, heated at 95 °C 
for 20 minutes before incubation at -20 °C for 5 minutes to aid bacterial lysis. 
Samples were briefly centrifuged to sediment bacterial debris and 3 µl of the 
supernatant was used as the PCR template. Primers were directed to a region of 
the hpdA gene and a region within the ClosTron intron sequence. 
R20291_hpdA::CT will give a product of 408 bp whereas R20291 will not form a 
product due to the absence of ClosTron mutation. The annealing temperature of 
the reaction was 50 °C. This was used in conjunction with MVLA analysis to 
ensure that animals were infected with the correct strain of bacteria (2.9.3). 
 In vitro growth of C. difficile with induction of para-cresol  production 2.8.2.2
in C. difficile 
To determine the relative growth rates of R20291 and R20291_hpdA::CT 
comparative analysis was performed. In brief, strains were grown in BHI with the 
addition of 480 mg/L para-hydroxyphenylacetic acid (p-HPA), a precursor of 
para-cresol to induce para-cresol production. This was added to determine if 
production of para-cresol has a negative impact on the growth of R20291. 
Samples were taken every 3 hours for 9 hours and at 24 hours, 48 hours and 72 
hours. At 24, 48 and 72 hours the proportion of spores was examined. To assess 
toxin production 1 ml of supernatant was taken and centrifuged at 18.8 g for 10 
minutes and filter sterilised using a 0.2 μm Ministart® syringe filter. Samples 
were stored at -20 °C before used in toxin assays as described in section 2.9.4. 
2.8.3 Prophylactic treatment with BSH-ve and BSH+ve L. murinus  
Experiments were carried out to investigate the potential protective effect of 
BSH producing L. murinus in vivo. To induce susceptibility to infection, mice 
were given clindamycin (250 mg/L) in the drinking water for 3 days, as described 
in section 2.8.2. To prepare L. murinus for use in vivo MRS broth was inoculated 
and incubated for 9 hours. After 9 hours cultures were pelleted and washed 
twice with PBS. Samples were adjusted to a concentration of approximately 
5x109 CFU/ml. Each mouse was given 200 µl of L. murinus at 24 hours and 6 
hours before infection mice equating to a dose of 109 CFU of L. murinus. At D0 
mice were administered 105 C. difficile BI-7 spores (Figure 2.4). 
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Figure 2.4  Timelines of experiments to test efficacy of BSH in vivo 
For all animals, clindamycin was delivered in the drinking water for 3 days.  This was then replaced 
with sterile water for the remainder of the experiment. Approximately 10
9 
CFU of L. murinus was 
administered to each mouse on 24 h and 6 h prior to infection with 10
5
 spores of C. difficile BI-7. 
Following C. difficile infection animals were monitored daily for changes in 
behaviour and weight loss. 
 General techniques for the measurement of in vivo 2.9
colonisation and toxin production 
A multitude of different mouse models were used in this work. The specifics of 
these are described in section 2.7. This section details the general techniques 
that are common to all in vivo experiments. 
2.9.1 Detection of C. difficile in faeces as a measurement of 
colonisation 
Total numbers of C. difficile in the faeces of mice were monitored daily post 
infection. Fresh faecal samples were collected, weighed and diluted tenfold in 
PBS. Dilutions were plated onto Braziers CCEY agar containing the appropriate 
antibiotic for selection and incubated at 37 °C for 48 hours before enumeration. 
2.9.2 Culturing of Clostridium difficile from the caecum and colon 
Upon post-mortem, the caecum and colon were harvested and cut 
longitudinally. C. difficile numbers in the caecum and colon were enumerated 
for lumen associated (LA) and tissue associated (TA) bacteria. Organ contents 
Morning-Lacto 
Afternoon- C. difficile 
Clindamycin in DW 
D-5 D-3 D0 
Infect 
Clindamycin in DW 
D-5 D-3 D0 D-1 
Lactobacillus 
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were washed in 5 mls of PBS and tissue in 2 mls. Organ washes represent the LA 
bacteria. TA bacteria were recovered by homogenising the tissue. Organs were 
homogenised in 2 mls of PBS in the Stomacher Lab Blender 80 (Seaward Medical) 
and serial dilutions were plated onto Braziers CCEY agar containing the correct 
selection antibiotic for the strain used.  Plates were incubated anaerobically for 
48 hours. For spores the same protocol was used but with the addition of a 
heating step of 30 minutes at 65 °C to kill any vegetative cells. The number of 
vegetative cells was calculated by subtracting the number of spores from the 
total C. difficile counts. 
2.9.3 Confirmation of identity of recovered bacteria using 
Multilocus Variant Number Tandem Repeat Analysis 
After clindamycin treatment animals become highly susceptible to C. difficile 
infection. Although the significant efforts are made to limit inadvertent 
infection with environmental C. difficile it is necessary to identify any C. 
difficile recovered. This is determined using Multilocus Variant Number Tandem 
Repeat Analysis (MVLA). MVLA analysis is a method for typing bacterial strains 
including C. difficile  (Marsh et al., 2006). It utilises 7 primer sets that amplify 
variable repeat regions from within the C. difficile genome resulting in the 
formation of a banding pattern that allows for discrimination of strains from one 
another. MVLA was used to confirm that C. difficile recovered from the faeces of 
mice was the same as the infecting strain in all experiments performed. In long 
term experiments numerous samples were taken for analysis each week. Primers 
used for MVLA are shown in Table 2-4. The annealing temperature of this PCR 
reaction was 50 °C. The expected banding pattern is different for each C. 
difficile strain.  
2.9.4 Cellular assays for detection of C. difficile toxins 
To semi-quantify the levels of TcdA and TcdB produced in the samples a cellular 
assay was used. HT29 cells which are sensitive to TcdA and Vero cells which are 
sensitive to TcdB were used to determine toxin levels in the caecum and colon. 
Cells were grown in Eagles Minimal essential medium (EMEM) supplemented with 
10 % heat inactivated foetal calf serum (Thermo Fisher), 2 mM L-glutamine, 1 % 
Fungizone Amphotericin B 250 ug/ml (Life Technologies) and 1% Penicillin-
Chapter 2- Materials and Methods 
85 
 
Streptomycin 10000 U/ml (Thermo Fisher). 96 wells plates were seeded with 
cells and grown at 37 °C with 5 % CO2 until a confluent mono-layer was formed. 
The media was removed and the cells were washed with PBS before fresh EMEM 
was added. Before use in the assays samples were filter sterilised. For the 
caecum samples, 10 fold dilutions were performed, and for the colon samples 5 
fold dilutions. To determine toxin levels in culture media, 2 or 5 fold dilutions 
were carried out using culture supernatant. In all cases, plates were incubated 
overnight at 37 °C with 5 % CO2 before being washed twice with PBS and then 
fixed in 1 % formalin. Cells were fixed for 15 minutes and washed twice more 
with PBS and stained with Giemsa for a minimum of 1 hour. Giemsa stain was 
gently removed with running water and the plates examined by eye. High toxin 
level causes cell rounding and disassociation of cells from the plate which results 
in a lack of staining. Toxin level was determined as the highest dilution in which 
no cells and therefore no staining is present.  
 Statistical analysis 2.10
All analysis of 16s microbiome data was carried out in R version 3.1.3. For all 
other statistical analysis GraphPad Prism was used. The tests and parameters 
used are detailed in the figure legends throughout. Tests used included Students 
T-test, T-test with Welch correction, ANOVA with Tukey’s correction and 
Kruskal-Wallis with Dunn’s multiple comparison. 
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3 The impact of the microbiota on C. difficile 
colonisation and disease severity 
 Introduction 3.1
C. difficile is a disease intrinsically linked to disruption of the microbiome, with 
antibiotic treatment associated with reduction in microbial diversity, known to 
play a key role in C. difficile infection and disease severity (1.4.4 and 1.6.2). 
However, the precise mechanisms by which individual or combinations of 
microorganisms are able to suppress C. difficile colonisation and toxin release 
are unclear. Evidence of the importance of microbiome diversity is provided by 
the successful use of FMT to treat this disease (van Nood et al.,2013). Although 
clearly efficacious its clinical application has been restricted to patients 
suffering multiple relapses of disease. This reflects both issues with screening of 
faecal donations to limit indirect spread of pathogens to vulnerable patients, 
and aesthetic issues associated with the direct instillation of filtered faecal 
material into patients. For these reasons, identification and generation of a 
synthetic mix of microbes with the metabolic capacity to limit C. difficile 
colonisation is attractive. To date, several studies in both mouse and man have 
indicated that such an approach is feasible, with bacteriotherapy shown to 
suppress infection and reduce carriage of C. difficile in mice and humans 
(1.5.2). However, whilst much attention has been focussed on restoring 
microbial diversity, little consideration has been given to the functional 
metabolic capacity of these microbes. Additionally, not all combinations of 
bacteria are able to suppress infection (Lawley et al., 2012), further supporting 
the hypothesis that important functional aspects expressed by the microbiota 
are required for the restoration of colonisation resistance.  
The aim of this study was to determine how different antibiotic combinations 
impact on the microbiota and how these changes modulate C. difficile disease 
severity. This required a combination of culture based and molecular techniques 
to investigate the diversity of the microbiome at different time points following 
antibiotic treatment and pre and post infection. Using these data, we hoped to 
identify those bacteria and their metabolic functions that influence disease 
outcome.  
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The TOF-mass spec data presented in this chapter was carried out by Dr Jia Li at 
Imperial College London. Bioinformatics analysis was carried out with the 
assistance of Dr Umer Ijaz. 
 Results 3.2
3.2.1 Optimisation of mouse models 
Animal models of infection have been widely used for many years to study 
infection dynamics of C. difficile in vivo. Until recent times the most commonly 
used model was the hamster, which is easily colonised by C. difficile after 
antibiotic exposure. However, this model reflects only acute infection with 
animals often rapidly succumbing to infection (1.6.1). The development of 
mouse models that more closely reflect the spectrum of symptoms seen in 
human disease has allowed the role of the commensal microbiota in infection to 
be unravelled. This chapter utilises multiple mouse models of infection in order 
to determine if specific microbes or microbial functions are responsible for 
changes in disease severity and outcome. In these models the outcome of 
infection is influenced by the spectrum of antibiotics administered before 
infection (1.6.2). Multiple methods of antibiotic delivery were tested including 
use of oral gavage, ad libitum delivery in water and by intraperitoneal (IP) 
injection. It was found that administering the ABC in the water followed with 
clindamycin by gavage was the best method of delivery as it most closely 
replicated what has been seen in the literature. It also required minimal 
handling of animals, which reduces the possibility of cross infection with other 
strains of C. difficile that may contaminate the environment.  
 Mouse body weights during infection 3.2.1.1
An important part of the licensure for these experiments is minimisation of 
animal suffering.  As a consequence animals placed on procedure are continually 
monitored and any changes in behaviour or appearance monitored so that 
animals can be culled at a previously established humane endpoint. Weight loss 
in the context of these experiments is a good indicator of disease severity.  
Consequently, all mice within these experiments were weighed daily and animals 
suffering losses of greater than 15% of their weight after infection were culled.  
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In these initial experiments mice were treated with different antibiotic 
combinations before infection with C. difficile BI-7 and weight loss measured 
(2.8.1). The average weight loss of these animals is shown in Figure 3.1. To note 
only one mouse from the group treated with ABC plus clindamycin group reached 
this point and was subsequently culled 3DPI. 
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Figure 3.1; Impact of different antibiotic pre-treatments on weight loss following infection 
with C. difficile  
Mice were infected with 1x10
5 
spores of C. difficile BI-7 at D0. After infection mice were weighed 
daily during the course of the experiment and this was used as an indirect correlate of disease 
severity. Untreated mice (black), clindamycin treated (blue) and those treated with ABC (green) 
alone did not appear to lose any weight, with the average weights remaining consistent during this 
period. In contrast mice treated with both ABC and clindamycin (red) suffered from weight loss 
although some recovery was seen by day 3DPI. Error bars represent +/- SEM. (untreated n=5, 
ABC n=5, clindamycin n=10, ABC and clindamycin n=10). Significance was determined using a 
One way Anova with Tukey’s correction. The untreated, ABC and clindamycin only treated groups 
were not significantly different from each other at any point. At 1DPI the ABC and clindamycin 
treated lost significantly more weight than the untreated and ABC groups (* = p <0.05). At 2DPI the 
ABC and clindamycin treated group lost significantly more weight than all other groups (* = p 
<0.05). At 3DPI the ABC and clindamycin group had lost significantly more weight than the ABC 
treated group (* = p <0.05). 
The weight of untreated and ABC only treated mice remained stable throughout 
infection with no weight loss observed. Clindamycin treated mice lost a small 
amount of weight but this was not significant when compared with untreated 
and ABC treated mice at any time point. In contrast mice treated with the ABC 
plus clindamycin with significantly higher weight loss seen at 1DPI (compared to 
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ABC and untreated), 2DPI (all other groups) and 3DPI (ABC), with recovery at 
3DPI. 
 Shedding of Clostridium difficile in the faeces 3.2.1.2
To determine the extent of infection, shedding of C. difficile in the faeces was 
measured for 3 days post infection (DPI) (Figure 3.2). 
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Figure 3.2 Shedding of C. difficile in the faeces of mice in the first 3 days of infection 
Recovery of colony forming units (CFU) of C. difficile per gram of faeces from clindamycin treated 
(blue n=10) ABC plus clindamycin (red n=10) ABC only (green n=5) and untreated (white n=5). 
Mice treated with clindamycin alone or in conjunction with the ABC lost significantly more weight 
than those treated with the ABC alone. No organisms were recovered from the untreated mice.  
Error bars show the standard error of the mean (SEM). Significance determined using Welch’s T- 
test (* indicates p = 0.0107 and ** indicates p= 0.0074). 
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These data reveal that in contrast to untreated mice, in which no bacteria were 
recovered from the faeces, samples from those treated with clindamycin or ABC 
plus clindamycin were highly colonised with C. difficile. These levels were 
significantly higher than those detected in faeces from animals treated with ABC 
alone at 3DPI. In addition, unlike the other groups, C. difficile colonisation in 
ABC only treated mice appeared to be initially lower (two logs) and was more 
rapidly cleared than the other two groups with very low levels (103CFU/g) of 
bacteria recovered. 
 Colonisation of the caecum and colon 3.2.1.3
To determine the extent of colonisation of the gut tissue directly, mice were 
culled at 4DPI and the caecum and colon tissue harvested. The organisms were 
enumerated from either the lumen or from more intimately associated organisms 
recovered by homogenates of the tissue. The proportion of vegetative cells and 
spores were also determined as described in section 2.6.5.1 (Figure 3.3). 
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Figure 3.3 Enumeration of C. difficile in the caecum and colon of infected animals 
CFU per ml of vegetative cells (blue) and spores (red) present in the caecum and colon of A) mice treated with clindamycin only (n=10) B) Antibiotic cocktail plus 
clindamycin (n=10) and C) ABC alone (n=5). Error bars represent +/- the SEM. No bacteria were recovered from the untreated mice.  Statistical analysis was 
performed using Kruskal Wallis test with Dunn’s comparison. This found that there were significantly more vegetative cells in the associated with the tissue in the 
caecum of the mice treated with the ABC and clindamycin (p= <0.5 although the impact of this is unclear.  
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This showed that mice treated with clindamycin alone, or, with ABC and 
clindamycin were highly colonised with C. difficile in both the caecum and 
colon. There was with no difference in the colonisation between these 
treatment groups. In contrast, no bacteria were recovered from either lumen or 
the tissue from untreated mice at 4DPI. Very low numbers of vegetative bacteria 
were recovered from the caecum of animals treated with ABC alone and no 
organisms recovered from the colon.  
  
3.2.2 Effect of different treatment groups on mouse body weight 
and disease severity 
 Haematoxylin and eosin stained colon sections 3.2.2.1
To assess disease severity, tissue from the caecum and colon from mice from all 
treatment groups was additionally fixed, sectioned and stained with 
haematoxylin and eosin (H and E) to allow assessment of tissue damage.  
Representative images from sections of colon tissue are shown in Figure 3.4. 
 
 
Figure 3.4 Hemotoxylin and eosin stained colon sections from animals pre-treated with 
different antibiotic combinations.  
Tissue samples were taken 4DPI and immediately fixed in formalin. Sections were cut and H and E 
stained.  Images represent typical histology in A) untreated but infected animals, those treated with 
clindamycin alone (B) those given ABC alone (C) and those given a combination of ABC and 
clindamycin. (D). Sections at 10X magnification. Scale bar in bottom right corner shows 100μm 
  
A B 
C D 
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These images reveal that whilst minimal damage to the tissue was observed in 
mice treated with clindamycin or ABC alone, disruption was apparent in the 
colon from those treated with the ABC/clindamycin combination. This includes 
damage to the epithelial surface and blood release into the epithelial tissue.  
An alternative but effective method of assessing inflammation and tissue 
thickness can be provided by calculation of caecal index (CI). This is determined 
by assessing the proportion of the total body weight that can be attributed to 
the caeca. This was calculated for all animals using washed tissue recovered 
from animals 4DPI.   
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Figure 3.5 Caecal index of mice from different treatment groups at 4DPI 
The caecal index for each animal was calculated by determining the relative proportion of the total 
body weight that can be attributed to the washed caecum from each animal. The CI for each animal 
is represented for untreated (black n=5), clindamycin alone (blue n=10), ABC/clindamycin 
combination (red n=10) and ABC alone (green n=5). The horizontal bar represents the mean CI for 
10 animals per group. Statistical significance was determined using a one way ANOVA with 
Tukey’s correction.  Mice treated with the ABC and clindamycin had significantly higher caecal 
index than mice treated with clindamycin (** indicates p = < 00.1) or those that were untreated (*** 
indicates p < 0.0001). 
These data revealed that mice that received ABC and clindamycin showed 
significantly higher CI than untreated animals or those given clindamycin alone. 
Although there are some slight differences between the other treatment groups 
none of these were significant. Mice treated with the ABC do have slightly 
elevated CI which suggests that there may be a role for the antibiotics alone in 
increased caecum weight. Interestingly, there is a significant increase in CI in 
mice treated with ABC plus clindamycin compared to clindamycin only treated 
animals. This suggests it is a combination of the ABC and high colonisation that 
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causes this increase in caecum weight which may be an indicator of 
inflammation 
 Toxin levels in the caecum and colon 3.2.2.2
Tissue damage associated with C. difficile is largely attributed to the release 
and activity of TcdA and TcdB. Thus to determine if extent of damage could be 
attributed to differential production of toxin, luminal contents from mice were 
filtered and toxin activity measured. This was determined using a cell based 
assay using HT29 cells, which are sensitive to TcdA and Vero cells which are 
sensitive to TcdB (Figure 3.6).  Using dilutions of these samples we were able to 
semi-quantify toxin activity by assessing the dilution at which toxin activity (as 
determined by cell rounding) was absent.  
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Figure 3.6 Measurement of toxin in the caecum and colon of mice pre-treated with different 
combinations of antibiotics and infected with C. difficile  
Samples were recovered from the caecum and colon of infected mice at 4DPI and were first filtered 
to limit bacterial contamination. Toxin titres were then calculated as the reciprocal of the first 
dilution of the sample that did not cause any cell rounding of HT29 cells (A1, B1) and Vero cells 
(A2, B2) reflecting TcdA and TcdB activity respectively. Figure 3.6.A reveals the measured activity 
in the caecum of animals from all 4 treatment groups, whilst Figure 3.6.B the toxin activity in the 
equivalent colon samples. The toxin activity measured for each animal sample is represented by a 
single symbol. Horizontal bars represent the mean toxin levels and error bar +/- the SEM. ABC and 
untreated (n=5) and ABC plus clindamycin and clindamycin (n=10).  Statistical analysis was 
performed using Kruskal Wallis test with Dunn’s multiple comparisons. This found no significant 
difference between clindamycin treated and ABC and clindamycin treated. 
These data show that toxin activity was only detected in mice either pre-treated 
with clindamycin or the ABC plus clindamycin combination.  This despite the fact 
that organisms were recovered at earlier time points from animals treated with 
ABC alone. In addition, the activity observed between the two groups was 
approximately equivalent and did not correlate with the level of tissue damage 
observed in animals from these different groups. In these assays, TcdA activity 
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was relatively low compared to TcdB. This is not unusual and reflects the 
differential sensitivity of these cell types to the individual toxins. 
3.2.3 Culturable diversity of the microbiota 
As microbiome diversity is known to be a major factor in C. difficile disease, we 
sought to determine whether the variety of culturable organisms varied between 
the different treatment groups. To facilitate this assessment, samples were 
taken from 2 animals from each treatment group and cultured to determine the 
diversity of the microbiota. This assessment was based on the number of unique 
colony morphologies that could be recovered from different types of 
agar/growth conditions used. Bacteria with unique colony morphologies were 
isolated and analysed further. In total 6 agar types were used both anaerobic 
and aerobic conditions. The use of this range of media types was to increase the 
diversity of organism recovered from the samples. This included multiple media 
types for the isolation of anaerobic bacteria including WCA and FAB. Several high 
nutrient media types including LB, BHI and CBM were used to enable the 
isolation of fastidious organisms. The final media type, MRS, was to aid in the 
isolation of Lactobacillus species. The identity of individual recovered bacteria 
was confirmed by amplification and analysis of a section of the 16SrRNA gene 
sequence. Although this is a very crude measure of diversity it does show the 
influence of different antibiotics upon the culturable members of the 
microbiota. These data confirmed that the greatest diversity of organisms were 
isolated from untreated animals. In contrast, several aerobic and anaerobic 
colony types were lost from animals treated with clindamycin and the 
ABC/clindamycin combination. Animals from both treatment groups had a >50% 
reduction in the number of unique colony types present after antibiotic 
treatment. In total 18 species were identified (Table 3-1) and retained for use in 
future experiments.  
 
 
 
Chapter 3- The microbiota in disease 
 
98 
 
 
 
Table 3-1 Identification of bacteria isolated from mouse faeces  
Family Isolate Isolation conditions 
Dermacoccaceae Dermococcus Aerobic 
Enterobacteriaceae  Citrobacter 
E. fergusonii, Shigella sonnei 
or E.coli 
E. fergusonii, S. sonnei or 
E.coli 
Anaerobic 
Anaerobic 
 
Anaerobic 
 
Enterococcaceae Enterococcus faecium 
Enterococcus casseliflavus 
Enterococcus 
Enterococcus 
Aerobic 
Aerobic 
Anaerobic 
Anaerobic 
Lactobacillaceae Lactobacillus apodemi 
L. apodemi 
Aerobic 
Anaerobic 
Micrococcaceae Kocuria rhizophila 
K. rhizophila 
Micrococcus luteus 
Aerobic 
Aerobic 
Aerobic 
Pseudomonadale Enhydrobacter or Moraxella Aerobic 
Staphylococcace  Staphylococcus lentus 
Staphylococcus warneri 
S. warneri 
S. warneri 
Aerobic 
Aerobic 
Aerobic 
Aerobic 
 
3.2.4 Molecular assessment of microbiome diversity 
As not all members of the microbiome can be directly cultured, the impact of 
antibiotic pre-treatment was further assessed by the amplification and analysis 
of the V4 region of the 16s rRNA gene. To determine the temporal changes in 
bacterial species, samples were taken from all animals in each group prior to 
antibiotic treatment (D-6), following 2 days of ABC treatment (D-3), post ABC 
and pre clindamycin (D-2), post clindamycin and pre-infection (D0) and at 3DPI 
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(D3). This allowed for comparisons of community structure throughout the 
experiment. 
 
 Measurement of alpha diversity 3.2.4.1
By examining alpha diversity it is possible to determine changes in OTU diversity 
within each treatment group. This allows the impact of the different regimes on 
bacterial diversity to be determined. Here 3 measures of alpha diversity were 
used, Observed, Simpson and Shannon. The Observed diversity simply shows 
changes in the number of different OTUs present within samples but does not 
take into account the relative abundance of these individual OTUs. Both Simpson 
and Shannon measures of diversity take into account the abundance of individual 
OTUs. The effects of the different antibiotic treatments are reflected in the 
changes to alpha diversity shown in Figure 3.7.  
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Figure 3.7 Alpha diversity in the microbiota of mice from all treatment groups over antibiotic treatment and infection 
This reveals 3 different approaches to the measurement of alpha diversity following different antibiotic treatments. The Observed gives the number of OTUs present in the 
sample at each time point and only takes into account species number, both Simpson and Shannon indexes use OTU number and the abundance of OTUs (calculated 
using Phyloseq ’s plot_richness() function). Each time point is represented by a box and whisker plot showing the minimum, maximum and mean values. Comparing mice 
treated with any of the antibiotic regimes at D-5 to the same mice at D0 show significantly lower Shannon diversity indexes compared to mice before the treatment. No 
sample is available at D0 for the untreated animals but there is no difference in diversity between D-5 and D3.   
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All antibiotic treatments resulted in a decline in the number of observed OTUs 
recovered. Use of ABC alone led to a transient reduction in the observed OTU 
number with the recovery of diversity seen immediately after of antibiotic 
treatment. Animals given clindamycin alone or the ABC/clindamycin combination 
suffered from dramatic loss of diversity that persisted until 3DPI with only minor 
recovery in the observed numbers of OTUs. This suggests that the most dramatic 
and persistent changes in community structure were due to the use of 
clindamycin. 
Although useful, observed diversity does not take into account the relative 
proportion of OTUs within the microbiota so gives only a limited view. Both 
Simpson and Shannon take into account not just the number of different OTUs 
but also the relative abundance of these OTUs. A low Simpson or Shannon 
diversity measure signifies overrepresentation and unequal distribution of OTUs 
within the microbiota. In animals treated with the ABC alone there is a reduction 
in the Simpson and Shannon measures of diversity. This means that although 
there was a reduction in OTU numbers these were still fairly evenly distributed. 
However, statistical analysis of Shannon measures of diversity showed that 
treatment with the ABC results in a significant decrease in this measure (p = 
0.009). However, clindamycin treatment results in an even more dramatic 
reduction in both Simpson and Shannon measures of diversity. Clindamycin 
treatment either alone (p =1x10-7) or in conjunction with the ABC (p = 2x10-4) 
results in a significant reduction in Shannon diversity index. This significant 
reduction represents overrepresentation of a subset of OTUs. Examination of the 
Taxa plots confirms this finding as after clindamycin treatment there is a bloom 
of Enterobacteriaceae (Figure 3.10 and Figure 3.12). In both groups of animals 
receiving clindamycin the majority of the sequences identified within the sample 
belonged to OTU_1, E. coli. This highlights the importance of examining multiple 
measures of diversity when considering microbiome data as the observed 
diversity alone would not highlighted such differences. Untreated animals show 
no changes in any measure of alpha diversity in samples taken at the beginning 
and end of the experiment. Sadly, no other samples were taken during the 
course of this experiment so no information is available about changes in 
diversity at the time of infection. 
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 Measurement of beta diversity 3.2.4.2
Comparisons of alpha diversity give an indication of how the different antibiotic 
regimes alter diversity within a treatment group. However, they offer no direct 
comparison of the bacterial community structures between treatment groups. 
Unlike alpha diversity, beta diversity allows comparison between treatment 
groups rather than within treatment groups. Figure 3.8 shows PcoA plots using 
Weighted Unifrac measurement of beta diversity. Weighted Unifrac uses a 
combination of OTU abundance and phylogenetic distance to group samples. 
Before treatment at D-5 there is significant overlap between each of the 
treatment groups suggesting that the structure of each of the mouse microbiotas 
is similar at the start of the experiment. At D-3 post antibiotic treatment there 
is clear grouping of the treatment groups suggesting that there are unique 
community structures associated with each. There is significant overlap between 
animals treated with ABC plus clindamycin and clindamycin alone however there 
appears to be greater variation in animals receiving both the ABC and 
clindamycin.   
 
Chapter 3- The microbiota in disease 
 
103 
 
 
Figure 3.8 Principle Co-ordinate analysis plots of all treatment groups at D-5, D0 and D3 
Samples are grouped according to treatment groups (Untreated, purple; clindamycin alone, blue, ABC plus clindamycin combination, green and ABC alone, red) using 
mean ordination values and spread of points. At D-5, before infection and antibiotic treatment, mice from all groups overlap suggesting similar structure of the microbiota at 
the beginning of the experiment. At D0, after the different antibiotic treatments the treatment groups begin to cluster together (There is no untreated sample at this time 
point). The ABC only treated group cluster separate from the other groups. Unsurprisingly the ABC plus clindamycin and clindamycin only treated groups overlap, although 
there is more variation in the ABC plus clindamycin group. At D3 the clear groupings are still clear although clustering is less tight than seen at D0, this is likely due to 
recovery and increased diversity of the microbiota at this time point.  
Chapter 3- The microbiota in disease 
 
104 
 
3.2.5 Taxa plots of abundant OTUs 
Comparisons of both alpha and beta diversity showed significant changes in the 
abundance and diversity of species present in the microbiota (Figure 3.7 and 
Figure 3.8). To more closely examine the specific changes associated with 
individual taxa plots of the most abundant phyla at each time point were 
constructed (Figure 3.9, Figure 3.10, Figure 3.11 and Figure 3.12). These plots 
allow for easy visualisation of changes in the community structure.  
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Figure 3.9 Taxa plots of the most abundant phyla in untreated and infected mice 
Stacked bar plot of the most abundant phyla present at the start (D-5) and end (D3) of the experiment with all sampling points are displayed. Each bar plot represents an 
individual mouse denoted by the number at the base of the bar plot. Diversity and species richness remain throughout the course of the experiment. In these animals the 
most abundant phyla are represented by Firmicutes and Bacteroidetes with these phyla representing the majority of sequences recovered. Infection with C. difficile in the 
absence of antibiotic pre-treatment does not seem to have any impact the structure of the microbiota as it remains very similar to the initial sampling point. 
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Figure 3.10 Taxa plots showing the most abundant phyla identified in mice treated with Clindamycin alone 
Stacked bar plot of the most abundant phyla present at all sampling points are displayed. Each bar plot represents an individual mouse denoted by the number at the base 
of the bar plot. This reveals that clindamycin alters the community structure of the gut with a shift from a community dominated by Firmicutes and Bacteroidetes to one 
inhabited almost exclusively by Proteobacteria. Closer inspection show of this data shows that at D0 the majority of Proteobacteria sequences recovered belong to 2 OTUs 
both identified as Enterobacteriaceae. At D3 some recovery is present with an increase in the number of Firmicutes. However, a large proportion of the Firmicute 
sequences are derived from Clostridium difficile (OTU_13). 
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Figure 3.11 Taxa plot of the most abundant phyla in mice treated with ABC alone 
The 20 most abundant phyla present at all sampling points are displayed. Each bar plot represents an individual mouse denoted by the number at the base of the bar plot. 
Treatment with the ABC causes changes to the community structure with increases in the proportion of Bacteroidetes to Firmicutes. The proportions start to resolve from 
D0. Treatment with the ABC does not cause sufficient changes to the microbiota to allow infection with C. difficile. 
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Figure 3.12 Taxa plot of the most abundant phyla in mice treated with the combination of ABC and clindamycin. 
The most abundant phyla present at all sampling points are displayed. Each bar plot represents an individual mouse denoted by the number at the base of the bar plot. As 
was seen in ABC treated mice the ABC altered the ratio of Bacteroidetes to Firmicutes. Subsequent clindamycin treatment has a dramatic impact on diversity with large 
blooms of Proteobacteria. At D3 there is some recovery with decreases in the number of Proteobacteria. Closer inspection revels that a large proportion of the sequences 
at D3 are derived from Clostridium difficile (OTU_13). 
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These data reveal that whilst there is some variation between sampling points, 
the microbiota of untreated animals remained diverse (Figure 3.9). In contrast, 
animals given a single dose of clindamycin either alone or in combination with 
the ABC showed significant changes in community structure, with huge increases 
in Proteobacteria, found to represent 2 OTUs (Figure 3.10 and Figure 3.12). 
Treatment with the ABC alone results in an increase of OTUs associated with a 
higher proportion of Bacteroidetes to Firmicutes than is seen in mice before 
treatment (Figure 3.11 and Figure 3.12). In both groups in which clindamycin is 
used, OTU 13 (C. difficile) is one of the dominant OTUs present. In contrast, 
OTU 13 is not present in untreated animals or those given ABC alone, supporting 
the culture based data as C. difficile was not detected at high levels in these 
animals at 4DPI. 
Please note that the colours representing specific phyla vary on each figure 
presented. 
3.2.6 Tax4Fun assessment of metabolic potential of the 
microbiome 
Whilst OTU abundance information is useful for determining which species are 
present within a sample and can show how antibiotics influence community 
structure, it provides limited insight into the functional changes within the 
microbiome. As functional capacity is more highly conserved than community 
structure (Figure 1.10), it is likely that significant changes to this may be 
important in infection. The use of new programs that allow the functional 
capacity of the microbiome to be evaluated using just 16s data are becoming 
popular. One such bioinformatics pipeline is called Tax4fun (Abhauer et al., 
2015). Application of this method allows the metabolic potential of a sample to 
be inferred through the use of reference genomes to indicate the potential 
metabolic activity of the OTUs identified within the sample. However, as many 
of the OTUs identified within these data sets are only resolved to genus level 
there will be limitations to this method. Although there are potential issues with 
these methods they can significantly increases the usefulness of these datasets 
as it helps to identify potential metabolic changes that may be important in the 
context of colonisation and infection of C. difficile. 
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 Abundance of BSH during antibiotic treatment 3.2.6.1
Due to the importance of primary bile salts in C. difficile spore germination, 
investigation of the microbiota was initially focused on determining the impact 
of antibiotic treatment on those organisms that express BSH and 7α- 
dehydroxylase enzymes. These two enzymes are involved in bile metabolism and 
have been proposed as potentially important enzymes in colonisation resistance 
due to their ability to modify BAs (1.3.2). Attempts were made to measure the 
abundance of both BSH and 7α-dehydroxylation enzymes within the Tax4fun 
datasets in the different treatment groups. The 7α-dehydroxylase enzymes were 
not found within the data sets although this is most likely due to poor annotation 
of these enzymes in reference genomes rather than actual absence. The 
abundance of BSH enzymes before and after antibiotic treatment was initially 
determined using data generated from Tax4fun analysis. As BSH are the first 
enzyme to act upon BAs during modification they were used as a proxy for the 
presence or absence of the pathway as these enzymes have to act to enable 
further BA modification (Figure 3.13). 
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Figure 3.13 Tax4fun assessment of BSH abundance in mice from different treatment groups 
Kruskal-Walis test was used to compare the abundance of BSH in the microbiome before and after 
antibiotic treatment. A) In untreated animals there was no change in the abundance of these 
enzymes. B) After clindamycin treatment there was a significant decrease (p= 5.9e-5) in BSH 
abundance. C) In ABC plus clindamycin animals there was a decrease after clindamycin treatment 
but this is not significant. D) In animals treated with the ABC alone there was a significant (p= 
0.048) increase in BSH abundance. 
Using this approach, it was observed that BSH producing species showed 
significantly lower representation after use of clindamycin. Animals treated with 
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the ABC/clindamycin combination also have the same decrease after 
clindamycin is administered, although this is not significant. Use of the ABC 
alone results in an increase in the abundance of BSH enzymes which may explain 
why animals given this treatment were only transiently colonised. Untreated 
animals have no change in the abundance of BSH suggesting that this function is 
normally stable within the microbiome. 
3.2.7 Impact of antibiotic treatment on presence of BSH enzymes 
and bile metabolism  
As Tax4fun analysis showed significant changes to the abundance of BSH 
enzymes within the different antibiotic treatment groups (Figure 3.13) we used 
PCR amplification to determine if these enzymes could be directly detected in 
the microbiome of animals. As the BSH genes from different bacterial species 
have very divergent nucleotide sequences, CODEHOP primers that allow for the 
amplification of multiple BSH genes using one set of primers were used. The 
primers used to investigate these enzymes were designed in this manner and 
were a kind gift from Prof Julian Marchesi (CU) (Figure 3.14). 
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Figure 3.14 Detection of BSH genes in the microbiome of mice treated with different 
antibiotic regimens 
BSH sequences were amplified using specific primers from microbiome samples collected from 
animals subject to different antibiotic treatment. Timing of ABC and clindamycin treatment is 
indicated in the figure. Each gel represents the typical amplified bands from untreated animals (A), 
those treated with clindamycin alone (B) those treated with a combination of ABC and clindamycin 
(C) and those given ABC alone (D). 
The PCR results from this analysis confirmed that BSH genes could be amplified 
in all samples taken from untreated animals.  Similarly, BSH could also be 
amplified in samples taken from animals treated with ABC. Conversely, there 
appeared to be a loss of BSH producing bacteria following treatment with 
clindamycin, either when used alone or in combination with ABC. Interestingly, 
animals in which the BSH genes could not be amplified were highly colonised 
whilst those in which BSH were detected were only transiently colonised (ABC) 
or not colonised at all (untreated group). These results support the initial 
Tax4fun analysis approach giving confidence to this approach in inferring 
metabolic potential. This additionally supports the idea that clindamycin is 
responsible for the loss of colonisation resistance and that this is mediated in 
part by bacteria involved in bile metabolism. 
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3.2.8 TOF-MS analysis of bile salts in the caecum 
BSH activity represents the gateway reaction in BA metabolism with 
deconjugation of the amino acid allowing for further modification. As both the 
PCR amplification and Tax4fun analysis revealed that clindamycin treatment 
reduced BSH abundance, we wished to determine if these changes correlated 
with changes in the abundance of primary bile salts in the gut. This was 
evaluated using time of TOF-MS analysis on caecal content samples from all 
groups taken at 4DPI. The relative abundance of TC to DCA was then compared 
and revealed that higher levels of TC were present in their caeca of animals 
treated with clindamycin (either alone or in combination with ABC). In contrast, 
untreated animals had higher levels of deoxycholic acid in these samples (Figure 
3.15-A, B). Direct comparison of samples from clindamycin only or ABC plus 
clindamycin showed no differences in the abundance of these bile salts (Figure 
3.15-C). Investigation of the abundance of specific BAs in ABC only treated 
animals is underway but the data has not yet been received.  
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Figure 3.15 Scatter plots of PLS-DA of faecal ions from mice in different treatment groups 
Each point represents a single faecal ion with ions identified as TC and DCA labelled. The p(corr)[1] p values show the differences between the groups and the p[1] 
values represent the abundance of ions A) Comparison of untreated animals and those given clindamycin. B) Comparison of untreated animals and those given ABC 
plus clindamycin C) Comparison of animals given clindamycin alone or ABC plus clindamycin. Clindamycin treatment, either alone or with ABC resulted in significantly 
higher levels of TC compared to untreated mice. Untreated mice had significantly higher levels of DCA compared to both clindamycin and ABC plus clindamycin 
treated animals. Clindamycin treated and ABC plus clindamycin treated animals showed no difference in the abundance of TC or DCA. 
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These data suggest that clindamycin treatment results in a loss of bacterial bile 
metabolism from the microbiome and that BSH can be used as a marker of this 
change. Comparison of DCA and TC abundance between clindamycin treated and 
ABC/clindamycin treated mice did not show any differences so it may be that 
whilst bile metabolism is important in colonisation resistance, it does not 
explain the enhanced tissue damage and weight loss observed when animals are 
given a combination of ABC and clindamycin. 
3.2.9 Comparison of community structure before and after 
clindamycin treatment 
To determine how the different antibiotic treatments may impact upon the 
microbiome it is important to compare the structure of the microbiota before 
and after the different treatments. Such comparison of the community structure 
before and after treatment with clindamycin showed that 120 OTUs were 
significantly altered in abundance by use of this antibiotic. In total, 8 OTUs 
(Table 3-2) were found to be increased after clindamycin with 102 significantly 
reduced (Table 3-3).  
Table 3-2; Comparatively increased OTUs following  clindamycin treatment 
DESeqDataSetFromMatrix() function from DESeq package with a significance value cut-off of 
0.001. This allows negative binomial GLM fitting and Wald statistics. Multiple testing corrections 
using (Benjamini and Hochberg 1995) to reduce false discovery rate. 
OTU Adjusted P value 
OTU_1 Escherichia coli 4.3031e−237 
OTU_21 Enterobacteriaceae 2.2604e−20 
OTU_233 Lactococcus 1.1169e−16 
OTU_558 Enterobacteriaceae 1.0536e−11 
OTU_547 Escherichia/Shigella 2.4532e−10 
OTU_600 Escherichia/Shigella 2.7872e−09 
OTU_781 Escherichia/Shigella 7.5277e−09 
OTU_460 Mannheimia 5.1012e−07 
 
Of the 8 increased OTUs there are 3 that are identified as Escherichia/Shigella 
(OTU 547, 600 and 781). In addition to this OTU_1, E. coli, is shown to be the 
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most significantly increased confirming the bloom of Enterobacteriaceae 
following clindamycin treatment that was identified in the Taxa plots.  
In total 102 OTUs were decreased after clindamycin treatment. For simplicity 
these have been assigned to bacterial families as several were represented by 
multiple OTUs. 
Table 3-3; Comparatively decreased OTUs following clindamycin treatment  
DESeqDataSetFromMatrix() function from DESeq package with a significance value cut-off of 
0.001. This allows negative binomial GLM fitting and Wald statistics. Multiple testing corrections 
using (Benjamini and Hochberg 1995) to reduce false discovery rate. 
OTU Adjusted P value 
5 Bacteroidales 4.6671e−20 - 4.6216e−05 
18 Porphyromonadaceae 9.8556e−15 - 4.7587e−05 
2 Flavonifractor 1.1115e−11 - 5.1202e−05 
OTU_92 Clostridium_XlVb 2.8024e−11 
45 Lachnospiraceae 2.6526e−10 - 8.8107e−05 
3 Oscillibacter 9.4232e−11 - 2.4789e−06 
5 Barnesiella 2.751e−10 - 3.6031e−06 
10 Ruminococcaceae 6.1919e−10 - 7.2647e−06 
10 Clostridiales 1.6439e−09 - 9.9022e−05 
2 Bacteroidetes 2.7872e−09 - 1.9396e−06 
OTU_50 Alistipes 1.1706e−08 
OTU_18 Prevotellaceae 4.7381e−08 
OTU_183 Clostridia 9.4571e−08 
3 Unclassified Bacteria 4.8608e−07 - 1.4466e−05 
OTU_44 Bacteroides acidifaciens 1.0783e−06 
OTU_69 Clostridium_XIVa 2.477e−06 
2 Odoribacter 7.1769e−06 - 6.1494e−05 
OTU_5 Allobaculum 9.1968e−06 
 
Large numbers of OTUs were significantly decreased after clindamycin treatment 
which would be expected as it is a broad spectrum antibiotic. Closer observation 
of this data shows that huge numbers of the OTUs belong to the class of bacteria 
identified as Clostridia. This includes OTUs assigned as Lachnospiraceae, with 
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this family of bacteria the most affected by clindamycin treatment with 45 OTUs 
decreased after clindamycin treatment. Multiple Bacteroidetes were also 
decreased including OTU_44 Bacteroides acidifaciens, a known BSH producer. 
Other strains known to produce BSHs that were impacted were members of the 
Clostridia and Clostridiales. Specifically there was a decrease in OTU_69 a 
Clostridium XIVa, species in this cluster are known to produce 7α-dehydroxylase, 
suggesting that these enzymes may also be lost from the microbiome post 
clindamycin. A combination of microbiome, PCR, TOF-MS and Tax4fun data 
suggest that bacteria involved in bile metabolism are important in mediating 
colonisation resistance. 
3.2.10 Comparison of significantly altered OTUs in 
colonisation and severe model 
Although important in colonisation resistance, changes in BA metabolism seem to 
play no role in differences in disease severity. However, modification of the 
flora may be responsible by altering other functions that contribute to gut 
health. To determine if these changes contribute to disease severity, the 
organisms identified in samples from clindamycin alone and ABC plus 
clindamycin treated animals were compared. This revealed that 34 OTUs were 
significantly different between the two treatment groups, with 24 (Table 3-4)  
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Table 3-4; Comparative increased OTUs in ABC plus clindamycin treatment group  
DESeqDataSetFromMatrix() function from DESeq package with a significance value cut-off of 
0.001. This allows negative binomial GLM fitting and Wald statistics. Multiple testing corrections 
using Benjamini Hochberg. 
OTU Adjusted P value 
OTU_780 Parabacteroides 1.77E-18 
OTU_ 11 Parabacteroides goldsteinii 2.55E-18 
OTU_ 3 Parabacteroides distasonis 2.51E-15 
OTU_ 2 Bacteroides thetaiotaomicron 1.76E-14 
OTU_ 784  Parabacteroides 9.94E-14 
OTU_772 Parabacteroides 3.52E-13 
OTU_34 Firmicutes 1.18E-10 
OTU_812 Parabacteroides 2.92E-09 
OTU_ 22 Erysipelotrichaceae bacterium Alo17 7.83E-09 
OTU_850 Parabacteroides 2.63E-08 
OTU_468 Bacteroides 2.92E-08 
OTU_24 Bacteroides intestinalis 3.07E-08 
OTU_7 Enterococcus 1.15E-07 
OTU_5 Allobaculum 1.25E-07 
OTU_10 Barnesiella 3.44E-07 
OTU_122 Unclassified bacteria 2.04E-05 
OTU_40 Porphyromonadaceae 2.04E-05 
OTU_17 Burkholderiales 2.65E-05 
OTU_733 Parabacteroides distasonis 3.91E-05 
OTU_755 Parabacteroides 3.95E-05 
OTU_750 Parabacteroides 5.14E-05 
OTU_734 Parabacteroides 5.25E-05 
OTU_756 Parabacteroides 8.68E-05 
OTU_ 64 Betaproteobacteria 9.65E-05 
 
OTUs found to be decreased in the ABC plus clindamycin treatment group 
compared to the clindamycin alone group with 10 OTUs reduced (Table 3-5). 
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Table 3-5; Comparatively decreased OTUs in ABC plus clindamycin treatment group 
DESeqDataSetFromMatrix() function from DESeq package with a significance value cut-off of 
0.001. This allows negative binomial GLM fitting and Wald statistics. Multiple testing corrections 
using Benjamini Hochberg. 
OTU Adjusted P value 
OTU_15 Lactobacillus johnsonii 7.87E-32 
OTU_ 36 Porphyromonadaceae 8.14E-12 
OTU_223 Lactococcus 2.37E-11 
OTU_21 Enterobacteriaceae 2.31E-10 
OTU_45 Lactobacillus intestinalis 2.92E-09 
OTU_91 Mucispirillum schaedleri 2.92E-09 
OTU_181 Enterorhabdus mucosicola 1.24E-05 
OTU_53 Porphyromonadaceae 2.60E-05 
OTU_47 Odoribacter 3.95E-05 
OTU_88 Lachnospiraceae 5.0929e−05 
 
In the severe disease model half of the 24 significantly altered OTUs were 
assigned to Parabacteroides. This included Parabacteroides goldsteinii (OTU_11) 
and Parabacteroides distasonis (OTU_3). Additionally there was an increase in 
OTU_2 identified as Bacteroides thetaiotaomicron a specialised mucin degrader. 
Interestingly there was a decrease in two other mucus dwelling species OTU_91, 
Mucispirillum schaedleri, and OTU_181, Enterorhabdus mucosicola. This suggests 
that ABC may somehow alter mucus homeostasis.  
3.2.11 The impact of antibiotic treatments on the functional 
capacity of the microbiota 
 Significantly altered KEGG pathways 3.2.11.1
Comparison of the metabolic potential of the microbiota between the 
clindamycin and ABC/clindamycin treatment groups provides an opportunity to 
associate specific metabolic functions with disease severity. Using Tax4fun we 
were able to map the majority of OTUs to KEGG metabolic pathways with 
significant differences between the clindamycin only and ABC plus clindamycin 
identified. In total 20 KEGG functions were significantly altered between the 
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two treatment groups with 14 functions increased (Table 3-6) and 6 decreased 
(Table 3-7) in the ABC plus clindamycin group.  
Table 3-6; KEGG functions that are significantly higher in the ABC plus Clindamycin 
compared to clindamycin alone 
Significantly altered pathways determined using a Kruskal-Wallis test with Benjamini Hochberg 
correction for multiple testing. Adjusted P values reported 
KEGG Information Adjusted P value 
K02014; iron complex outer membrane receptor protein 0.045117 
K03296; hydrophobic/amphiphilic exporter−1 (mainly G− 
bacteria), HAE1 family 
0.045117 
K02004; putative ABC transport system permease protein 0.045117 
K16089; outer membrane receptor for ferrienterochelin and 
colicins 
0.045117 
K01190; beta−galactosidase [EC:3.2.1.23] 0.045117 
K05349; beta−glucosidase [EC:3.2.1.21] 0.045117 
K07085; putative transport protein 0.045117 
K03737; putative pyruvate−flavodoxin oxidoreductase 
[EC:1.2.7.−] 
0.045117 
K03088; RNA polymerase sigma−70 factor, ECF subfamily 0.045117 
K01187; alpha−glucosidase [EC:3.2.1.20] 0.045117 
K03585; membrane fusion protein 0.045117 
K03654; ATP−dependent DNA helicase RecQ [EC:3.6.4.12] 0.045117 
K03169; DNA topoisomerase III [EC:5.99.1.2] 0.045117 
K01897; long−chain acyl−CoA synthetase [EC:6.2.1.3] 0.045117 
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Table 3-7; KEGG functions that are significantly lower in the ABC plus clindamycin 
compared to clindamycin alone 
Significantly altered pathways determined using a Kruskal-Wallis test with Benjamini Hochberg 
correction for multiple testing. Adjusted P values reported.  
KEGG Information Adjusted P value 
K00123; formate dehydrogenase, alpha subunit [EC:1.2.1.2] 0.045117 
K01752; L−serine dehydratase [EC:4.3.1.17] 0.045117 
K01581; ornithine decarboxylase [EC:4.1.1.17] 0.045117 
K15580; oligopeptide transport system substrate−binding 
protein 
0.045117 
K07258; D−alanyl−D−alanine carboxypeptidase 
(penicillin−binding protein 5/6) [EC:3.4.16.4] 
0.045117 
K07306; anaerobic dimethyl sulfoxide reductase subunit A 
[EC:1.8.5.3] 
0.045117 
 
Significantly altered KEGG functions include potential mucus degrading and 
utilising enzymes; beta−galactosidase, beta-glucosidase and alpha-glucosidase. 
This data is in agreement with the inferred increase in the mucin degrader B. 
thetaiotaomicron identified in the microbiome data and may represent a 
disruption of mucus homeostasis. In addition to these changes, there is also an 
upregulation of multiple transport proteins that may be involved in nutrient 
uptake, iron uptake and antibiotic efflux. This reflects adaptation of the 
resident microbiota to the niche created by the antibiotic treatment. 
Differences in inferred KEGG functionality between the clindamycin alone and 
ABC plus clindamycin group highlight the significant impact such treatments can 
have on nutrient and metabolite availability.   
It is possible to use additional analysis techniques to determine the importance 
of specific metabolic functions in placing an animal into the treatment group it 
originated from. By doing this is it possible to determine if it is possible to use 
the changes identified to sort the samples into the correct groups. Using a 
Random Forest Classifier (RFC) it is possible to determine which metabolic 
functions identified by Tax4fun are important in classifying samples into the 
different antibiotic treatment groups. The plot shown in Figure 3.16 shows the 
mean decrease accuracy, which ranks the variables in order of importance in 
classifying a sample into its treatment groups. So the higher up the ranking the 
variable the more important it is in helping to classify samples. Figure 3.16 
shows the 20 significantly altered KEGG pathways between the clindamycin 
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alone and ABC/clindamycin groups ranked in order of importance in placing 
samples into the ABC/clindamycin treatment group.  
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Figure 3.16 Use of Random Forest Classifier on Tax4fun data to determine which metabolic functions correlate with different antibiotic regimes 
Metabolic functions that classify samples between ABC plus clindamycin and clindamycin only groups. Variables are ranked in order of importance in helping to correctly 
classify samples . Importance of variables calculated using randomForest() function. The higher the mean decrease accuracy score the more important the variable is in 
helping group the samples. 
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The mean decrease accuracy (Figure 3.16) shows that the 20 KEGG functions 
identified in tables 3-5 and 3-6 are sufficient to separate the ABC plus 
clindamycin from the clindamycin only treated mice. Use of this information can 
be successfully used to sort these samples into the correct treatment groups 
using a RFC (Figure 3.17).  
 
Figure 3.17 Confusion matrix showing grouping of microbiome samples into treatment 
groups 
The Random Forest Classifier is able to successfully group all of the samples into the treatment 
groups. 
Analysis of the OTUs present and the functions of these OTUs show that there 
are both structural and metabolic differences between the clindamycin only and 
ABC plus clindamycin treated animals. These differences have potentially 
important roles modulating disease severity and warrant further investigation. 
For example beta-glucosidase activity is ranked as the second most important 
variable in distinguishing mice from the clindamycin only group to the ABC plus 
clindamycin group. This suggests that further investigation of mucin degradation 
and homeostasis may be beneficial in increasing our understanding of disease. 
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 Discussion 3.3
3.3.1 Infection Outcome 
In this study analysis of how different antibiotic pre-treatments alter 
colonisation resistance and disease outcome were studied. As described in 
section 2.8.1, mouse models were established to ensure that the outcome of 
infection mirrored that previously reported in the literature including significant 
weight loss after infection and damage to tissue (Chen et al.,2008; Collins et al., 
2015; Sun et al.,2011). The mortality rate seen here was lower than in some of 
these studies; however as these studies often used the high toxin producer VPI 
10463 this may provide an explanation for the differences observed. Additionally 
it has been noted that different C. difficile strains have varying levels of 
virulence in the mouse model (Theriot et al., 2011). It has recently been shown 
by Collins et al., (2015) that severity can be increased further by extending the 
duration of the ABC to 5 days. It has been previously shown that the inclusion of 
metronidazole in drinking water results in a bitter and unpleasant taste, 
reducing the consumption of water by the mice (Hou et al., 2007). This may 
mean that the dosage is not as high as expected which may explain why the ABC 
alone is not able to render the mice susceptible to infection and why the 
Simpson and Shannon diversity remains high. To ameliorate this some studies 
include a sweetener in the water when delivering antibiotics to encourage 
consumption. 
In brief, in our experiments animals treated with clindamycin alone were 
colonised, with little weight loss or damage to tissue. In contrast animals treated 
with the ABC plus clindamycin combination suffered from significantly more 
weight loss, had significantly higher CIs and with epithelial damage present in 
tissue samples. Untreated but infected animals were not colonised, whilst those 
given ABC alone were only transiently colonised with very low numbers of C. 
difficile detectable 4 DPI, reflected in by both shedding and microbiome data.  
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3.3.2 Impact of the different treatment regimens on microbiome 
structure 
Treatment with clindamycin had the biggest impact on the structure of the 
microbiome, with a bloom of Enterobacteriaceae observed in both groups 
treated with this antibiotic. Interestingly, the majority of the organisms 
recovered at D0 belonged to 2 OTUs from this phylum, one of which was E.  coli. 
This bloom in Enterobacteriaceae is well documented in the literature and is 
commonly reported to be a consequence of antibiotic treatment in animals and 
people (Peniche et al., 2013; Rea et al.,2012; Reeves et al., 2011). 
3.3.3 Clindamycin results in loss of colonisation resistance 
In these experiments significant C. difficile colonisation was restricted to 
animals treated with clindamycin or ABC plus clindamycin. Mice treated with 
ABC alone were only transiently colonised suggesting that clindamycin removes 
those species that influence C. difficile persistence. In this work attention was 
focused on BSH enzymes, which act as the gateway reaction in bile metabolism. 
Tax4fun analysis supported this hypothesis by revealing that relative abundance 
of BSH enzymes was reduced in animals that became highly colonised with C. 
difficile. Amplification of BSH genes by PCR confirmed the loss of organisms 
expressing BSH after clindamycin treatment, which in turn was associated with 
long term colonisation. Untreated animals and those given ABC only retained 
these enzymes as part of the flora, and either did not become colonised or were 
only transiently affected suggesting rapid recovery of the microbiota. 
Additionally TOF-MS analysis of filtered caecum samples 4DPI revealed an 
increase in TC compared to untreated animals. This decrease in the abundance 
of BSH during C. difficile infection has recently been demonstrated in patients 
with recurrent infection with decreases in 10 OTUs accounting for a 67.3% 
decrease in BSH abundance in these patients compared to controls (Allegretti et 
al., 2016). 
Another important process in this pathway is the multistep 7α-dehydroxylation 
pathway. Attempts to determine the abundance of the baiCD gene from this 
pathway using PCR and Tax4fun were unsuccessful. This may be because this 
pathway is much less abundant and restricted to a few members of the 
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microbiota, thus making detection in databases and amplification more difficult. 
Members of the Clostridium XIVa cluster are known to carry out this function. 
OTU_69, one member of this cluster, was significantly decreased after 
clindamycin treatment indirectly suggesting a potential decrease in this 
function. Loss of this OTU cluster has been associated with reduced colonisation 
resistance to C. difficile and has been described in previous studies (Collins et 
al.,2015). A recent study showed that a single bacterium from this cluster, C. 
scindens, was able to reduce C. difficile disease severity in mice as a 
consequence of DCA production (Buffie et al.,2014). Further experiments to 
validate this observation including the creation and testing of an isogenic C. 
scindens strain in which this gene is deleted are needed. Interestingly the use of 
C. scindens did not confer full protection, suggesting other members of the flora 
play a role in protection. Previously, BSH producing bacteria have been shown to 
restore 7α-dehydroxylase function to the microbiota, even though these bacteria 
do not harbour these enzymes. This is thought to reflect selection pressure 
created by the high concentration of CA, encouraging bacteria that are able to 
detoxify it to bloom (Gustafsson et al.,1998). Additionally the 7α-dehydroxylase 
enzymes are unable to act on conjugated bile salts, with upstream 
deconjugation by BSH required for these enzymes to function. This suggests that 
restoration of both functions may be required for colonisation resistance to be 
restored (Batta et al., 1990). Furthermore, the reduction of taurine to H2S has 
been found to be an essential substrate for 7α-dehydroxylase producing 
bacteria, suggesting that these bacterial populations interact with each other in 
vivo (Van Eldere et al.,1996). These studies show the importance of 
understanding bacterial interactions as multiple pathways are intertwined with 
production of some metabolic products directly influencing other functions in 
the gut.  
It is clear that bacterial bile metabolism plays an important role in colonisation 
resistance but does not appear to be involved with increase severity. The work 
presented here suggests that BSH might be a good biomarker of bile metabolism 
which could indicate potential susceptibility to C. difficile colonisation. 
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3.3.4 The microbiome impacts upon disease severity 
From our data, it would appear that disease severity is not pathogen driven as 
there were no significant differences in colonisation and toxin levels between 
clindamycin alone or the ABC plus clindamycin combination. However, there 
were significant differences in weight loss, CI and differences in damage to the 
guts of infected animals. Therefore additional severity may be due to the impact 
of the different antibiotic regimes on the microbiota. ABC treatment results in 
an increase in B. thetaiotaomicron a specialised mucin degrader with large 
portions of the its genome dedicated to utilising mucin (Martens et al., 2009). An 
increase in B. thetaiotaomicron suggests that treatment with ABC may result in 
an increase in mucin degradation activity. Further investigation of Tax4fun data 
showed that increase in enzymes involved in mucin degradation were important 
in classifying mice from the severe group from those in which only colonisation 
was observed. However, as explained previously, the majority of OTUs could not 
be resolved to species level. This could potentially impact the ability of Tax4fun 
to accurately infer the metabolic potential. For this reason it would be useful to 
experimentally investigate changes in the abundance of mucin degrading 
enzymes. This could be done using reverse transcription PCR or by directly 
measuring the activity of these enzymes in the faecal samples of mice that have 
been treated with the ABC. 
Previous studies have shown that B. thetaiotaomicron facilitates C. difficile 
infection in mice through the production of succinate which can be utilised as a 
carbon source by C. difficile promoting expansion of the organism in the colon 
(Curtis et al., 2014; Ferreyra et al.,2014). Increased degradation of mucus leads 
to a spike in free sialic acid which can then be utilised by C. difficile (Ng et al., 
2013). Interestingly an increase in the abundance of mucosal bacteria has been 
found in patients in patients with IBD and is associated with more severe 
inflammation (Swidsinski et al., 2002). The impact of mucin degraders in this 
context is interesting as many organisms have previously been described as being 
beneficial organisms within the microbiome. For example, B. thetaiotaomicron 
has been shown to aid development of the postnatal gut (Xu & Gordon, 2003) 
and facilitate angiogenesis in the intestine (Stappenbeck et al., 2002). This 
highlights how the influence of a particular organism can vary depending on 
individual circumstances.  
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The observed increase in mucin degraders seems to correlate with a loss of other 
mucus dwelling species. This most likely reflects disruption of mucus layer 
homeostasis with an increase in mucus degraders likely to disrupt the stable 
mucus layer, potentially reducing mucus thickness or preventing proper 
formation of the mucus layer. In mono associated rats B. thetaiotaomicron has 
been shown to increase goblet cell differentiation and expression of mucus 
related genes. This was ameliorated by administering the mice Faecalibacterium 
prausnitzii which then restored homeostasis of this system (Wrzosek et al., 
2013). This suggests that F. prausnitzii may have some therapeutic potential, 
mediated by the restoration of mucus layer homeostasis and further 
investigation of this is warranted. It may be that in these mice there is increased 
mucus production which may prevent proper formation of the protective mucus 
layer. Interestingly, it was noted during the experiments that animals treated 
with the ABC had large quantities of mucus in their faeces. Additionally, 
disruption is supported by the observation that there is a significant decrease in 
two mucus dwelling species M. schaedleri and E. mucosicola following ABC plus 
clindamycin treatment. Such a change in mucus structure may allow C. difficile 
greater access to the epithelia resulting in more direct delivery of toxins, 
leading to increased weight loss and tissue damage. Dysregulation of the mucus 
layer may also mean greater activation of innate inflammatory responses 
through activation of TLR’s on epithelial cell surfaces by bacterial antigens 
(Figure 3.18). 
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Figure 3.18 Potential impact of the microbiota on mucus thickness 
The mucus is made up of two distinct layers the inner mucus layer (IML) and the outer mucus layer 
(OML). Increases in mucin degraders may result in a decrease in mucus layer thickness and 
stability allowing C. difficile cells and toxin to better access to the epithelial cell surface.  
In addition to alterations in the abundance of mucus associated bacteria there 
were alterations in the number of Parabacteroides. Of the 24 OTUs significantly 
altered between the two disease models 12 belong to the Parabacteroides. This 
includes P. goldsteinii and P. distasonis which have the potential to invade 
epithelial cells so may also increase disease severity (Nakano et al., 2008). It has 
also been found that mice with increased numbers of Parabacteroides and 
Bacteroides have a more diffuse mucus layer (Jakobsson et al., 2015) which may 
explain the increased quantity of mucus in the faeces of these mice. Increases in 
Parabacteroides have been associated with super shedding mice (Lawley et al., 
2012) and also significantly associated with mice that succumb to C. difficile 
infection (Collins et al., 2015). Similarly increases in Parabacteroides have been 
noted in humans infected with C. difficile suggesting a role for these bacteria in 
both mouse and human infection (Chang et al., 2008; Rea et al., 2012; Rea et 
al., 2013).  
This study suggests that both colonisation resistance and disease severity are 
modulated by the microbiota and can be altered by the antibiotics used before 
infection. The antibiotic regimes used in these experiments impact the 
microbiota in different ways, leading to changes in microbial diversity that alter 
metabolism. These alterations can favour pathogenesis by changing the 
availability of substrates that C. difficile can utilise and additionally by creating 
an environment primed for damage and inflammation. Knowledge of which 
antibiotics destroy bacteria involved in bile modification or alter mucus 
structure may be useful when prescribing to vulnerable patients. This data also 
offers the opportunity to use these microbial genes as markers of disease 
susceptibility. BSH in this study serve as a good marker for healthy bile 
metabolism in the gut, and could be used to highlight susceptibility to infection. 
Additionally increased proportions of mucus degrading enzymes seem to be a 
good indicator of disease vulnerability and it will be interesting to see if over 
representation of enzymes could predict onset of more severe disease in a 
clinical setting. 
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The work undertaken in this chapter has shown the importance of the microbiota 
in both colonisation resistance and disease severity. Severity seems to be 
mediated by an increase in invasive bacterial species and disruption of mucus 
homeostasis whereas colonisation resistance is controlled by changes to bacterial 
bile metabolism. Chapter 4 will focus on the ability of BSH to modify the 
efficiency of C. difficile spore germination in vitro and in vivo. 
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4 Inhibition of germination by Bile Salt Hydrolase 
producing strains 
 Introduction 4.1
In the previous chapter, a link between BA metabolism and resistance to C. 
difficile colonisation was established. These data, together with that presented 
in the literature, indicate that in particular loss of bacteria expressing BSH 
enzymes correlates with decreased colonisation resistance. This is because BSH 
producing bacteria modify BAs and open them up to further modification 
including dehydroxylation. Such modifications potentially limit the availability of 
TC to induce spore germination (1.3.2). Although this link has been alluded to in 
many publications, the capacity of the individual bacteria producing these 
enzymes to limit C. difficile spore germination has not been investigated 
formally. If such a link could be made, it would provide significant justification 
to the instillation of such bacteria therapeutically and would support the use of 
defined bacteria in colonic replacement therapies rather than the undefined 
mixtures used currently in faecal transplants. 
In this chapter, the isolation and characterisation of several BSH producing 
bacteria is described. Their capacity to inhibit germination and outgrowth of C. 
difficile in vitro and in vivo was also determined.  
  Results 4.2
4.2.1 The impact of incubation with different bile salts on spore 
germination and growth 
It has been suggested that modification of BA by intestinal bacteria from primary 
BA (TC) to secondary BA (CA and DCA) reduces the capacity of C. difficile to 
germinate and grow. To confirm this observation, C. difficile spores were 
exposed to different BAs and the growth within the culture observed. Spores 
were added to BHI with and without the addition of 0.1% TC, 0.1% CA or 0.1% 
DCA. Growth was determined by changes in OD600 of the culture with samples 
taken for OD measurements every 3 hours for 12 hours and finally at 24 hours. 
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Using this approach we determined if incubation with different BAs had any 
impact on the time taken for spores to germinate and grow (Figure 4.1).  
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Figure 4.1 Growth of C. difficile BI-7 spores after exposure to different bile salts 
Germination and growth of C. difficile in BHI broth alone (Black), BHI supplemented with 0.1% TC 
(Dark blue), CA (Light blue), and DCA (red). Spores incubated with TC had reached significantly 
higher ODs than all spores in all other growth conditions at 9 (** indicates p = < 0.01) and 12 hours 
(*** indicates p < 0.0001). At 24 hours spores from all growth conditions reached significantly high 
ODs than those incubated with DCA (*** indicates p = <0.0001). Additionally spores grown in BHI 
alone reached significantly higher ODs than those grown with CA or TC (** indicates p = 0.01). 
Error bars represent +/- the SEM of 3 biological replicates. Significance was determined using 
ANOVA with Tukey’s post-test. 
 
Incubation of spores in BHI with 0.1% TC resulted in rapid germination and 
growth of the bacteria with increases in OD observed from 6 hours post 
inoculation and significant differences in growth recorded at 9 (p = <0.01) and 12 
hours (p= <0.0001). Growth reached stationary phase by 12 hours. In contrast no 
growth was observed within the first 12h when the spores were inoculated into 
BHI alone or BHI containing CA. This suggests that TC plays an active role in 
stimulating efficient spore germination. Inclusion of additional time points 
between 12-24 hours would have further helped to determine more precisely 
whether CA had any impact on germination. As expected, spores incubated with 
DCA did not germinate or outgrow within the 24 hour time period measured with 
the OD in this group significantly lower (p = < 0.0001) than those observed at 24 
hours for all other growth conditions.  As DCA is known to be a potent inhibitor 
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of C. difficile growth this is the outcome that was expected. The OD of cultures 
grown with TC or CA were significantly lower at 24 hours than those grown in BHI 
alone (p = < 0.01), suggesting some inhibition of growth by these BAs. These 
results suggest that germination and vegetative growth are most efficient after 
exposure to TC and reflect the huge differences that individual BAs appear to 
have on rates differential effects on germination and subsequent growth of the 
organism. 
4.2.2 Detection of BSH activity in bacteria isolated from the 
mouse gut 
As bacteria alone help to modify BAs, bacteria expressing BSH were chosen for 
further investigation. In chapter 3, several different species of bacteria were 
isolated from the colon of mice (Table 3-1). The exact identity of these strains 
was confirmed by sequencing the V4 variable region within the 16s rRNA gene. 
Subsequent analysis of the microbiome confirmed that clindamycin treatment of 
these animals resulted in a reduction of many of these bacteria.  
A plate based assay was used to identify bacteria possessing BSH activity. This 
activity was determined by the precipitation of deconjugated BAs into the media 
resulting in the formation of white granular colonies. As TC is the most potent 
inducer of germination, strains were tested for their ability to deconjugate TC 
into CA. Of the 18 strains originally isolated, 5 were able to successfully to 
deconjugate TC to CA. This included a number of isolates identified as 
Staphylococcal species (Table 4-1). 
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Table 4-1 BSH activity against TC in strains isolated from the mouse gut 
Isolate LB LB + TC (0.5%) 
S. warnei 
 
 
 
  
S. warnei 
 
 
 
  
S. warnei 
 
 
 
  
S. lentus 
 
 
 
  
4.2.3 Impact of other BSH producing bacteria on C. difficile spore 
germination 
To determine if BSH activity and its subsequent modification of TC affected 
spore germination the following experiment was performed. In brief, bacteria 
were grown in BHI containing 0.1% TC for 24 hours. The organisms were then 
removed by centrifugation and the media was filtered sterilised. This filtered 
material was then tested to determine if it influenced the efficient germination 
of C. difficile spores. Of these strains, 8/18 different bacterial isolates were 
able to inhibit C. difficile BI-7 spore germination (Table 4-2). 
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Table 4-2 Ability of different bacterial strains to inhibit spore germination 
Family Organism Inhibition of 
germination 
Dermacoccaceae Dermococcus - 
Enterobacteriaceae Citrobacter 
Escherichia fergusonii 
Shigella sonnei or E.coli 
E. fergusonii Shigella 
sonnei or E.coli 
- 
- 
 
- 
Enterococcaceae Enterococcus faecium 
Enterococcus casseliflavus 
Enterococcus 
Enterococcus 
+ 
+ 
- 
+ 
Lactobacillaceae 
 
Lactobacillus apodemi 
L. apodemi 
- 
+ 
Micrococcaceae Kocuria rhizophila 
K. rhizophila 
Micrococcus luteus 
- 
- 
- 
Pseudomonadale Enhydrobacter or 
Moraxella 
- 
Staphylococcace  
 
Staphylococcus lentus 
Staphylococcus warneri 
S. warneri 
S. warneri 
+ 
+ 
+ 
+ 
 
Of the 8 strains that could inhibit germination 5 had been previously shown to 
possess BSH activity against TC in a plate based assay (Table 4-1). These assays 
suggest that BSH activity may be able to decrease rates of spore germination in 
vitro. However, for 3 of these isolates inhibition of germination did not appear 
linked to BSH activity. This could either suggest that these strains were 
identified falsely as non BSH producers using the BSH plate assay or it may be 
that there are other bacterial factors that could be impacting on spore 
germination.  
In addition to the Staphylococcus isolates shown in Table 4-1, a L. murinus 
isolate was identified with BSH against TC. Interestingly, a second L. murinus 
isolate displayed no equivalent BSH activity (Figure 4.2).  
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Figure 4.2 Detection of BSH activity in Lactobacillus murinus isolates 
L. murinus strains were plated onto MRS (A and C) and MRS with 0.5% TC (B and D) and 
incubated for 72 hours. BSH activity was determined by the presence of white granular colonies 
and the precipitation of cholic acid into the media (D). 
 
To further unravel the role of BSH production in inhibition of spore germination 
these two strains were studied in greater detail. Firstly to determine if 
differences in BSH production were readily attributable to specific genetic 
sequence differences, the whole genomes of both L. murinus strains were 
sequenced and compared.   
 Genome sequencing of Lactobacillus murinus isolates 4.2.3.1
Genomic DNA was extracted from each L. murinus strain and sequencing carried 
out on the MiSeq at the Glasgow Polyomics Facility. The genomes of both L. 
murinus isolates were assembled and annotated as described in section 2.7.1.5. 
Once assembled, annotated genomes were mined for sequences annotated as 
BSH by the bioinformatic software PROKKA. Genomes were also analysed for the 
presence of the 7α-dehydroxylation genes (the baiCD gene of the bai operon), 
which did not appear to be present in either genome. Further inspection of the 
BSH specific sequences showed that these were almost identical, with the 
majority of the DNA and protein sequences conserved. However, the main 
difference between these two sequences was the absence of 39 nucleotides at 
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the start of annotated BSH gene, which is equivalent of a loss of the first 13 
amino acids (Figure 4.3). 
 
Figure 4.3 Alignment of BSH protein sequences from BSH-ve and BSH+ve L. murinus 
strains 
Alignment of both L. murinus BSH protein sequences was carried out in Clustalw2. The important 
Cys1 catalytic domain is highlighted in yellow. The BSH from BSH-ve is missing the first 13 amino 
acids of the protein including  both the methionine needed for expression and the Cys1 which is 
essential for function rendering the BSH inactive.  
Amongst the missing amino acids is the one of the key cysteine residues, Cys1, 
which is essential for BSH activity (Ridlon et al., 2006) (Figure 4.4). As protein 
also lacks the methionine start codon it is unlikely that the protein is expressed. 
As a consequence, truncation of the BSH gene in the BSH-ve L. murinus strain is 
the most likely explanation for the lack of BSH activity in this isolate. To confirm 
the truncation of this gene, both the full length BSH and truncated BSH (tBSH) 
were amplified by PCR. 
BSH-ve      -------------LGRNFDYEFSYGEKAVIIPRNYVFELRKLPALSKHYAMVGLTSVFDD 
BSH+ve      MCTAVSFKTKDHYFGRNFDYELSYGEKAVIIPRNYVFELRKLPALSKHYAMVGLTSVFDD 
                         :*******:************************************** 
 
BSH-ve      TPLLYDAVNEHGLAMAGLNFEGNAVFYDFDPEMDNVTPFEFIPYILGQCKNVAEAKQMLT 
BSH+ve      TPLLYDAVNEHGLAMAGLNFEGNAVFYDFDPEMDNVAPFEFIPYILGQCKNVAEAKQMLT 
            ************************************:*********************** 
 
BSH-ve      KTNLVNEAFRADLPLSPLHWIISDSEDNTIVVETLADGMKVYDDPVDVMTNNPTFDKQLF 
BSH+ve      KINLVNEAFSADLPLAPLHWIISDSEDNTIVVETLADGMKVYDDPVGVMTNNPTFDKQLF 
            * ******* *****:****************************** ************* 
 
BSH-ve      NLNNYRGLSAKTPENTFDPTFELPAYSRGMGTLGLPGDLTSSSRFVKAAFVKAHSVCEPD 
BSH+ve      NLNNYRGLSAKTPENTFDPTVELPAYSRGMGTLGLPGDLTSSSRFVKAAFVKAHSVCELD 
            ********************.************************************* * 
 
BSH-ve      ESSSVSQGFHILSAIEQQRGCCEVSEGKYEYTIYSACYNKDKGILYYKTYEDSQITALDM 
BSH+ve      ESSSVSQGFHILSAIEQQRGCCEVSEGKYEYTIYSACYNKDKGILYYKTYEDSQITALDM 
            ************************************************************ 
 
BSH-ve      HKVDLESDRFTLYPLSQTQHFNYAN 
BSH+ve      HKADLESDRFTLYPLSQTQHFNYAN 
            **.********************** 
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Figure 4.4 Predicted structure of the full length BSH from L. murinus  
The predicted structure of the full length BSH from L. murinus with the essential cysteine that forms 
the catalyst centre highlighted in purple. 
 Amplification of BSH and truncated BSH genes from L. murinus 4.2.3.2
Primers were designed to allow amplification of both the full length BSH and 
tBSH from the L. murinus isolates. This analysis confirmed that the full length 
BSH could not be amplified from the strain lacking BSH activity, whereas primers 
designed for the amplification of the tBSH allowed amplification from both 
strains (Figure 4.5). 
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Figure 4.5 Amplification of tBSH and BSH from both L. murinus strains 
Primers directed to the full length BSH and tBSH were used to detect BSH in both L. murinus 
isolates. Only the tBSH could be amplified from L. murinus that did not have BSH activity. Both the 
tBSH and full length BSH could be amplified from the L. murinus isolate with BSH activity. The BSH 
gene has an expected product size of 978bp and tBSH expected product size of 939bp. 
This result suggests that this gene truncation in the BSH-ve L. murinus strain 
renders the gene inactive and explains the lack of BSH activity by this strain. As 
BSH are involved in resistance to high concentrations of BA in vivo it is likely 
that truncation of this gene may increase the sensitivity of this strain to BA. To 
investigate the impact of this truncation on the growth of this strain, cultures 
were grown in the presence and absence of TC. 
4.2.4  The impact of TC on the growth rates of L. murinus strains 
Analysis of the growth of both L. murinus strains was determined by inoculation 
of MRS broth with or without the addition of 0.1% TC. Viable counts were taken 
every 3 hours for 9 hours and viable counts performed to determine if TC had an 
impact on L. murinus viability and growth (Figure 4.6). 
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Figure 4.6 Growth of Lactobacillus murinus isolates in MRS broth with and without the addition of 0.1% TC 
A) BSH-ve L. murinus isolate and B) BSH+ve L. murinus isolate were grown in MRS broth alone (black) and MRS broth with 0.1% TC (red). Data points represent the 
mean and error bars are +/- the SEM of 3 biological replicates. The BSH-ve L. murinus strain showed a growth defect in the presence of TC with a significant reduction 
at 9 hours. Significance was determined using a student’s t test (* signifies p=0.0156).   
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From these data, it would appear that addition of 0.1% TC to the media 
dramatically slowed the growth of the BSH-ve strain of L. murinus. The 
difference in growth was only significant at 9 hours (p = 0.0156) potentially due 
to variation at the earlier time points. The strain was still able to grow to 
relatively high bacterial loads suggesting that BSH activity is only responsible in 
part to the bile tolerance observed within these strains. However, inactivation 
of this gene does have an impact on growth. Never the less, the ability to adapt 
to the presence of bile may mean that the strain carrying the intact BSH gene is 
more competitive within the host. However, this does not help explain why the 
seemingly low bile tolerance strain was originally isolated from the mouse 
faeces. One possible explanation is that in vivo the combinations of bacteria 
found in this niche are able to deconjugate BA more efficiently than a single 
strain. This may mean that the toxicity of these compounds overall remains low 
allowing BSH-ve strains to flourish. 
 
4.2.5 BSH producing L. murinus can inhibit C. difficile spore 
germination 
As previously described, BAs play an important role in C. difficile spore 
germination with modification of BAs decreasing their ability to induce 
germination. To determine if BSH activity and its subsequent modification of TC 
to CA affected spore germination the following experiment was performed. In 
brief, the two described L. murinus strains were grown in BHI containing 0.1% TC 
for 24 hours. The organisms were then removed by centrifugation and the media 
was filtered sterilised and adjusted to pH7. This filtered material was then 
tested to determine if it influenced the efficient germination of C. difficile 
spores (Figure 4.7). 
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Figure 4.7 Percentage spore germination of C. difficile BI-7 after incubation with supernatant 
from BSH-ve and BSH+ve L. murinus 
Percentage C. difficile spore germination after incubation with 0.1% TC as a positive control of 
maximal germination (dark blue) and CA as a negative control of reduced germination (light blue). 
L. murinus strain were grown in BHI with 0.1% TC for 24 hours before being filtered and the 
supernatant used to stimulate spore germination. The BSH-ve L. murinus (black) and the BSH+ve 
L. murinus (red) showed differing capacities to inhibit spore germination. To calculate the 
percentage germination the number of vegetative cells and spores was determined using 
differential counts of heated and unheated samples. From this the percentage germination could be 
calculated as the percentage loss of bacteria after heating. Error bars represent +/- the SEM of 3 
biological replicates. Statistical analysis was carried out with a ANOVA with Tukey’s post-test. The 
BSH +ve L. murinus strain was found to significantly reduce germination compared to incubation 
with TC alone or incubation with a BSH –ve L. murinus strain (p= <0.001). 
The media recovered from the BSH+ve isolate contained a substance that did not 
stimulate germination efficiently, with rates of germination mirroring those 
found after exposure to CA. This would suggest that modification of bile salts by 
bacteria has an important role in regulating the efficiency of C. difficile spore 
germination. However, it is also possible that L. murinus is able to impact upon 
C. difficile germination and outgrowth by other as yet undefined mechanisms. 
These could include the production of inhibitory compounds such bacteriocins 
that could inhibit C. difficile germination and growth (Y. S. Chen & Yanagida, 
2006; Lee, Chung, & Seo, 2013; Weese et al., 2004; Yun, Oh, & Griffiths, 2014). 
Therefore, to further examine the impact of BSH on germination attempts were 
made to express both the full length BSH and tBSH in E. coli.  
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4.2.6 Cloning and expression of BSH from L. murinus 
Primers were designed to contain the restriction sites Sph1 and Xba1 to allow 
cloning of both the BSH and tBSH gene into the pnz44 vector. This system allows 
for constitutive and high levels of expression of BSH in E. coli. To promote 
expression of the tBSH gene, an additional methionine start codon was added 
during the amplification step. Although restriction digest analysis of these 
plasmids suggested that cloning was successful, neither was found successfully 
expressing the BSH protein. 
4.2.7 Germination assays with BSH expressing E. coli 
Although BSH activity seemed to reduce the ability of C. difficile spores to 
germinate in vitro, we were aware that other factors expressed by the L. 
murinus strains may be influencing spore germination. However, as we had not 
been able to make this link directly through the expression of the BSH genes 
from this organism, we chose to indirectly establish this relationship using BSH 
expressing clones generated from the bacteria recovered from the human gut 
(Jones et al., 2008). A library of BSH expressing clones was kindly provided by 
Prof Julian Marchesi (CU), which were generated by cloning the amplified BSH 
genes from the human gut microbiome into the constitutive pnz44 plasmid. 
Members of this library had been previously screened for BSH activity and clones 
selected that expressed functional BSH with differing substrate specificity (Jones 
et. al., 2008). To identify clones with activity appropriate for study, a screen 
using TC was used. This identified two clones, one with high activity against TC 
and a second with undetectable levels of activity against TC (Figure 4.8). 
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Figure 4.8 Plate assay for BSH activity against TC from BSH isolated from the human gut 
microbiome 
E.coli containing BSH were plated onto LB agar containing 0.5% TC. Different BSHs have different 
substrate specificities. A) An E. coli clone containing a BSH with no activity against TC and B) an 
E. coli clone with high activity against TC as demonstrated by the formation of white granular 
colonies and the precipitation of TC into the media. These clones were used in subsequent 
germination assays. 
 
These strains were utilised in germination assays, using the E. coli strain 
expressing a BSH with no activity against TC as a negative control. The BSH 
genes are expressed in the same plasmid from identical XL1-blue E. coli. This 
makes it easier to unravel the role of BSH expression on C. difficile spore 
germination, as the only factor that should differ between the clones is the 
activity of the BSH gene. It was found that the E. coli containing a BSH with 
activity against TC was able to inhibit spore germination with levels reduced to 
the levels seen when spores are incubated with CA alone. The E. coli containing 
the BSH with no activity against TC was unable to inhibit spore germination with 
levels the same as those seen in spore incubated with TC (Figure 4.9). 
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Figure 4.9 Percentage germination of C. difficile BI-7 spores after growth with the TC-ve and 
TC+ve BSH clones 
Percentage germination of spores incubated with TC (dark blue), CA (blue) and TC-ve E coli 
(black) and TC+ve E. coli (red) BSH stains. The number of vegetative cells and spores was 
determined using differential counts of heated and unheated samples. From this the percentage 
germination could be calculated. Error bars represent +/- the SEM of 3 biological replicates. 
Statistical analysis was carried out with a ANOVA with Tukey’s post-test. The E. coli with activity 
against TC (TC +ve) was found to significantly reduce germination compared to incubation with TC 
alone or incubation with the  TC–ve E. coli clone (p= <0.001). 
This supports the mechanism for inhibition of germination being the modification 
of TC to CA through BSH production. 
4.2.8 Testing of L. murinus as a prophylactic treatment of C. 
difficile  
Germination of spores is clearly a fundamental step in C. difficile pathogenesis. 
Consequently identification of a strain of L. murinus that is capable of 
decreasing spore germination of C. difficile offers a potential new prophylactic 
treatment. To determine if animals colonised with the BSH producing L. murinus 
and subsequently infected with C. difficile spores showed reduced colonisation, 
experiments using both strains of L. murinus were tested in vivo.  
 Time line of prophylactic treatment experiment  4.2.8.1
For these experiments, 10 mice were placed into 3 different treatment groups, 
with 2 cages of 5 mice per treatment. The 3 groups were as follows, a control 
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group given no L. murinus, mice treated with the BSH–ve L. murinus and animals 
treated with the BSH+ve L. murinus. In all groups, animals were pre-treated 
with clindamycin to remove any members of the flora that naturally protect 
against C. difficile colonisation including those that produce BSH. The 
appropriate L. murinus strains were administered to the mice on 2 occasions 24h 
and 6h prior to C. difficile delivery. To determine the impact of this treatment 
on the gut flora, microbiome samples were taken from 6 mice (3 per cage) per 
group throughout the experiment. As the L. murinus strains were not specifically 
genetically marked (being originally isolated as members of the natural flora), it 
was hoped that use of the microbiome data may provide indirect evidence of 
successful colonisation. 
 Shedding of Clostridium difficile in the faeces 4.2.8.1
During the course of these experiments, shedding of viable C. difficile in the 
faeces was used as an indicator of successful germination and growth within the 
animal (Figure 4.10). 
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Figure 4.10 Shedding of C. difficile in the faeces of mice from all experimental groups up to 
25 DPI 
Mice were given 1x10
9
 CFU of L. murinus on D-1 and 6 hours prior to C. difficile on D0. 1x10
5
 CFU 
of C. difficile spores were given on D0. Faecal samples were collected daily and colony forming 
units (CFU) of C. difficile per gram of faeces were determined as a measurement of successful 
colonisation. Control mice given no L. murinus (blue), mice given BSH-ve L. murinus (black) and a 
final group given BSH+ve L. murinus (red) were shown to be equally colonised by C. difficile after 
infection. Error bars show +/- SEM (n=10). 
As can be seen from the data, no differences were observed between any of the 
experimental groups with each showing very similar levels of C. difficile in the 
faeces at all time points tested. This high level of colonisation suggests that the 
BSH producing L. murinus strain was unable to prevent colonisation of these 
animals, as shedding in this group closely mirrored the control group and the 
BSH-ve group. This suggests that C. difficile spores were still able to germinate 
and grow effectively. However, closer inspection of the data revealed that of 
the two cages of animals given the BSH producing L murinus, all animals in one 
of the cages had levels of C. difficile below the limit of detection by D14, with 
no further shedding detected after this point. This would be a decrease in 
infection time of at least 11 days when compared to the other groups. In 
contrast, no other cage of animals reached this point during the 25 days of the 
experiment. It is not clear if this reduction is due greater efficiency of 
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colonisation by the BSH+ve L. murinus strain or whether other members of the 
flora from these mice are affecting C. difficile persistence. Clearly this is an 
area that requires more attention. 
 Body weight of mice during C. difficile infection 4.2.8.2
As described previously, the extent of infection and indirectly the degree of 
suffering of the animals was monitored continually throughout the course of the 
experiment. In previous experiments we had observed that weight loss 
correlated with disease severity, so mice were weighed daily to determine if 
administration of L. murinus had any impact on this (Figure 4.11). 
 
Figure 4.11 Average percentage body weight of mice following C. difficile challenge  
Control animals (blue), BSH-ve animals (black) and BSH+ve animals (red) were weighed daily 
during the course of the experiment. Animals suffered from weight loss post infection with recovery 
by 4DPI. There were no differences in weight loss between the groups. Error bars represent +/- 
SEM of 10 mice per group. 
Treatment with either strain of L. murinus had no impact on weight loss during 
infection, with the BSH-ve and BSH+ve strains closely mimicking the weight loss 
observed in the untreated animals. Whilst culture of L. murinus from the faeces 
was attempted, use of MRS agar was not selective enough to discriminate 
between the many different isolates recovered. To further investigate whether 
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animals were successfully colonised with L. murinus, PCRs for the BSH genes 
expressed by the strains were carried out on total bacterial DNA recovered from 
the faecal samples.    
 Detection of BSH genes in the microbiome as a marker of L. murinus 4.2.8.3
colonisation 
Amplification of the BSH by PCR was performed using DNA recovered from the 
faecal samples at different time points during the experiment. Data is presented 
from samples collected prior to clindamycin treatment (D-5), post clindamycin 
treatment (D-3) and post treatment with L. murinus (D1) (Figure 4.12). 
 
Figure 4.12 Detection of L. murinus BSH in the microbiota of mice 
PCRs directed to the L. murinus BSH were carried out on samples collected before clindamycin 
treatment (D-5), after clindamycin treatment (D-3) and after both doses of L. murinus were 
administered (D1) from control, BSH-ve and BSH+ve groups (n=6). Each gel is representative of 
an animal from each group. Variations are explained fully in the text. 
 
All animals in this experiment tested positively for the BSH gene prior to 
clindamycin treatment. As observed previously (Figure 3.14), this amplification 
was not possible post clindamycin suggesting that the organisms expressing this 
gene were sensitive to this antibiotic. After infection, animals given BSH+ve L. 
murinus appeared to have regained the BSH gene within the microbiome, in 
contrast to those treated with the BSH-ve strain which did not regain the gene. 
However, examinations of later time points during infection (7DPI, 10DPI and 
14DPI) suggest that colonisation was only transient. This may explain why there 
were no apparent differences in the recovery of C. difficile from these animals. 
Further analysis of BA profiles in vivo would be needed to determine the full 
impact of the different treatment regimes. This would help to determine if the 
different L. murinus strains used in this experiment have an impact on BA 
metabolism in vivo. 
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 Discussion 4.3
4.3.1 BSH producing bacteria can inhibit C. difficile spore 
germination in vitro 
In the previous chapter, BSH activity was shown to play an important role in 
colonisation resistance. Loss of theses enzymes was linked to a change in BA 
metabolism (confirmed by TOF-mass spectrometry - Figure 3.15) resulting in 
increased germination and growth of C. difficile in vivo.  In this chapter, several 
different bacterial species were identified as able to express BSH, the activity of 
which modified C. difficile spore germination in vitro. Further investigation 
revealed that E. coli clones expressing the BSH enzyme (Jones et al.,2008) were 
also able to inhibit spore germination, but only if this activity was specifically 
associated with the breakdown of TC.   
Recovery of two L. murinus strains, which were genetically highly related, 
showed that only the isolate that expressed an intact and functional BSH was 
able to inhibit C. difficile germination. In mice, Lactobacillus are responsible for 
~86% of BSH activity measured (Tannock et al., 1989) making these strains a 
good candidates for prophylactic use in vivo. Whilst, experimental data outlined 
here would indicate that whilst the use of BSH+ve clones of L. murinus had little 
impact on C. difficile colonisation in vivo, there is increasing evidence that 
restoration of BSH function can help to recover BA metabolism both directly and 
indirectly. In particular, recovery of BSH activity has been linked to greater 7α-
dehydroxylation activity within the microbiome after clindamycin treatment 
(Gustafsson et al., 1998). This most likely reflects an increase in the amount of 
CA following BSH breakdown of TC, thus providing a selection pressure that 
allows bacteria that encode genes for the 7α-dehydroxylation pathway to thrive. 
Interestingly, another study, in which mice were fed CA showed a significant 
increase in the Clostridial composition of the microbiota. There was also a large 
increase in DCA levels suggesting an increase in the population that are capable 
of 7α-dehydroxylation, an activity linked mainly to Clostridial species (Saiful 
Islam et al., 2011). A similar study carried out by Ridlon et al., (2013) found that 
feeding mice 1% CA resulted in an increase in 7α-dehydroxylation and Clostridia. 
These studies strengthen the hypothesis that restoration of bile metabolism 
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could be achieved by introduction of BSH producing bacteria or through direct 
feeding of CA. However, such approaches must be performed with caution as 
changes in the relative composition and concentration of BAs can be harmful. 
This is because BAs and their derivatives are capable of damaging mammalian 
cell membranes and have been linked to increased risk of carcinoma (Barrasa et 
al., 2013; Tsuei et al., 2014), potentially making ingestion of these compounds 
unwise. Altering this pathway using bacteria may be a safer alternative as this it 
is more likely to be associated with microbiome homeostasis. Overall, it is the 
production of DCA that is ultimately required to inhibit C. difficile growth. Our 
data in vitro would suggest that BA metabolism is associated with different 
aspects of C. difficile pathogenesis with BSH activity linked to reduction in 
germination and 7α-dehydroxylation preventing vegetative growth. 
4.3.2 L. murinus producing BSH are unable to inhibit spore 
germination in vivo 
Use of L. murinus in vivo did not show any prove successful in vivo. However, 
shedding data showed that there was a difference between the 2 cages of mice 
in the BSH+ve group, with one cage having no detectable C. difficile after 14DPI. 
Evidence from both the literature and this thesis suggest that bacteria possessing 
BSH offer good prospects as potential probiotics. However, the evidence at least 
in the mouse experiments is less than compelling with no difference between 
the average shedding between control animals and those given the BSH 
expressing L. murinus. However, there could be several explanations for these 
disappointing data; firstly it may be that the dosage given was insufficient to 
restore the bacteria to the gut. PCR analysis for the BSH genes showed regained 
BSH in animals given the BSH+ve L. murinus strain but not those given the BSH-
ve strain. PCR analysis of later time points showed that this colonisation was 
transient. Further study (including the direct marking of strains) would be 
required to directly confirm strains colonisation of the animals. This is important 
as it would allow the relative efficiency of colonisation by each strain to be 
determined. At present within this study it is unclear whether a sufficient 
number of bacteria survived passage through the acidic environment of the 
stomach to allow effective colonisation of the colon and restoration of BSH 
function. In the study by Gustafsson et al., (1998) in which 7α-dehydroxylation 
was recovered following treatment with BSH producing strains, bacteria were 
Chapter 4- BSH in vitro and in vivo 
 
154 
 
delivered for 5 days, in a freeze dried form at a concentration of 109 CFU 
bacteria. This would have exposed the mice to much higher numbers of bacteria 
than used in these experiments. Therefore working out the appropriate dose of 
probiotic bacteria and timing of delivery is essential. However, as these 
experiments are dependent on pre-treatment with clindamycin to remove the 
existing microflora, extension of the dosing times could allow sufficient recovery 
of the animals own flora that could influence infection outcome.  
Another explanation for the failure of this approach may relate to the rate at 
which the L. murinus was able to deconjugate the bile salts in vivo.  If this was 
insufficient to influence the balance of bile salts in the gut, normal BA 
metabolism to the gut would not return. As such the activity of the BSH 
produced may be important and subsequent isolation of bacteria revealed other 
strains with higher activity for TC than the L. murinus tested in vivo (Figure 
4.13). 
 
Figure 4.13 BSH activity of L. murinus and an additional BSH producing strain 
BSH activity of A) BSH+ve L. murinus and B) an additional BSH producing bacterial strain isolated 
from MRS agar from a mouse faecal sample. Although both result in the precipitation of CA into the 
media there is a much higher concentration precipitated around the bacterial strain in B which 
suggests higher BSH activity in this strain. 
In contrast to the situation in vivo, in vitro experiments use a finite amount of 
TC in the media, the majority of which can be deconjugated to CA. In vivo bile 
salts are released regularly, meaning very high levels of BSH activity are 
continually needed to efficiently and rapidly deconjugate these compounds. In 
addition to this, it has been shown that antibiotic treated animals produce 
higher levels or taurine conjugated bile salts than untreated animals (1.3). It 
A B 
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may be that a cocktail of BSH producing bacteria with varying substrate 
specificities are required to allow effective deconjugation of bile salts and 
therefore replacement of only one strain is insufficient to achieve this 
effectively.   
As described in the introduction, several studies have been performed in which 
replacement of the normal flora has been shown to effectively treat C. difficile 
infection, both in mice and humans. Closer inspection of these mixtures reveals 
that many contain bacteria that are capable of BSH activity. In fact, one of the 
successful cocktails used by Lawley et al., (2012) to treat mice contains one of 
the bacterium identified in this study, S. warneri, a BSH producer. Another 
bacteriotherapy is ‘rePOOPulate’ a mixture of 33 bacterial isolates successfully 
used to treat two patients suffering with relapsing C. difficile. Within this mix 
are several potential BSH producers, including several Lactobacillus and 
Roseburia species. It also contains bacteria that may be capable of 7α-
dehydroxylation including several Clostridia and Eubacterium. So far one study 
has been published that claims to restore bile metabolism and therefore reduce 
colonisation and toxin levels in vivo. During this study mice were given C. 
scindens, a 7α-dehydroxylating species, before infection. Animals given C. 
scindens had a reduced death rate, lower rates of colonisation and lower faecal 
toxin titre. Although promising it may be necessary to repeat these experiments 
with a 7α dehydroxylase knock out strain of C. scindens to demonstrate that 
inhibition in vivo is mediated through the production of DCA and not by 
competition for the same niche. Similar studies have shown analogous decreases 
in disease severity when animals were treated with non-toxigenic C. difficile in 
both mice and humans, however, the mode of protection here is more likely to 
reflect niche competition (Gerding et al., 2015; Zhang et al., 2015). Unravelling 
bacterial interactions in vivo is challenging but the continued development of 
targeted microbiome therapeutics is showing promising signs. 
This chapter has built upon the potential use of BSH producing bacteria as part 
of a therapeutic for difficult to treat C. difficile infections. Use of these 
bacteria warrants further investigation as an alternative treatment to FMT, in 
which undefined bacterial combinations are used to treat patients suffering from 
recurring disease. The data presented in this chapter and in chapter 3 show how 
important the microbiota is in determining the outcome of C. difficile infection. 
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In the next chapter the influence of TC on genetic regulation of germination and 
outgrowth will be investigated. 
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5 The influence of taurocholic acid on genetic 
regulation of germination and outgrowth 
 Introduction 5.1
BAs have been shown to influence a range of processes involved in virulence and 
BA resistance in a multitude of enteric bacteria (1.3.3). In C. difficile BAs, 
specifically TC, are known to be important in regulating spore germination (Sorg 
& Sonenshein, 2008) however, the influence of TC on genes expressed post 
germination is unknown. A range of new molecular techniques are making it 
easier to unravel the genetic regulation of these processes. In C. difficile the 
genes involved in germination are becoming more clearly defined after 
improvements in methods of genetic manipulation including ClosTron 
mutagenesis (Heap et al., 2010). In these situations, the importance of specific 
genes can now be established by mutation in those genes linked to (or inferred 
by association with homologous genes in other sporulating bacteria) germination. 
However, this approach does not allow identification of novel genes associated 
with this process. Transposon mutagenesis has traditionally allowed the rapid 
production of libraries of single gene mutants which can be tested 
phenotypically. Additional linkage of mutagenesis with whole genome 
sequencing (WGS) is a powerful tool that allows for rapid and high-throughput 
analysis of multiple mutants. However this technique is less useful in identifying 
genes involved in gene regulation post germination as it can only identify 
essential genes. BA resistance is a complicated process with many of the genes 
involved having functional redundancy. This means that loss of one gene 
involved in the process can result in upregulation of another that can 
compensate. This would make the construction of a mariner transposon (MT) 
library inappropriate for investigating this process. A technique that allows for 
the identification of genes whose expression is significantly altered under 
specific conditions is RNA-seq. Use of this technique allows for the identification 
of genes whose expression is significantly altered and may allow for the 
identification of genes in C. difficile that are important in modulating virulence 
and bile tolerance. These genes may yield important information on the 
infection process. 
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Analysis of RNA-seq data was carried out with the assistance and support of Dr 
James Connolly. Production of the transposon mutant library was carried out in 
collaboration with Kassie McLaren. Microscopy was performed using procedures 
and protocols optimised by Dr Anthony Buckley.  
 Results 5.2
Initially unique genes involved in spore germination were identified through the 
production of a random transposon library of C. difficile mutants. 
5.2.1 Creation of a random transposon library of C. difficile 
In order to identify genes that are involved in TC mediated spore germination it 
was first necessary to create a transposon mutant library.  
 Conjugation of pRPF215 into C. difficile 5.2.1.1
The first step in creating the transposon mutant library required the introduction 
of the pRPF215 plasmid (a kind gift from Dr Robert Fagan, University of 
Sheffield). The pRPF215 plasmid contains the transposon and ermB gene 
required for the selection of mutants. To create a transposon mutant library the 
plasmid was first conjugated into C. difficile R20291 by conjugation using the 
donor strain of E. coli CA434 (Purdy et al., 2002) using the approach described in 
section 2.7.1.2. Successful transfer of the plasmid was confirmed by PCR 
amplification of a region of the ermB gene from C. difficile colonies recovered 
after conjugation experiments.  
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Figure 5.1 Confirmation of the transfer of pRPF215 into C. difficile R20291 by conjugation 
Primers directed to a region of the ermB domain within the plasmid were used to confirm the 
successful conjugation of the plasmid from E. coli into C. difficile. DNA was extracted from colonies 
and amplified to confirm plasmid carriage. The expected fragment size was 600bp. 
The transposon mutant library was subsequently generated from C. difficile 
isolates in which plasmid carriage was confirmed. In brief, a single colony of C. 
difficile containing the plasmid was grown to an OD600 of 0.4 before being 
diluted and cultured on plates containing lincomycin and anhydrotetracycline. 
This allows for simultaneous induction of the MT and selection for mutants.The 
induction of the transposon is controlled under a pair of promoters with 
overlapping Tet operator sequence (TetO). One of these promoters (PtetR) 
controls the expression of TetR which acts as transcriptional regulator that 
represses both promoters. As expression of the MT is under the control of PTet, 
addition of anhydrotetracycline results in a conformational change in TetR 
ending repression of the system and allowing expression of the MT (Cartman & 
Minton, 2010). Incorporation of the transposon containing the ermB gene into 
the genome renders the mutant lincomycin resistant, allowing mutants to grow 
in the presence of this antibiotic. The vast majority of isolates will represent 
mutants with only 1 transposon present within the genome. This is because once 
the transposon has integrated into the genome the transposase inhibits further 
integration, although the precise mechanism of this is not understood (Cartman 
& Minton, 2010; Muñoz-López & García-Pérez, 2010). The growth from plates 
that contained well isolated colonies were scrapped and the mutants pooled for 
use in subsequent experiments. 
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5.2.2 Screening of the transposon mutant library for germination 
mutants 
In order to screen the library for germination mutants it was first necessary to 
allow them to form spores. To select for germination mutants, spores from the 
mutant library were incubated in 10% TC for 24 hours, a concentration 100 times 
higher than would be typically used. To screen for those spores that were unable 
to germinate under these conditions the culture was heated at 65°C for 30 
minutes killing vegetative cells and leaving spores. The remaining spores that 
had failed to germinate in the presence of TC were artificially germinated using 
a combination of thioglycollate and lysozyme. 
Using this approach, we recovered hundreds of colonies that appeared only able 
to germinate in response to artificial germination. These colonies were all 
resistant to lincomycin suggesting that all contained the transposon within the 
genome. As such we presumed that these were germination deficient mutants 
that were unable to germinate in the presence of high concentrations of TC. To 
allow greater characterisation of these mutants, 20 were selected for further 
analysis. 
 Verification of germination deficient mutants 5.2.2.1
To verify that the mutants selected were unable to germinate in the presence of 
TC, spores of each mutant were plated onto BHI agar containing 0.1% TC, or 
artificially germinated using thioglycollate and lysozyme. True germination 
mutants should only form spores after artificial germination. Of the 20 mutants 
tested, only 6 (highlighted in red) were subsequently identified as ‘true’ 
germination mutants with the other 14 able to form small colonies in the 
presence of TC (Table 5-1). 
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Table 5-1 Verification of germination null phenotype in 20 presumed germination mutants 
 Artificial germination Taurocholic acid 
Colony Colonies formed 
WT + + 
1 + + 
2 + + 
3 + + 
4 + + 
5 + + 
6 + + 
7 + + 
8 + + 
9 + - 
10 + - 
11 + + 
12 + - 
13 + - 
14 + + 
15 + - 
16 + + 
17 + + 
18 + + 
19 + - 
20 + + 
 
The high number of false positives suggests that only ~30% of the germination 
mutants were ‘true’ germination mutants. The reason for this poor level of 
discrimination is unclear and suggests that modification of the protocol would be 
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necessary to further increase the numbers of true germination mutants isolated. 
Traditionally the site of insertion of a transposon would be determined using 
Transposon Directed Insertion Sequencing (TraDIS). This system allows for rapid 
and high throughput identification of transposon insertion sites by allowing 
amplification from the transposons into the flanking gene (Barquist et al., 2016; 
Dembek et al., 2015; Langridge et al., 2009). However, as the selection of 
mutants appeared poorly discriminating, it was decided that whole genome 
sequencing (WGS) of the 6 ‘true’ germination mutants would be used to 
determine the insertion location of the individual transposons. 
 Genome sequencing and determining site of transposon insertion 5.2.2.2
Genomic DNA was extracted from each germination mutant (2.4.1.1) and sent 
for genome sequencing on the MiSeq platform at Glasgow Polyomics Facility 
(GPF). Assembly and annotation of mutant genomes was carried out as described 
in section 2.7.1.5. Annotated contigs were imported into CLC genomics work 
bench for visualisation. To identify the transposon insertion site an internal 
BLAST search was carried out for the MT in the annotated contigs. In all 6 
genomes the MT was found in the cspBA gene with two different insertion 
positions within mutants identified.  
Germination mutants Location from start of gene 
1 3757bp 
2 3757bp 
3 3757bp 
4 415bp    
5 415bp    
6 3757bp 
  
The cspBA gene produces CspB, a protease involved in the activation of SleC and 
CspA a catalytically inactive pseudoprotease that is involved in controlling levels 
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of CspC (1.2.2.1). Inactivation of CspB is known to halt germination in its first 
stage as it prevents activation of SleC, a spore lytic enzyme, preventing spore 
cortex hydrolysis and therefore halting germination at this stage (Figure 5.2).  
 
Figure 5.2 Inhibition of germination by inactivation of cspBA genes 
The genes involved in C. difficile spore germination with the genes disrupted by insertion of the 
transposon shown. Disruption of the cspBA gene results in the halting of germination immediately 
after germinant sensing by CspC. 
5.2.3 Modification of the transposon system with the addition of a 
phiLOV domain 
The successful identification of a gene known to be involved in germination 
stimulated further interest in the use and extension of this technology. In recent 
years, work by this group has focussed on the use of a fluorescent reporter that 
can be used under the anaerobic growth conditions required by C. difficile.  In 
particular, we have tested LOV domains as reporters of gene expression. LOV 
domains are found in plants, bacteria, fungi and algae. Excitation of these 
domains by blue light, results in a conformational change leading to the 
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formation of a covalent bond between an FMN chromophore and a cysteine. 
Decay of this bond results in the release of energy in the form of green 
fluorescence. Unlike other fluorescent reporters such as green fluorescent 
protein (GFP), LOV does not require molecular oxygen to function making it ideal 
for use in obligate anaerobes such as C. difficile (Figure 5.3). These domains 
have successfully been used as fluorescent reporters in plant viruses (Chapman 
et al., 2008) and bacteria (Gawthorne et al., 2012, 2016) and work by this group 
has demonstrated their use in C. difficile (Buckley et al., 2016).   
 
Figure 5.3 Excitation of phiLOV domains. 
Schematic showing the reversible photo bleaching cycle of the phiLOV domain adapted from 
Christie (2007). 
The LOV domain has been modified to enhance its photostability and fluoresce 
resulting in the creation of improved photostable LOV (phiLOV) (Christie et al., 
2012). Transposon mutant libraries can be used to determine genes that are 
essential to a process and although incredibly useful, this approach provides 
little detail of genes that are significantly upregulated in particular 
circumstances but which are non-essential for that process. To try and address 
this issue, we attempted to harness the power of transposon mutagenesis and 
the phiLOV fluorescence. Modification of the pRPF215 plasmid to incorporate the 
phiLOV domain was carried out by Dr Rob Fagan (UoS). Incorporation of the LOV 
domain into the plasmid backbone was achieved by Gibson assembly of the 
amplified LOV domain into the plasmid. The LOV domain was modified to 
contain a ribosomal binding site to allow for expression. Expression of the LOV 
domain and fluorescence was dependent on the extent of expression of the gene 
in which the transposon was inserted (Figure 5.4).  
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Figure 5.4 Schematic of mariner-phiLOV system 
Diagram showing the structure of the MT-phiLOV pRPF215 plasmid and gene insertion. 
The ultimate aim of this approach, was to allow identification of those mutants 
in which expression of particular genes were upregulated to particular stimuli 
(such as growth in vivo).  As fluorescent light is the read out, it was hoped that 
such mutants could be selected and isolated using a Fluorescent Automated Cell 
sorter (FACs). It was hoped that by using this approach, several pools of mutants 
with differential levels of gene expression may be identified including those 
genes that are not essential but are highly upregulated under those conditions. 
 Conjugation of PYAA023 into C. difficile  5.2.3.1
Conjugation of PYAA023 was carried out as described in 5.2.1.1. Successful 
conjugation of this plasmid was confirmed by PCR using primers that specifically 
amplified the phiLOV domain within the PYAA023 plasmid.  
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Figure 5.5 Confirmation of the transfer of pYAA023 into C. difficile R20291 by conjugation 
Primers directed to the LOV domain within the plasmid were used to confirm the successful 
conjugation of the plasmid from E. coli into C. difficile. DNA was extracted from colonies and 
amplified to confirm plasmid carriage. Expected fragment size of 336bp. 
 Visualisation of phiLOV expressing transposon mutants 5.2.3.2
To test whether insertion of the transposon could result in differential 
expression of the LOV domain, the library was initially tested by inoculating the 
recovered mutants into BHI broth, which was cultured for 24 hours. Small 
volumes of this culture were then removed, washed with PBS and fixed in 10% 
formal saline. These fixed bacteria were then placed on a slide and air dried. 
Before use slides were stored in the dark to ensure maximal visualisation of LOV. 
Slides were visualised using an Axio-Zeiss Imager M1 light microscope to 
determine if fluorescent mutants displaying differential levels of phiLOV 
expression could be visualised (Figure 5.6). 
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Figure 5.6 Visualisation of library of modified mariner transposon mutants of C. difficile 
expressing the phiLOV domain  
10ul of spores from the mutant library were taken and inoculated into BHI broth and incubated for 
24 hours. Differential expression of the LOV domain is apparent. Bacterial slides were examined 
using an Axio-Zeiss Imager M1 light microscope. Deconvolution of raw data was performed using a 
point-spread function with 30 rounds of iteration.  Microscopy was carried out with the assistance of 
Dr Anthony Buckley.  
Observation of these cultures by microscopy confirmed that phiLOV expressing 
bacteria were identifiable within the culture. Bacteria expressing differential 
levels of fluorescence were observed (Figure 5.6). This suggests that insertion of 
the phiLOV domain into different genes may allow identification of mutants with 
differing levels of gene expression. However, to allow enrichment and isolation 
of these high phiLOV expressers, it was essential that these cells could be 
differentiated by FACS. To determine whether this was feasible, the remaining 
culture was washed with PBS, fixed with formalin and subject to FACs (Aria III). 
As the optimal wavelength for excitation of phiLOV (450nm) was not available 
using the FACs used, cultures were subject to suboptimal stimulation using the 
wavelength used for GFP (525–550nm). Under these conditions, attempts to sort 
the library proved unsuccessful. While the lack of optimal excitation light may 
provide one explanation, others include the size and natural autofluorescence of 
C. difficile. Using the suboptimal settings, the fluorescence of the phiLOV 
domain was not sufficiently high to allow differentiation from the natural levels 
of green autofluorescence expressed by these bacteria. In addition, the small 
size of bacteria (C. difficile are approx. 5μm) makes sorting individual cells is 
very challenging. Without an appropriate high throughput screening approach, it 
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did not seem relevant to continue our attempts to use this technology. This still 
remains a valid approach and time might provide the improvements that will 
make this approach feasible in the future.  
Focus was then moved to investigating the potential role of TC on regulation of 
genes expressed during outgrowth. 
5.2.4 Investigation of the role of TC on gene expression during 
outgrowth 
In multiple bacterial species including Vibrio parahaemolyticus, Campylobacter 
jejuni and Salmonella typhimurium bile salts have been found to regulate an 
array of virulence and resistance genes (1.3.3). Although TC plays an important 
role in regulation and induction of C. difficile spore germination, its impact on 
gene regulation post germination has not been previously investigated. To 
further explore the role of BAs in C. difficile pathogenesis, we chose to study 
the impact of TC on gene expression in the vegetative, post germination 
bacteria. This was undertaken using RNA-seq, which allows identification of 
genes whose expression is modified resulting in increased specific mRNA 
transcripts. This offers an opportunity to identify genes involved in bile 
tolerance and potentially virulence in C. difficile.  
 Preparation of the RNA seq library 5.2.4.1
To analyse the impact of TC on expression of genes in C. difficile, the bacteria 
were grown to an OD600 of 0.4. Once bacteria had reached this density TC was 
added to one sample to a final concentration of 0.1% whilst the other was 
adjusted to the same volume using fresh media. Bacteria were then harvested 
and RNA extracted as described in section 2.7.2. In total 3 biological replicates 
were prepared for each sample. In the first attempt the concentration of RNA 
was low and the quality poor so sample isolation was repeated with new 
reagents to ensure that no RNase contamination of the samples. To ensure that 
RNA samples were free from DNA contamination amplification of the 16s rRNA 
gene was performed. Lack of band formation suggested that the RNA was DNA 
free. Additionally, samples were checked for quality, DNA contamination and 
RNA degradation using a 2100 Bioanalyzer (Agilent). After RNA was found to be 
of good quality mRNA was reverse transcribed into cDNA before library 
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preparation and single ended sequencing on the Miseq platform. Analysis with 
the Bioanalyzer, cDNA production, library prep and sequencing was all carried 
out at GPF.  
 Identification of significantly altered genes after exposure to 5.2.4.2
taurocholate 
Analysis to identify genes whose expression was significantly altered after TC 
exposure was carried out using CLC genomics workbench as described in section 
2.7.3. In total 10 genes were found to be significantly altered after incubation 
with 0.1% TC compared to growth in BHI alone. Of these 10, 4 were rRNA subunit 
genes (data not shown). These rRNA subunits most likely represent differences in 
rRNA depletion efficiency between samples rather than anything of biological 
interest so were not investigated further. Other significantly upregulated genes 
are shown in Table 5-2. 
Table 5-2 Genes that are significantly upregulated after 1 hour exposure to 0.1% TC 
Gene Potential function Adjusted P value 
CDR20291_2128 Efflux pump 1.2477e−9 
CDR20291_2298 Multidrug efflux pump 6.5192e-4 
rpoD RNA polymerase sigma 
factor 
3.9447e-3 
CDR20291_2296 Efflux pump 7.0659e-3 
CDR20291_2297 Efflux pump 7.5207e-3 
CDR20291_1886 S-adenosyl-L-methionine 
-dependent 
methyltransferase (SAM 
dependent MTase) 
7.6637e-3 
 
Unsurprisingly, 4 or the 6 genes reported here are efflux pumps. These efflux 
pumps are most likely involved in increasing C. difficile tolerance to bile salts, 
minimising the biological impact of these molecules. Bile salts are able to 
disrupt membranes and cause DNA damage so rapid efflux of these molecules 
can help to prevent damage to the cell. Upregulation of efflux pumps is a 
generalised response to various environmental stresses, including bile, and it 
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would be interesting to see if bile exposure increases C. difficile resistance to 
other environmental stresses such as antibiotic exposure.  
Interestingly a S-adenosyl-L-methionine (SAM) dependent methyltransferase 
(MTase) was also upregulated following exposure to bile. These enzymes are 
important in a number of biological processes; using SAM as a methyl donor 
these enzymes methylate various biological molecules including proteins, lipids, 
DNA and RNA. The potential function of these enzymes with the cell is huge as 
they mediate many essential biological processes such as protein trafficking, 
signal transduction and gene expression. In this case, the role of SAM dependent 
MTase within the cell is not clear however it is likely it enables the bacteria to 
respond to bile salt exposure. In addition, there was also an increase in rpoD 
expression. This is an RNA polymerase sigma factor that is frequently linked to 
the transcription of housekeeping genes. This suggests protection from bile salts 
is mediated by rapid response to exposure and induction of genes that enable 
the cell to protect its DNA, RNA and membrane. 
During collection of the samples for RNA extraction it was noted that exposure 
to TC resulted in a change in the way the cells interacted, with the bacterial 
pellet formed following exposure to TC much more difficult to resuspend (Figure 
5.7).  
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Figure 5.7 Aggregative phenotype of C. difficile after exposure to 0.1% TC 
Resuspension of bacterial pellets grown in A) BHIS only and B) BHIS with 1 hour exposure to 0.1% 
TC. Exposure to TC results in increased aggregation of C. difficile. 
As a consequence of this observation, we wished to determine if bile salt 
exposure altered the capacity of the bacteria to aggregate and form biofilms 
that can have relevance in clinical disease. 
5.2.5 Biofilm formation at 24 and 48 hours 
To further investigate the impact of TC on biofilm formation, two types of 
biofilm assay were performed. The first aimed to qualitatively determine the 
extent of biofilm formation in non–sedimentary liquid culture, whilst the second 
provided quantitative assessment of biofilms in sedimentary cultures using 
crystal violet staining. 
 Biofilm formation in non-sedimentary liquid culture 5.2.5.1
To investigate if exposure to TC affected the capacity of bacteria to interact, 
bacteria were grown in 25cm2 tissue culture flasks, incubated upright and 
statically at 37oC for 24 and 48 hours. The capacity of the bacteria to form 
biofilms was tested with and without 0.1% TC in four different growth media.  
These included samples with/without the addition of 0.1% TC to the overnight 
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culture or biofilm media. TC, either added during the preparation of an 
overnight culture used to seed the biofilm or in the media in which the biofilms 
were cultured, resulted in biofilms that were more adherent than those grown 
only with BHIS. Measuring adherence is challenging and in these experiments it 
was measured crudely by agitating the flasks to disrupt the biofilm (Figure 5.8).  
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Figure 5.8 Biofilm formation in non-sedimentary liquid culture 
Overnight cultures grown either in BHIS+C alone or with the addition of 0.1%TC were used to seed tissue culture flasks containing either BHIS+C alone or with 0.1%TC. 
These were incubated for A) 24 or B) 48 hours before the adherence of the biofilm to the flask was tested by mechanical disruption. 
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Biofilms grown in BHIS alone were easily dislodged from the base of the flask 
whereas biofilms grown with TC, either as part of the overnight or as part of the 
biofilm media, required vigorous shaking before the biofilm was dislodged. This 
suggests that TC may increase biofilm adherence although the mechanism for 
this is unclear. 
 Crystal violet staining to quantify biofilms 5.2.5.2
Static biofilm assays show that the addition of TC increases biofilm adherence to 
an abiotic surface. However these assays cannot show any changes in the 
quantity of biofilm formed. To investigate this CV assays were carried out with 
the same growth conditions at 24 and 48 hours. These assays involve staining the 
biofilms with CV and then quantifying the amount of stain retained by the 
biofilms by measuring the OD. Measurements were taken at 24 and 48 hours 
(Figure 5.9). 
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Figure 5.9 C. difficile biofilm formation under different growth conditions 
Biofilms were grown in multiple different media compositions to determine the impact on biofilm formation at A) 24 hours and B) 48 hours. Overnight cultures to seed the 
biofilms were grown in the first media noted and biofilms in the second. BHI indicates BHIS+C media and TC is this media with the addition of 0.1%TC. 3 biological 
replicates, each with 3 technical replicates, were carried out for each condition. At 24 hours the addition of TC in the overnight of biofilm resulted in a slight increase in 
biofilm abundance although this was not significant. At 48 hours there were no differences in biofilm abundance. 
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At 24 hours there seemed to be higher levels of biofilm formed in growth 
conditions that used a combination of BHIS and TC, either as the media for the 
overnight culture or the biofilm itself. Although there was an increase in OD 
values this is not significant. Additionally, biofilm assays showed high variation 
making it difficult to determine if these changes represent any significant 
increase in biofilm abundance. At 48 hours all growth conditions show very 
similar levels of biofilm abundance suggesting that TC does not alter biofilm 
quantity. It is unclear how the inclusion of TC in the media increases adherence 
and the RNA seq data does not show any changes that can obviously associated 
with this. It may be that if any changes in expression that are responsible fall 
below the significance threshold or do not occur within the time frame 
examined. It is also possible that incubation with bile results in changes to 
membrane charge that may promote aggregation. It may also be that 
extracellular factors such as release of DNA may facilitate aggregation.  
 Discussion 5.3
5.3.1 Identification of germination mutants 
The creation of a transposon mutant library was used to identify genes involved 
in bile mediated spore germination. Germination is an essential process in C. 
difficile infection so understanding genetic regulation of this process is 
important. Much of the pathway is now understood, however there are still some 
gaps in our understanding. Germination response varies between C. difficile 
isolates meaning studying the process in multiple isolates is important and may 
give more insight into the role germination plays in infection and disease 
outcome (Bhattacharjee et al., 2016). Attempts to utilise a MT coupled with 
phiLOV fluoresce to identify non-essential but upregulated genes proved 
unsuccessful. Although the fluorescence of the phiLOV domain was above 
background levels (Figure 5.6) it was not sufficient to allow high throughput 
sorting of cells from those not expressing the domain. Unfortunately C. difficile 
has high levels of background green autofluorescence, making the use of 
fluorescence reporters for this kind of process challenging. For this reason 
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attempts to use this system for identifying genes involved in germination were 
not continued. 
When the MT was used to identify mutants that were unable to germinate many 
hundreds of colonies were formed, however further investigation showed that 
only 30% of these were true germination mutants. The reason for 
overrepresentation of non-specific mutants may reflect to poor selection for 
spores from the vegetative cells. It may be that heating at 65°C for 30 minutes 
was insufficient to kill all of the vegetative cells. However this has always 
proved sufficient during other experiments in our lab. Insufficient heating would 
allow these cells to remain within the pool resulting in false positives after 
selection. In this study a total of 6 confirmed mutants were sent for WGS and 
the site of transposon insertion identified. All 6 mutants were found to have a 
mutation in the same gene, cspBA. This is unsurprising as it has previously been 
shown to play an essential role in spore germination. The small sample size of 
mutants dramatically reduced the likelihood of identifying multiple different 
genes. A similar study that used chemical mutagenesis to create germination 
mutants sequenced the genomes of 10 of these mutants. All of the mutants in 
their study were found to have mutations localised in the cspBAC operon 
suggesting that disruption of these genes are the most common in germination 
mutants. One advantage of the MT system of creating mutants is that there 
should only be one insertion site and therefore one gene disrupted per mutant 
whereas chemical mutagenesis may result in large numbers of mutations within 
many genes. If the phiLOV domain had enabled sorting it may have been possible 
to identify some of the non-essential but upregulated genes in this process. For 
example genes that may have functional redundancy such as CspB which is the 
main protease responsible for activation of SleC although potentially not the 
only one (Adams et al., 2013). 
The method here was further limited by the way the MT insertion was identified. 
Genome sequencing is cheap but selection of only a few mutants limits the 
possibility of identifying novel genes. Use of high throughput methods for 
identifying the transposon insertion site, such as TraDIS, were not possible here 
due to the high rate of false positives in the selection for germination mutants. 
However, the successful identification of genes involved in spore germination 
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means that this method is appropriate for investigating genes involved in spore 
germination and other biological processes which could be potentially utilised 
further. 
5.3.2 The impact of TC exposure on C. difficile 
 Comparison of genes expressed with and without exposure to TC 5.3.2.1
Bile salts have previously been shown to play a number of roles in the expression 
of a host of genes including some involved in virulence in various bacterial 
species (1.3.3). Our investigation used RNA seq to identify changes in gene 
expression following exposure for 1 hour to 0.1% TC. In total 6 genes were found 
to be significantly upregulated. The reason for this low number of significantly 
differentially expressed genes is unclear as sequence coverage was acceptable in 
all samples. Within these 6 there were 4 efflux pumps. The role of efflux pumps 
in bile resistance has been well described in many bacterial species including 
both commensals (Fang et al., 2009; Gueimonde et al., 2009)  and pathogens 
(Baucheron et al., 2014 ; Quillin et al., 2011). Response to environmental 
stressors is important for increasing in vivo survival. Increased expression of 
efflux pumps can result in increased resistance to other environmental stressors 
and in some cases exposure to bile has been shown to increase antibiotic 
resistance (Prouty et al., 2004). One of the efflux pumps that is upregulated is 
CDR20291_2297, which has been identified as a LexA controlled efflux pump 
which is suggested to be involved in mediating antibiotic resistance in C. 
difficile (Walter et al., 2014). LexA is an important stress response regulator and 
multiple genes involved in antibiotic resistance, sporulation, house-keeping and 
virulence controlled by LexA (Walter et al., 2015; Walter et al., 2014). Although 
only one gene from this operon was upregulated it shows that bile induces 
common stress response pathways within C. difficile. Further investigation of 
the response of C. difficile to bile salts that more closely mimic the range and 
levels seen in a healthy gut and antibiotic treated gut may be interesting and 
give a clearer picture of how C. difficile interacts with bile salts in vivo.  
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 Exposure to bile increases adherence 5.3.2.2
It was noted that after exposure to TC bacterial pellets became difficult to 
resuspened and seemed to aggregate more than the bacteria grown in BHIS 
alone. Biofilm quantity was measured and it was found that exposure to TC did 
not seem to increase the quantity of biofilm formed. It may be interesting to 
carry out viable counts of these biofilms in the future as this may give a more 
precise measure of biofilm quantity. Although there did not seem to be 
increased abundance of biofilm those that were formed seem to adhere more 
strongly to the plastic flasks with increased agitation required to disrupt these 
biofilms compared to those grown without TC. Interestingly this included 
samples where TC was only present in the overnight culture used to seed the 
biofilm. This suggests that addition of TC induces some phenotypic or 
morphological change that persists once TC is removed. Many bacterial species 
have been shown to form biofilms after exposure to bile salts (1.3.3.2). 
Increased aggregation has been noted as a precursor to biofilm formation in 
Bifidobacteria and this aggregation was linked to increased cell surface 
hydrophobicity (CSH). Increased CSH meant that cells were able to bind more 
tightly to mucin, something that would increase survival in vivo (Ambalam et al., 
2013). Measurement of CSH in C. difficile with and without exposure to bile may 
provide further insight to the role of aggregation and its role in vivo. In 
Bacteroides fragilis exposure to bile salts results in increased aggregation and 
also the production of fimbria like appendages (Pumbwe et al., 2007). It could 
be that in C. difficile similar phenotypic changes occur that result in the 
increased aggregation seen. 
BAs, especially TC, play an important role in C. difficile germination and 
outgrowth, as described in chapters 3 and 4. Work here has shown that exposure 
of C. difficile to TC leads to an induction of multiple efflux pumps and an 
increase in bacterial aggregation. These changes may aid the survival of C. 
difficile within the host and further investigation of these mechanisms may help 
to increase understanding of the process of colonisation and persistence. Loss of 
colonisation resistance and dysbiosis are clearly essential for initiation of C. 
difficile disease, however, little is known about how the organism is able to 
maintain the gut in a dysbiotic state in order to persist. The next chapter will 
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investigate the production of the bacteriostatic compound para-cresol, and its 
potential role in limiting the capacity of the microflora to re-establish its 
complexity. 
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6 The role of para-cresol production in acute and 
relapsing infection 
 Introduction 6.1
The structure and diversity of the host microbiota has been shown to play a vital 
role in determining the extent and outcome of C. difficile infection (Chapter 3). 
Whilst dysbiosis is initially linked to the use of broad-spectrum antibiotics which 
can lead to a reduction in colonisation resistance, it is the long term 
maintenance of reduced diversity that is associated with susceptibility to 
relapsing disease (Chang et al., 2008). The microbiota consists of trillions of 
bacteria in a highly competitive and densely populated environment. 
Microorganisms must compete for resources, space and nutrients in order to 
thrive within the ecosystem. Competition between bacterial species is well 
documented and includes the production of antimicrobials and toxic by-products 
(1.4.5). A classical example of this is the production of bacteriocins. These 
typically narrow spectrum protein antibiotics inhibit closely related species, 
providing the producer with a competitive edge over closely related bacteria 
that may be competing for the same niche. The mechanism by which C. difficile 
can similarly suppress recovery of the microbiota is unknown but the production 
of the toxic metabolite para-cresol has been hypothesised the mechanism by 
which C .difficile may secure its niche (Dawson et al., 2011; Dawson et al., 
2008; Selmer & Andrei, 2001). The ability of C. difficile to produce para-cresol 
seems to be rare, with the process not found many other bacterial species 
(Elsden et al., 1976; Hafiz & Oakley, 1976). Supporting this hypothesis is the 
evidence that C. difficile can tolerate high concentrations of para-cresol , with 
the epidemic and virulent 027 strains able to produce and tolerate the highest 
concentrations (Dawson et al., 2011; Dawson et al., 2008). These strains have 
been linked with more persistent dysbiosis in patients infected with C. difficile 
(Skraban et al., 2013). 
Para-cresol is produced by the degradation of tyrosine via the intermediate 
para-hydroxyphenylacetate (p-HPA). The genes involved in the conversion of 
tyrosine to p-HPA are currently unknown, but the decarboxylation of p-HPA is 
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carried out by the p-HPA decarboxylase encoded by the hpdBAC operon (Figure 
6.1) 
 
Figure 6.1 The hpdBAC operon that is involved in the conversion of p-HPA to para-cresol  in 
C. difficile adapted from Selmer & Andrei (2001) 
The hpdBAC operon consists of 3 genes hpdA, hpdB and hpdC. The function of hpdC is unknown. 
The hpdB gene encodes the pHPA decarboxylase that catalyses the conversion of p-HPA to para-
cresol. The hpdA gene is thought to encode an activator of the hpdB gene. Independent mutants in 
all of these genes halt the production of para-cresol from p-HPA suggesting that all of the genes 
are essential for the production of para-cresol  (Dawson et al., 2011). 
Independent mutants in each of the genes described in this pathway have been 
generated by Dawson et al., (2011) and result in the inability of these C. 
difficile strains to produce para-cresol in media supplemented with p-HPA. 
These modified strains were produced using ClosTron mutagenesis (Heap et al., 
2010; Kuehne et al., 2011). ClosTron is a system that allows disruption of a gene 
of interest using a targeted intron system. This results in the insertion of an 
antibiotic resistance gene, in this case lincomycin resistance, into the gene of 
interest allowing for easy selection of mutants. All mutants used in this chapter 
are derived from the archetypal 027 ribotype parental strain, R20291. The 
mutant used in this chapter is in the hpdA gene and will be referred to as 
R20291_hpdA::CT, however similar observations have been observed using a 
second mutant R20291hpdC::CT. A third independent mutant was also included 
in these experiments to ensure that experimental differences were not 
influenced by ClosTron mutagenesis. This third mutant was in a gene encoding 
an unrelated RNA polymerase sigma factor (CD1754) from the extra cytoplasmic 
function (ECF) subfamily, the specific function of which is unknown. The mutant 
in this sigma factor was used as a control in some of these experiments and will 
be referred to as R20291_1754::CT. This was required as insertion of the ermB 
cassette during ClosTron mutagenesis leads to increased resistance to 
clindamycin and potentially greater survival compared to the parental strain in 
the clindamycin treated gut. The strains R20291_hpdA::CT and R20291_1754::CT 
were kindly provided by Dr Lisa Dawson (London School of Hygiene and Tropical 
Medicine). 
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 Preliminary phenotypic observations in vivo  6.2
The hamster model of C. difficile infection performed by Dr Anthony Buckley 
provided early intriguing data that warranted further investigation. This data is 
described below and provides the scientific foundations on which this chapter 
was based. The Golden Syrian Hamster has been widely used as a model for 
acute C. difficile infection and has proved useful for studying in vivo infection 
dynamics (1.6.1). In preliminary experiments, hamsters were treated with a 
single dose of clindamycin 5 days before oral administration of 1x104 spores of C. 
difficile. Hamsters were challenged with R20291, R20291_hpdA::CT or 
R20291_1754::CT to determine the role of the production of para-cresol in acute 
infection (Table 6-1).  
Table 6-1; Times to death of Hamsters infected with R20291 and different ClosTron mutants 
 
 
These initial experiments showed that animals infected with the 
R20291_hpdA::CT or R20291_1754::CT succumbed more rapidly to disease than 
those infected with R20291. As both mutants appeared to show increased 
virulence it is likely that the method of ClosTron mutation influences the 
survival and growth rate of the mutants in vivo in the hamster model. However, 
it was interesting to note that animals infected with the R20291_hpdA::CT 
mutant had significantly slower times to death than those infected with 
R20291_1754::CT (p=0.00375). This increased time to death suggests an 
important role for para-cresol production in vivo during acute infection. 
Strains Time to death (Mean +/- 
SEM) 
Number of 
animals 
R20291 51h 21 min ± 4h 17m 7 
R20291_hpdA::CT 40h 30m ± 4.5h 18 
R20291_1754::CT  25h 56m ± 57m 7 
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 Results 6.3
6.3.1 Optimising the relapsing model of infection 
One key clinical feature of C. difficile infection is the capacity for the disease to 
reoccur (or relapse) in recovering patients, either as a consequence of 
reinfection from the environment or recovery and growth of the strain 
responsible for the initial infection. Understanding the mechanism of relapse is 
important as multiple bouts of relapsing disease are associated with increased 
patient morbidity and mortality (1.4.5.1).  
As para-cresol production may be associated with maintenance of microbiome 
dysbiosis and thus allow C. difficile to persist and flourish in the gut, the 
hamster model in which initial colonisation and acute disease is determined, 
may not provide the best model in which this phenomenon can be assessed. 
Therefore, to study the impact of para-cresol production on long term 
persistence, the mouse model was used.  Mice, in contrast to hamsters appear to 
be more resistance to toxin production by these strains, allowing longer term 
experiments to be conducted. However, initial attempts to test these mutants in 
a mouse model of infection proved difficult.  
Early attempts to infect animals focussed on the use of the parental strain 
R20291 and the same infection schedule as had been used for hamster 
experiments (animals infected with spores 5 days post treatment with a single 
oral dose of clindamycin). Colonisation was determined by collection and plating 
of faecal samples from all animals (Figure 6.2). 
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Figure 6.2 Shedding of C. difficile in the faeces of mice infected with R20291 after a single 
dose of clindamycin 5 days before infection 
Recovery of colony forming units (CFU) of C. difficile per gram of faeces from animals infected with 
R20291 after a single dose of clindamycin 5 days before infection (n=10). Shedding was lower than 
expected and infection was not established in all mice. Error bars represent +/- the SEM. 
Although some shedding was observed, recovery of bacteria was low and varied 
considerably between individual animals with only 3/10 found to shed the 
organism 1DPI. Whilst this increased to 8/10 animals 2DPI, the majority of these 
were at very low levels of 103-104 CFU/ml, whilst data from the literature and 
from other studies carried out in this lab suggested levels should be closer to 
107CFU/ml. By 3DPI, bacteria were only recovered from 4 mice suggesting that 
the infection had not been stably established. This difference between 
susceptibility in mice and hamsters following the same treatment regimen is 
intriguing and may reflect differences in the composition of the microbiome 
between these animal species.   
To more rationally determine the antibiotic treatment required to successfully 
initiate infection multiple regimes of clindamycin treatment were used. This is 
because longer antibiotic exposure is known to increase susceptibility to 
infection due to increased dysbiosis of the microbiota (Chapter 3). To determine 
the impact of this treatment we compared colonisation, in animals treated with 
a single oral dose of clindamycin, exposure to clindamycin in water for 7 days or 
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3 days respectively.  The outcome of these experiments is summarised in Figure 
6.3.  
 
Figure 6.3 Multiple antibiotic regimes were used to induce susceptibility to infection in mice 
Due to the problems with initiating stable colonisation in animals given the same clindamycin 
treatment used in hamsters multiple regimes were tested in parallel. A single oral dose of 
clindamycin was not sufficient to allow stable colonisation. Use of clindamycin in the water for 7 
days resulted in animals infected rapidly becoming moribund. Use of clindamycin in the water for 3 
days resulted in high levels of colonisation and lower levels of mortality.  
This work revealed that a single oral dose of clindamycin 5 days prior to 
infection failed to modify the gut microbiome sufficiently to allow establishment 
of C. difficile infection, with no bacteria recovered from the faeces of any 
animals up to 3DPI. In contrast, inclusion of the antibiotic in the water increased 
susceptibility to infection, with animals highly colonised after infection. Animals 
that were treated for up to 7 days and infected with C. difficile developed very 
severe disease with high rates of mortality and weight loss (Figure 6.6). To 
determine the impact of longer-term treatment of clindamycin on disease 
outcome, animals were pre-treated with clindamycin for 3 or 7 days and then 
infected with either R20291 or R20291_hpdA::CT  
6.3.2 Determining the impact of hpdA mutation on colonisation 
and persistence in the mouse model   
In these experiments, extent of infection and disease severity was determined 
by variation in the weight of individual animals and by recovery of bacteria from 
faeces. Plating of faeces is used to determine the levels of colonisation in mice 
post infection.  
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Figure 6.4 Shedding of C. difficile in the faeces of animals infected with R20291 and 
R20291hpdA after 3 days pre-treatment with clindamycin 
Recovery of colony forming units (CFU) of C. difficile per gram of faeces from animals infected with 
R20291 (black) and R20291_hpdA::CT (red) after 3 days of clindamycin pre-treatment. There is no 
difference in the recovery of C. difficile from either group of mice. Error bars represent +/- the SEM 
(n=5). 
Data in Figure 6.4 suggests that although animals infected with R20291 appeared 
to shed the organism at higher levels at 1DPI infection, colonisation appeared 
equivalent 2DPI.  This contrasted significantly with the weight loss experience by 
these animals with those infected with R20291_hpdA::CT suffering from 
significantly more weight loss than those infected with R20291 (Figure 6.5). 
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Figure 6.5 Mouse body weight post infection with R20291 and R20291hpdA after 3 days 
pre-treatment with clindamycin 
Body weights of animals infected with R20291 (black n=5) and R20291_hpdA::CT (red n=9). Error 
bars represent +/- SEM. One animal infected with R20291_hpdA::CT was culled as it had lost more 
than 15% body weight. Animals infected with R20291_hpdA::CT lost significantly more weight on 
D1 and D3 than those infected with R20291. Significance was determined with unpaired two tailed 
students t-test (* indicates p = 0.0376 ** indicates p= 0.0027). 
In contrast to animals pre-treated with clindamycin for 3 days, animals given 
clindamycin for 7 days in the drinking water and infected with R20291_hpdA::CT 
experienced very severe disease symptoms with 7/9 animals reaching the 
experimental endpoint (loss of >15% body weight) at 2DPI. Interestingly animals 
infected with R20291 following 7 days of clindamycin did not suffer from as 
significant weight loss as those mice infected with R20291_hpdA::CT that 
survived (Figure 6.6). 
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Figure 6.6 Body weights of animals infected with R20291 and R20291hpdA following after 7 
days of pre-treatment of clindamycin 
Body weights of animals infected with R20291 (black n=5) and R20291_hpdA::CT mutant (red 
n=9). Error bars represent +/- SEM. At 2DPI, 7 of the animals infected with R20291_hpdA::CT were 
culled as they had lost more than 15% body weight. Animals infected with R20291_hpdA::CT 
suffered from more severe infection and lost significantly more weight that those infected with 
R20291 on D2 and D3. Significance was determined with unpaired two tailed students t-test (* 
indicates p = 0.0256 ** indicates p= 0.0012). 
Differences in severity seen between these two models suggest that the extent 
of disease severity is linked to length of clindamycin exposure. It was also found 
that R20291_hpdA::CT is more virulent than R20291, mimicking what was 
observed in the hamster model of infection. In support of the data from the 3 
day pre-treatment experiment, increased disease severity did not appear to be 
linked to increased colonisation as the bacterial counts of C. difficile recovered 
in the faeces did not differ significantly between these two groups (Figure 6.7). 
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Figure 6.7 Shedding of C. difficile in the faeces of animals infected with R20291 and 
R20291_hpdA::CT after 7 days pre-treatment with clindamycin 
Recovery of colony forming units (CFU) of C. difficile per gram of faeces from animals infected with 
R20291 (black n=5) and R20291_hpdA::CT (red n=9). At 2DPI 7 of the animals infected with 
R20291_hpdA::CT were culled as they had lost more than 15% body weight. After 2DPI only 2 
mice remained in the R20291_hpdA::CT group, for this reason statistical analysis was not carried 
out after this time point due to the lack of statistical power. Error bars represent +/- the SEM. 
As a result of these data sets, a regimen of 3 days of clindamycin treatment, 
delivered in the water was adopted as a standard treatment. This was 
considered sufficient to allow stable and robust colonisation of animals whilst 
limiting disease severity. 
6.3.3 Is increased severity due to ClosTron mutagenesis 
During this optimisation phase of the work, we became aware of a correlation 
between disease severity and infection with the mutant strain R20291_hpdA::CT. 
To determine if this increased severity was due to the mutation or as an indirect 
consequence of the insertion of the ClosTron cassette, the capacity of a second 
unrelated mutant R20291_1754::CT to initiate disease severity was assessed.   
 Mouse body weight during infection 6.3.3.1
Following the previously used infection regimen, the body weight of animals 
infected with R20291, R20219_hpdA::CT and R20291_1754::CT were monitored 
(Figure 6.17). As observed previously, animals infected with R20291_hpdA::CT 
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lost significantly more weight than those infected with R20291. Interestingly, 
those infected with R20291_1754::CT showed similar weight loss to R20291 
infected animals, suggesting that disease severity was not linked to the presence 
of the ClosTron cassette directly (Figure 6.8). 
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Figure 6.8 Mouse body weight post infection 
Percentage body weights of mice infected with R20291 (black) R20291_hpdA::CT (red) and 
R20291_1754::CT. Animals infected with R20291_hpdA::CT suffered from significantly more 
wiehgt loss than those infected with R20291 or R20291_1754::CT. Error bars represent +/- SEM. 
Significance was determined using ANOVA with Tukey’s post-test. (At D1 R20291 vs 
R20291_hpdA::CT * signifies p=<0.5). At D2 * indicates p=<0.05 (R20291 vs R20291_hpdA::CT) 
and ** indicates p=<0.001 (R20291_hpdA::CT vs R20291_1754::CT) There was no difference 
between R20291 and R20291_1754::CT). Error bars represent +/- SEM (n=5) 
 Shedding of C. difficile is not linked to disease severity 6.3.3.2
To determine if differences in weight loss could be linked to germination and 
growth rates of the bacteria, the number of bacteria recovered from the faeces 
1DPI were quantified (Figure 6.9). 
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Figure 6.9 Shedding of C. difficile in the faeces of animals infected with different strains of 
C. difficile  
Recovery of colony forming units (CFU) of C. difficile per gram of faeces from animals infected with 
R20291 (black) R20291_hpdA::CT (red) and R20291_1754::CT (n=5). Shedding collected showed 
no difference between the animals from each infection group. Error bars represent +/- the SEM. 
As observed previously, increased severity did not appear linked to differences 
in levels of colonisation with almost identical number of organisms recovered 
from each group of infected animals. However, measurement of bacterial 
numbers in the faeces can provide an inaccurate picture of colonisation directly 
on the mucosal surface. This is because faecal shedding can also represent 
growth and excretion of bacteria located within the lumen of the gut. As it is 
likely that weight loss reflects damage to the mucosal surface, most likely as a 
consequence of bacterial interaction, it became important to understand 
whether these strains showed differential interactions with the mucosal surface.   
 Measurement of direct mucosal colonisation  6.3.3.3
To give a more complete picture of the in vivo dynamics of R20291, 
R20291_hpdA::CT and R20291_1754::CT, animals were sacrificed at 2DPI to 
determine the number of bacteria associated with the caecum and colon. 
Differential counts of heated and unheated samples allowed comparison of the 
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form of the bacteria (vegetative cell versus spore) within the sample and 
location of the bacteria (lumen or tissue associated) (Figure 6.10). 
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Figure 6.10 Levels of C. difficile vegetative cells and spores in intestinal tissue 2DPI 
CFU/ml of bacteria recovered from the caecum (Cae) and colon (Col) at 2DPI. Both the lumen associated (La) and tissue associated (Ta) bacteria were enumerated as 
where the numbers of vegetative cells (No fill) and spores (horizontal stripes). Kruskal Wallis test were used to determine if the numbers of vegetative cells and spores 
in different sites differed between groups. It was found that mice infected with R20291_1754::CT there were significantly more spores in Col-La compared to R20291 (p 
<0.05). Additionally mice infected with R20291_1754 had significantly higher numbers of spores in the Col-Ta than those infected with R20291_hpdA::CT (p <0.01). 
The impact of these differences is unclear. Error bars represent +/- SEM (n=5) 
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These data revealed that colonisation of the caecum and colon did not differ 
significantly between any of the infection groups. A small difference in the 
number of spores produced by the R20291_hpdA::CT mutant was discernible, 
although the relevance of this observation to disease severity is unclear. 
 Toxin production in vivo  6.3.3.4
Production of TcdA and TcdB by C. difficile results in the symptoms of disease. 
Therefore, it was important to determine whether these strains produced 
differing amounts of toxin in vivo. Toxin production by each strain was 
determined using the filtered extracts of luminal washes from caecal and colonic 
tissue. These samples were tested for toxin activity by their capacity to cause 
cell rounding in vitro (2.9.4) (Figure 6.11).  
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Figure 6.11 Toxin production in vivo 
Samples were recovered from the caecum and colon of infected animals 2DPI and filtered to limit 
bacterial contamination. Toxin titres were then calculated as the reciprocal of the first dilution of the 
sample that did not cause any cell rounding of HT29 cells (A1, B1) and Vero cells (A2,B2) reflecting 
toxin A and toxin B activity respectively. Figure 6.11.A reveals the measured activity in the caecum 
of animals, whilst Figure 6.11.B the toxin activity in the equivalent colon samples. The toxin activity 
measured for each animal sample is represented by a single symbol. Horizontal bars represent the 
mean toxin levels and error bar the calculated standard error of the mean of 5 samples for each 
group. ANOVA with Tukey’s post-test showed no significant differences between the infection 
groups. 
These data confirmed that toxin production did not differ significantly between 
the groups. Levels of TcdA were low in both the caecum and colon with very 
little variation between animals. Overall, TcdB measurements were higher in 
both the caecum and colon. This is typical of the pattern of toxin detection 
observed in vivo and is similar to that shown in chapter 3 when mice were 
infected with BI-7. Whilst small variations were observed between the groups 
these did not appear to correlate with disease severity in vivo.  
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 Histology 6.3.3.5
Assessment of pathology can further assist in determining disease severity and 
toxin production in vivo. Increased damage would suggest more severe infection 
and potentially higher toxin levels. Tissue sections were taken from the colon at 
2DPI in order to assess pathology associated with each of the strains. Assessment 
of this tissue would suggest there is little difference between strains. There is 
some blood release into the tissue and the disruption of the epithelia does seem 
to be more severe in animals infected with R20291_hpdA::CT, however it would 
be necessary to examine more tissue sections from more animals to draw 
significant conclusions.  
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Figure 6.12 H + E stained colon sections from mice 2DPI 
Tissue samples were taken 2DPI and immediately fixed in formalin. Sections were cut and H and E stained.  Images represent typical histology in R20291, 
R20291_1754::CT and R20291_hpdA::CT infected animals. Sections at 10X magnification. Scale bar in bottom right corner shows 100μm 
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6.3.4 In vitro growth curves of R20291, R20291_hpdA::CT and 
R20291_1754::CT    
Whilst analysis of growth and toxin production in vivo is essential, the data is 
limited to a single time point. To extend understanding of the growth 
characteristics of these strains, further analysis was performed in vitro. This 
enabled multiple time points to be tested and analysis of parameters that may 
help to explain the differences observed in severity.  
 Outgrowth, sporulation and toxin production in BHI broth 6.3.4.1
Vegetative growth, sporulation and toxin production was analysed over a 72 hour 
period in two different growth mediums, BHI and FAB, which were additionally 
supplemented with p-HPA to induced para-cresol production. This was included 
to determine if production of this compound negatively impacts growth of C. 
difficile. 
Initial growth curves were carried out in BHI broth. Total counts were taken 
every 3 hours for 9 hours and then at 24, 48 and 72 hours. Spore numbers and 
toxin samples were taken at 24, 48 and 72 hours (Figure 6.13). 
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6.3.4.1.1 Vegetative counts and spore production in vitro 
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Figure 6.13 Growth curves and sporulation rates in BHI Broth 
Growth curves were carried out and the number of vegetative cells and spores determined using 
differential counts of heated and unheated samples. Graph shows A) Vegetative cells and B) spore 
formation of R20291 (black), R20291_hpdA::CT mutant (red) R20291_1754::CT (blue). 
R20291)hpdA::CT showed a slight delay in sporulation at 48 hours but this was not statistically 
signifiacnt Error bars are +/- SEM of 3 biological replicates. 
All strains exhibited similar growth rates with exponential growth observed over 
the first 9 hours after which sporulation was initiated. The R20291_hpdA::CT 
mutant showed a slight delay in sporulation at 48 hours, although this is not 
statistically significant, with a log less produced at this time point. Interestingly 
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animals infected with the R20291_hpdA::CT mutant also showed a similar 
reduction in spore numbers at 2DPI (Figure 6.10). It may be that the 
R20291_hpdA::CT strain is able to persist in the vegetative form for longer. 
6.3.4.1.2 Toxin production in vitro in BHI broth 
To analyse toxin production, samples of culture were removed at 24, 48 and 72 
hours, centrifuged to remove the majority of bacterial growth and then filtered 
before serial dilution and application to Vero cells to determine relative 
concentrations of TcdB (Figure 6.14). 
 
Figure 6.14 Toxin B production in BHI broth 
Supernatant was collected after 24, 48 and 72 hours of growth and filter sterilised to remove 
bacteria before used in assays. Toxin B titres were determined after A) 24 hours B) 48 hours and 
C) 72 hours growth. Horizontal line represents the mean of 3 biological replicates. There were no 
significant differences recorded in toxin production between the strains. Error bars represent +/- the 
SEM of three biological replicates. 
Chapter 6- Para-cresol production 
 
202 
 
Production of TcdB in BHI was very low at 24 and 48 hours. At 72 hours TcdB 
production was low in 2 replicates and very high in the other, consequently, it 
difficult to draw any conclusions about the relative amounts of toxin produced 
by the strains. However, It is known that the concentration of glucose can 
influence toxin production (Karlsson et al., 1999) and that these differences may 
reflect different concentrations of available glucose in the different batches of 
BHI used for this assay. For this reason, the experiments were repeated using 
fastidious anaerobe broth (FAB), which does not contain glucose.  
 Outgrowth, sporulation and toxin production in FAB broth 6.3.4.2
Growth curves were carried out in FAB broth in exactly the same way as those 
carried out in BHI with vegetative cell outgrowth, sporulation and toxin 
production measured. 
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6.3.4.2.1 Vegetative counts and spore production in vitro 
 
Figure 6.15 Growth curves and spore production in FAB broth 
Growth curves were carried out and the number of vegetative cells and spores determined using 
differential counts of heated and unheated samples. Graph shows A) Vegetative cells and B) spore 
formation of R20291 (black), R20291_hpdA::CT mutant (red) R20291_1754::CT (blue). Error bars 
are +/- SEM of 3 biological replicates. 
All C. difficile strains grew well in FAB reaching equivalent growth to that 
observed in BHI broth. In contrast to previous observations during in vivo (Figure 
A 
B 
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6.10) and growth in BHI broth (Figure 6.13), no delay in sporulation was observed 
with the R20291_hpdA::CT mutant.  
 
6.3.4.2.2 Toxin production in vitro in FAB broth 
As described previously, samples were collected from cultures grown for 24, 48 
and 72 hours respectively and analysed for production of TcdB (Figure 6.16). 
 
Figure 6.16 Toxin production in FAB broth 
Supernatant was collected after 24, 48 and 72 hours of growth and filter sterilised to remove 
bacteria before used in assays. Toxin B titres were determined after A) 24 hours B) 48 hours and 
C) 72 hours growth. R20291_hpdA::CT produced more toxin on average at ever time point. This 
was only significant at 72 hours (p= < 0.05). Significance was determined using ANOVA with 
Tukey’s post-test Horizontal line represents the mean. Error bars represent +/- the SEM of 3 
biological replicates.  
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In agreement with the literature, production of toxins was much higher when the 
strains were grown in FAB broth, supporting the idea that the presence of 
glucose inhibits toxin production. Under these conditions R20291_hpdA::CT 
produced more toxin at every time-point measured. Whilst this increase is only 
statistically significant at the 72 hour time point, such incremental increases in 
production in vivo could have impact upon disease severity. Similarly elevated 
toxin production was only observed in the colon of animals infected with 
R20291_hpdA::CT so it is unknown if this increased production occurs in vivo. 
However it is important to consider that when examining toxin production in 
vivo only a very small snap shot in time is considered. 
These data may suggest that increased severity is both linked to increased 
production of toxin and reduced diversity of the microbiome as a consequence of 
extended exposure to antibiotics. If antibiotic exposure modifies the microbiota 
associated with maintenance of mucus thickness (as described in chapter 3) this 
may increase sensitivity to toxin activity meaning increased production by this 
strain could be linked to more severe disease. Alternatively, the failure to 
produce para-cresol could modify the metabolism of tyrosine in the 
environment, the impact of which is unknown. At present, the only conclusion 
that can be drawn is that prevention of para-cresol production affects the 
severity of the acute phase of infection.  
6.3.5 Investigating the role of para-cresol  production in relapsing 
disease  
As para-cresol is toxic to many members of the bacterial flora, it has been 
postulated that its production is required for long term maintenance of the 
dysbiotic gut. To investigate its role in relapsing disease, infected mice that 
were no longer shedding the organism within the faeces, were subject to a 
second, single oral dose of clindamycin. This is sufficient to stimulate the 
outgrowth of C. difficile that are persisting within the gut. Treated animals were 
monitored for relapse and disease severity through measurement of body weight 
and recovery of C. difficile from faecal samples. 
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 Mouse body weight during long term infection and relapse 6.3.5.1
Animals were weighed daily as a determinate of disease severity. As observed 
previously (6.3.2 and 6.3.3.1) in the initial stages of infection, animals infected 
with R20291_hpdA::CT suffered greater weight loss than those infected with 
R20291 (Figure 6.17).  
 
Figure 6.17 Body weight of mice during infection and relapse 
Body weights of mice infected with the R20291_hpdA::CT mutant (red) and WT (black) during the 
initial infection and relapse. Error bars represent the +/- the SEM (n=5). One animal from the 
R20291_hpdA::CT group reached the experimental endpoint at 2DPI and was culled. 100% body 
weight was recalculated at D35 before relapse of infection. To induce relapse clindamycin was 
given at D35 (black arrow). Significance determined using an unpaired T-test (* represents p= 
0.0376, *** represents p = < 0.0001). 
As in the previous experiments, weight loss in these animals also occurred 
infected with R20291_hpdA::CT with animals losing significantly (p=< 0.0001) 
more weight than R20291 infected mice at 1DPI, t). After initiation of relapsed 
infection weight loss was reduced suggesting that either the animals were 
protected against bacteria induced pathology or that the microbiota was not 
modified sufficiently by a single dose of clindamycin to disrupt the mucus 
thickness and hence increase sensitivity to the toxin.  
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 Shedding of C. difficile in the faeces during initial infection and 6.3.5.2
relapse 
To determine if there were any differences in initial colonisation levels and the 
ability of strains to persist in the gut, faecal samples were tested to determine 
the presence of R20291 and R20192ΔhpdA (Figure 6.18). 
 
Figure 6.18 Shedding of C. difficile in the faeces during initial infection and relapse 
CFU/g of C. difficile recovered from the faeces of animals infected with the R20291 (black) and 
R20291_hpdA::CT (red) during initial infection and relapse. One animal from the 
R20291_hpdA::CT group reached the experimental endpoint at 2DPI and was culled. 100% body 
weight was recalculated at D35 before relapse of infection. To induce relapse clindamycin was 
given at D35 (black arrow). Shedding showed no difference in the ability of the strains to cause 
relapsing infection. Error bars indicated the +/- SEM (n=5). 
These data indicate that R20291 and R20291_hpdA::CT persist equally well in 
the mouse gut despite R20291_hpdA::CT being unable to make para-cresol. 
These data would suggest that para-cresol production is not involved in 
maintenance of dysbiosis within the gut. To confirm this observation, and to 
ensure that the animals were only infected with the appropriate C. difficile 
strains, samples taken on a weekly basis were subject to MVLA. This method, 
which can be used diagnostically, required the amplification of 7 independent 
repeat regions from the bacterial chromosome (Marsh et al., 2006). In this 
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context, this was undertaken to shown that bacteria recovered from the animals 
belonged to the R20291 parental strain background. The expected banding 
pattern of R20291 is shown in Figure 6.19.  
 
Figure 6.19 MVLA banding pattern for R20291 
MVLA typing uses sets of 7 primers to differentiate between different strains of C. difficile. The 
above gel shows the expected banding pattern for R20291. Samples were taken from all cages 
weekly and MVLA analysis conducted.  All C. difficile recovered from the mice throughout the 
experiment were found to be R20291. Expected band sizes are as follows; primer set 1 ~500bp, 
primer set 2~450bp, primer set 3 ~260bp, primer set 4 ~800bp, primer set 5 ~750bp, primer set 6 
~400bp and primer set 7~490bp. 
MVLA analysis was conducted on multiple samples from each group weekly and 
confirmed that the correct strain of C. difficile was recovered from the mice 
throughout the experiment. As all of the strains used in these experiments are 
from the same parental background additional analysis was required to ensure 
that the correct strains were colonising the mice. Further amplification of 
sequences using specific primers was used to differentiate between the 
unmodified R20291 strain and R20291_hpdA::CT. Using this approach, we 
confirmed that mice were infected with the expected strain of C. difficile. As 
with MVLA analysis samples were taken weekly from multiple mice in each group 
to confirm presence of the correct strains in each group (Figure 6.20). 
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Figure 6.20 Screening for the ClosTron intron sequence in bacteria isolated from faeces 
A PCR directed to a region of the ClosTron intron sequence and the hpdA gene for identification of 
R20291_hpdA::CT. WT yields no product whereas R20291_hpdA::CT gives a product of 408bp. 
Samples were taken weekly from multiple mice in each cage to confirm the presence of the correct 
mutants in each group. This gel represents samples taken at D40. Two colonies were taken from 
some of the animals to rule out the possibility of mixed infections. 
These data confirmed that animals were infected with the correct strains during 
the course of the experiment. 
 Discussion 6.4
6.4.1 Increased disease severity 
During the initial optimisation phase of this work, it became clear that animals 
infected with para-cresol mutant strain, R20291_hpdA::CT developed more 
severe symptoms of disease than those infected with the parental strain, 
R20291. Animals were subject to more significant weight loss and higher a 
mortality rate than those infected with R20291. Interestingly onset of weight 
loss was observed at least 24 hours earlier in R20291_hpdA::CT than R20291 
infected animals. However, based on the data generated from these 
experiments, it is not possible to provide an explanation that directly explains 
this difference, as shedding, toxin production and sporulation rates between 
these two strains appear similar. The same observations were made when 
animals were culled 2DPI, with animals infected with R20291_hpdA::CT showing 
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increased weight loss compared those infected with R20291 or R20291_1754::CT. 
However it is important to highlight that analysis of these virulence traits only 
represents a very brief snap shot in time and that differences in toxin production 
may precede the peak of weight loss. Further experiments investigating toxin 
levels and colonisation earlier in infection could help to address these questions.  
Previously, increased severity of ClosTron mutants in the hamster model has 
been linked to indirect increase in clindamycin resistance as a consequence of 
the ClosTron mutagenesis (Kelly et al., 2016). R20291 is naturally sensitive to 
clindamycin, with a minimum inhibitory concentration of 16 mg/ml (Buckley et 
al., 2011) and inhibitory levels of clindamycin can be detected in the hamster 
gut up to 11 days post treatment (Larson & Borriello, 1990). Thus mutant strains 
resistant to this antibiotic are able to survive and proliferate more rapidly in this 
environment. However, this does not appear to be the explanation in mice as 
animals challenged with a second unrelated ClosTron mutant R20291_1754::CT, 
showed no enhanced virulence. This suggests that in mice and hamsters there 
are different selection pressures that impact the outgrowth of C. difficile 
strains. It may be that in mice levels of clindamycin in the gut are not high 
enough at the time of infection to impact upon outgrowth which would explain 
why there was no increase in severity in R20291_1754::CT. This suggests that 
ClosTron mutagenesis was not the cause of increased severity in the mouse 
model of infection. 
As neither the in vivo or in vitro data could explain the increase in disease 
severity it may be that the increase in severity is not linked to the pathogen 
itself, as was seen in chapter 3. One factor that was not investigated was the 
host immune response. Interestingly, para-cresol has been linked to suppression 
of various aspects of the immune response including endothelial cell response to 
inflammatory cytokines and leukocyte migration (Dou et al., 2002; Rie Faure et 
al., 2006.). Thus, in its absence, the inflammatory response to infection could 
be enhanced. Therefore it may be interesting to investigate the host immune 
response to both the R20291 strain and the R20291_hpdA::CT mutant as it may 
be that increased immune response plays a role in increased severity. 
Additionally the structure of the microbiota was not investigated and it may be 
that differences in the microbiota may influence infection outcome in these 
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animals. As C. difficile is one of the few bacteria able to produce para-cresol it 
may be that in animals infected with the mutant R20291_hpdA::CT have an 
alteration in the metabolism of tyrosine or para-HPA. Changes in the levels of 
these compounds could alter the structure of the microbiota and increase 
virulence through modification of microbiota metabolism, although further 
investigation of this would be required.  
6.4.2 Impact of Para-cresol production on relapsing infection 
Whilst mutation in the para-cresol pathway appeared to modify the response to 
acute infection, its production did not appear to play a role in long term 
persistence of the intestinal niche. It was found that R20291_hpdA::CT mutant 
was able to successfully cause relapsing infection to the same extent as R20291. 
Relapse was observed in all animals with no difference in the levels of shedding 
in the faeces and no delay to relapse seen in R20291_hpdA::CT. The level of 
shedding was consistent between animals in each group with shedding observed 
at the temporal point, making it likely that this was true relapse and not 
reinfection of the mice. This suggests that para-cresol production may not be 
involved in enabling C. difficile to persist in the gut, but may be important in 
suppression of responses that may be involved in bacterial clearance to the 
initial infection.  
6.4.3 Identification of a SNP in codY 
Since the end of this project full genome sequencing has since been carried out 
on the R20291_hpdA::CT strain. Comparison of this to the parental R20291 strain 
has resulted in the identification of a single nucleotide polymorphism (SNP) in 
codY (Personal communication from Dr Lisa Dawson). This gene is known to play 
an important role in regulating toxin production (1.1.2.2). It may therefore be 
that this SNP results in the increased toxin production due to reduced function 
of codY. This increased toxin production may explain this increased virulence in 
vivo. The impact of this SNP means that it is likely that these experiments would 
need to be repeated as it is unknown what impact the increased toxin 
production would have on relapsing infection. 
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7 Final discussion 
The initial aims of this thesis were to gain a greater understanding of the 
contribution played by host BA metabolism in C. difficile disease pathogenesis. 
This included evaluation of the contribution of the microbiota in the breakdown 
of these compounds, focussing particularly on the influence of organisms that 
express BSH enzymes. Additionally the role of para-cresol production on acute 
and relapsing disease was investigated. Within this final chapter, the influence 
of these factors on germination, colonisation and persistence will be discussed.  
 Investigation of the role of the microbiota in 7.1
colonisation and severity 
Previous work has shown that pre-treatment of animals with antibiotic 
combinations can significantly modulate the outcome of C. difficile infection 
(Chen et al., 2008; Reeves et al., 2011). The microbiota is important in C. 
difficile infection with changes in structure particularly associated with 
infection, relapse and severe disease (1.4.5). However, an understanding of the 
exact mechanisms involved in disease progression has not been thoroughly 
investigated. The work presented in this thesis (chapter 3) showed that specific 
microbiome profiles were linked to particular disease states (colonisation and 
severity), with loss of colonisation resistance associated with changes to bile 
metabolism. This correlated with a loss of organisms expressing BSH genes. This 
loss was confirmed by PCR and through examination of the abundance of these 
genes in the microbiota of animals following different treatments. A recent 
investigation of the abundance of these genes in patients infected with C. 
difficile echoed the findings here, with decrease in BSH abundance a marker of 
colonisation (Allegretti et al., 2016). In addition to the loss of BSH producing 
bacteria there was also a significant reduction in OTU_69, a potential 7α- 
dehydroxylating bacteria. As this is the other important enzyme in this cascade, 
this suggests that antibiotic treatment of animals results in dysfunction of BA 
metabolism. This was confirmed using TOF-MS that showed clindamycin use was 
associated with loss of BA metabolism with significantly increased abundance of 
TC. This loss of BA metabolism is now known to be an important factor in C. 
difficile infection and much work is now focused on restoring this pathway as a 
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treatment for infection (Weingarden et al., 2016; Weingarden et al., 2014; 
Buffie et al., 2014). 
An area that is less well understood is that of disease severity. Comparison of 
the microbiome structures between animals that were colonised and animals 
that suffered from weight loss highlighted changes in the abundance of mucus 
degrading and mucus dwelling species. There were significant increases in the 
mucus degrading species B. thetaiotaomicron and decreases in two mucus 
dwelling species M. schaedleri and E. mucosicola. Taken together this could 
suggest that disruption of mucus homeostasis is significant and may result in 
increased accessibility to the epithelial surface resulting in greater toxin 
mediated damage. Increase in B. thetaiotaomicron has been previously shown to 
exacerbate both infection with C. difficile and E. coli by modifying the 
metabolic landscape to one that favours pathogen growth (Ferreyra et al., 2014; 
Curtis et al., 2014). This data taken in conjunction with that from the literature 
suggests that further investigation of this process is warranted. In order to 
examine this process further it may be worth placing more focus on changes in 
the mucosal associated microbiota as the composition is likely to be very 
different than that found in the lumen (Ouwehand et al., 2004; Swidsinski et al., 
2002; Zoetendal et al., 2002). This may allow association of specific changes in 
this subset of microbes with disease. Additionally further examination of the 
mucus layer may be useful in determining if these antibiotics directly or 
indirectly impact mucus layer thickness and mucus production. A recent study by 
Jakobsson et al., (2015) found that mice displayed variable mucus layers. They 
utilised a method in which ex vivo sections were taken and mucus layer 
thickness directly measured. Bacterial diffusion into the mucus layer was also 
assessed with the use of fluorescent bacteria sized beads coupled with 
microscopy which allowed the depth of diffusion of these beads into the mucus 
layer to be measured. Performing such analysis on sections from animals treated 
with different antibiotic combinations would help to determine if the 
microbiome data does actually indicate changes in mucus layer structure and 
whether these changes do result in closer association of bacteria to the 
epithelia. It would also be interesting to use molecular and biochemical methods 
to investigate the expression of mucus degrading enzymes such as, beta 
galactosidase and beta glucosidase, in the faeces of mice. Various studies have 
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used API strips direct from faecal samples to detect this (Vlková et al., 2005; 
Rada et al., 2006). It may also be possible to detect expression of these genes 
using RT-PCR on RNA extracted from faecal samples. This could offer potential 
as a way of identifying patients that are at risk from more severe disease.  
Another factor that should be considered is the observation that the anatomy of 
the mouse and human gut differ significantly and this may influence the 
composition of the microbiota. Key differences include caecum size and the 
relative ratio of intestine to colon length (Nguyen et al., 2015) (Figure 7.1). 
 
Figure 7.1 The structures of both mouse and human GI tracts from Nguyen et al., (2015) 
Although both mouse and human GI tracts have similar structures there are some key differences 
that may influence C. difficile infection. First the caecum of the mouse is much larger than that in 
humans and is the main site of C. difficile infection whereas in humans this is the colon. 
In addition to these differences, variation in the distribution of important mucin 
producing goblet cells and antimicrobial secreting paneth cells exist. Goblet 
cells are abundant throughout the human GI tract whereas in the mouse distal 
colon these are found at the base of crypts in reduced numbers. In humans 
paneth cells are found in the colon and caecum (Cunliffe et al., 2001) whereas 
in mice these cells are only present in the caecum (Ouelleyite et al., 1994). Such 
differences may lead to the creation of species specific niches in which elected 
microbes may flourish. Although there are differences between the microbiota 
of humans and mice the two most abundant phylotypes in both species are the 
Bacteroides and Firmicutes (Eckburg et al., 2005; Ley et al., 2005). A study by 
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Krych et al., (2013) found that mice and humans shared 90% of bacterial phyla 
and 89% of bacterial genera. Mice were reported to have one unique genus, 
Mucispirillum, which interestingly was one of the microbes identified as being 
significantly decreased during more severe infection. As this is likely a murine 
specific isolate it makes it more difficult to directly translate this observation 
into the context of human infection. This is why it may be preferable to examine 
the functional capacity of the microbiome rather than changes to specific 
organisms as it is likely that functional aspects are more highly conserved 
between the species.  
In an attempt to improve the mouse model and to make it as representative of 
the human microbiota models are now being developed using GF mice that are 
colonised with microbiota from human donors. Such work has shown that the 
human flora successfully colonises the mouse and can transfer between 
successive generations (Collins et al., 2015). Humanised mice show structural 
changes in the microbiota that make it more similar to that of a human than 
that of a naïve mouse, although some specific species are still not present 
(Turnbaugh et al., 2009). A recent study found that a high number of bacterial 
species were enriched within the mouse gut compared to the human gut, 
suggesting host specific selection (Lagkouvardos et al., 2016). One potential 
issue is that as these microbes have not co-evolved with the host the host 
microbiota interactions in this model may not be appropriate. This was 
confirmed by a study by Chung et al., (2012) which found that immune systems 
of humanised mice did not mature properly compared to those inoculated with 
mouse microbiota. Although such drawbacks exist, these models do provide an 
opportunity to manipulate the human microbiota in the context of infection, a 
unique opportunity that deserves more consideration. Use of these models in 
studies such as this may allow specific hypothesis to be tested and help to 
confirm findings from previous experiments. 
Another interesting difference is the make-up of the bile acid profile between 
these animals. As described previously BAs are of great importance in C. difficile 
infection, impacting on both spore germination and outgrowth (1.2.2). Mice are 
known to produce muricholic acids which can influence C. difficile germination 
and growth (Francis et al., 2013). Additionally the proportion of different BAs in 
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mice is different to that seen in humans with a large abundance of muricholic 
acids (Figure 7.2). 
 
Figure 7.2 BA profiles in mice and humans from De Aguiar Vallim et al., 2013. 
There are several differences between the BA profiles of mice and humans. Mice produce a murine 
specific BA and lower quantities of CDCA. It may be that these differences impact upon C. difficile 
infection. 
These differences in BA profiles are likely to reflect differences in diet and in BA 
production and regulation. Although nothing can be done to alter this it is 
important to take this into consideration. 
Although differences between mice and humans exist, mouse models remain 
incredibly useful in helping to study C. difficile infection. Many of the symptoms 
of infection and varied disease outcomes can be replicated in this model making 
it invaluable for studying C. difficile infection dynamics and pathogenesis. 
Additionally the findings presented here have in part been observed in humans. 
Restoration of BA metabolism is known to be an important function of FMT and 
alterations in the abundance of BSH genes have now been shown to be predictive 
of disease. This shows that the use of mouse models, complemented with data 
from patients, are invaluable in aiding our understanding of infection. 
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 Inhibition of germination by BSH 7.2
In this thesis, a role for bacteria that are able to modify BAs was established 
with particular focus placed on those that carry out the key first step in bile 
metabolism, the BSH producers. The ability of bacteria expressing BSH to 
influence spore germination in vitro was determined using a BSH producing L. 
murinus strain and E. coli expressing BSH from the human gut. Bacteria that 
were able to express BSH were found to limit C. difficile spore germination in 
vitro possibly by conversion of the effective germinant TC to the less potent 
germinant CA. This adds weight to the hypothesis that these bacteria may be 
important in limiting C. difficile colonisation by significantly reducing 
germination rates. The importance of this pathway has been reinforced recently 
with particular emphasis on restoration of bile metabolism as a treatment for C. 
difficile (Buffie et al., 2014; Weingarden et al., 2014, 2016). However, many of 
these studies focus on 7α-dehydroxylating bacterial species with the focus 
placed on inhibition of C. difficile growth rather than on spore germination. A 
study by Theriot et al., (2015) found that C. difficile germination could be 
stimulated by the contents of the mouse small intestine, even in the absence of 
antibiotic treatment. This may suggest that inhibition of germination by bile 
alone is not sufficient to prevent infection with inhibition of outgrowth also 
essential. However it has been shown that restoration of BSH function alone can 
also rescue 7α-dehydroxylation function which is mediated through production of 
CA (Gustafsson et al., 1998). Careful examination of several bacterial therapies 
described in the literature often confirms that each therapeutic combination 
contains at least one or more BSH producing species (Petrof et al., 2013; Lawley 
et al., 2012). Whilst in our experiments, direct use of a BSH producing bacteria 
was not sufficient to prevent colonisation, it may be that use of higher doses 
over a longer period of time were required to fully restore this function. The use 
of a cocktail of BSH and 7α-dehydroxylase producing bacteria may be preferable 
to restore colonisation resistance and diversity to the gut. Recovery of these 
microbes may then allow the rest of the microbiota to recover. 
The work presented in these chapters highlights the importance of the 
microbiota in determining infection outcome. Understanding changes in the 
microbiota and bacterial functions that underlie colonisation and infection 
outcome may help with the development of a more effectively targeted 
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bacteriotherapy. There have been many studies published in the literature that 
highlight the importance of bacterial bile metabolism in colonisation resistance. 
Restoration of this pathway, either through FMT or with the use of bacterial 
therapies has been shown to either resolve or lessen colonisation of C. difficile 
(Weingarden et al., 2014; Weingarden et al., 2016; Buffie et al., 2014). As BAs 
have a vital role in stimulating C. difficile germination (chapter 4) and 
controlling colonisation resistance (chapter 3) then greater understanding of 
genetic regulation of bile mediated germination and bile tolerance during 
growth is required. This is because, genes involved in these processes are 
important in mediating in vivo survival.  
 Genetic regulation of germination and bile acid 7.3
resistance 
BAs, particularly TC are closely involved in the induction of spore germination. 
Here, we attempted to identify novel genes involved in TC mediated spore 
germination but these were unsuccessful. However, the identification of a gene 
known to be essential for germination led to attempts to modify the MT 
mutagenesis system to allow screening of strains using a fluorescent reporter 
system. The aim of this approach was to identify genes that were upregulated 
but not essential for germination, in the hope that novel, but potentially 
functionally redundant genes in this process could be identified. This however 
was unsuccessful due to the small size and the high autofluorescence of C. 
difficile, which limited the capacity for high throughput screening using FACs. It 
was however useful to verify the use of such a system in the lab and it may be 
useful in investigating other biological processes in the future. It also has 
potential for identification of genes associated with germination through the 
creation and testing of mutant libraries. For example, it is known that the CspB 
protease, although the main, is not the only protease involved in the activation 
of SleC (Adams et al., 2013). Therefore creation of a mutant library in a strain 
lacking SleC activity may allow this additional protease to be identified. Through 
understanding of the genetic regulation of these vital processes it may be 
possible to identify new treatment targets.  
It is widely appreciated that bacteria that inhabit the gut have to adapt to the 
environmental challenges present. This includes contact with BAs, which are 
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present in high concentrations in the small intestine. The mechanisms by which 
many bacteria are able to resist BAs are becoming clearer (Gunn 2000; Begley et 
al., 2005; Sistrunk et al., 2016), but there are many aspects that require further 
investigation in Gram positive bacteria generally and in C. difficile in particular 
(Sistrunk et al., 2016). As the balance of bile acids in the antibiotic treated gut 
is altered, with increased abundance of primary BAs it is likely that C. difficile 
has adapted to survive in these conditions. In the context of this work, we have 
revealed that possession of BSH genes is important for resistance to the effects 
of BAs, as the strain of L. murinus that expressed an inactive BSH grew poorly in 
media containing TC. In contrast, the strain expressing the intact BSH gene 
showed no equivalent growth impairment. Whilst the genome of C. difficile does 
not encode any BSH genes, the use of RNA seq allowed us to identify a number 
of genes involved in BA resistance. In total 6 genes were identified as being 
upregulated in the presence of 0.1% TC including a 4 efflux pumps, an RNA 
polymerase sigma factor and SAM dependent MTase. Upregulation of efflux 
pumps is a common response to bile exposure among many different enteric 
bacteria (Baucheron et al., 2014; Quillin et al., 2011; Gunn 2000; Gueimonde et 
al., 2009). It would be interesting to investigate whether exposure to BA can 
increase resistance to antibiotics as this has been reported in other bacterial 
species. Further, it would be relevant to investigate whether the combination of 
BAs found in the antibiotic treated gut can influence the regulation of these 
genes.  
During the preparation of cells for RNA extraction it was noted that bacterial 
aggregation frequently occurred following their exposure to TC. This 
characteristic has been described in a number of other bacteria, including V. 
cholera and C. jejuni (Hung et al., 2006; Svensson et al., 2014). As aggregation 
and biofilm formation may be important in persistence and survival in vivo this 
process was investigated further. Exposure of C. difficile to TC either as part of 
an overnight culture used to seed the biofilms, or as part of the biofilms growth 
media resulted in a slight increase in biofilm mass with increased aggregation 
and adherence. Further investigation of the mechanism of this may shed light on 
how these bacteria behave in vivo. Such investigation is important as the 
mechanisms involved in persistence are still poorly defined and understood.  
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 Para-cresol production in acute and relapsing 7.4
infection 
Para-cresol is a bacteriostatic compound produced by a limited number of 
bacteria including C. difficile (Hafiz & Oakley, 1976). C. difficile strains that are 
most likely to cause relapsing and severe disease have the highest levels of 
production and tolerance of para-cresol (Dawson et al., 2011; Dawson et al., 
2008). This hints at a role for its production in acute and relapsing infection and 
the work in chapter 6 aimed to investigate this further. Interestingly, animals 
infected with R20291_hpdA::CT, a mutant unable to produce para-cresol, 
suffered from more severe disease than those infected with the parental strain. 
The severity of infection was directly linked to the antibiotic treatment 
administered before infection with longer treatment with clindamycin resulting 
in increased weight loss and mortality. This increased severity however was not 
seen in those mice infected with parental the strain R20291 or those infected 
with an unrelated mutant, R20291_1754::CT. This suggests that the increased 
severity observed was not linked to increased clindamycin resistance as a result 
of ClosTron mutagenesis, although preliminary data suggests that this does 
impact upon severity in the hamster model. This most likely reflects differences 
in the microbiotas of these animals although this is yet to be investigated 
formally. It may also be that clindamycin concentrations in the hamster gut 
remain high for a longer period of time compared to in the mouse. This would 
explain why increased clindamycin resistance only seems to be an advantage in 
the hamster infection model.  
To determine the cause of this increased severity, extensive in vitro 
experiments and short term 2 day infections were conducted to determine if 
there were any differences in growth rates and toxin production between the 
strains of C. difficile. Both studies showed a slight increase in the production of 
toxin by the para-cresol knockout strain R20291_hpdA::CT. Whilst this increase 
was not significant, it could be biologically relevant as these toxins are highly 
potent. Furthermore if the increased antibiotic exposure disrupts the mucus 
homeostasis as seen in chapter 3 it may be that this rise is sufficient to cause 
significant damage. An additional line of investigation that could be interesting 
to explore is the impact of para-cresol production on the immune system. 
Several papers have shown that this compound is able to dampen down various 
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aspects of immune response (Dou et al., 2002; Faure et al., 2006). It may be 
that animals infected with R20291_hpdA::CT generate a more significant 
inflammatory response to the infection. Investigation of this could be carried out 
in a number of ways including extraction of mRNA from the tissue to look at 
specific immune markers in the different models of infection. 
 Final conclusions 7.5
The work presented in this thesis has helped to further our understanding of the 
role that the microbiota plays in modulating C. difficile infection. The 
importance of BAs and bile metabolising bacteria has been further clarified and 
bacteria with potentially therapeutic traits have been identified. Potential 
therapeutic markers in the form of BSH genes and changes in BA profiles have 
also been identified and it may be that these could be utilised in a clinical 
setting to identify at risk patients. In addition, bacteria that potentially 
influence disease severity have been described and further investigation of the 
role of these microbes is warranted. Focus then turned towards the pathogen 
itself with the examination of the genetic regulation of germination and bile 
resistance investigated. Although attempts to identify novel genes involved in 
germination were unsuccessful, the identification of genes involved in BA 
resistance are the first described and more in-depth analysis of the regulation of 
these genes is warranted. Finally the production of a bacteriostatic compound 
para-cresol in acute and relapsing infection was examined. Increased disease 
severity seen in animals infected with R20291_hpdA::CT suggesting that para-
cresol production may be involved in limiting severity in the acute infection.   
Overall, this work has helped to improve our understanding of several important 
areas of infection including the modulation of infection by the microbiota and 
the importance of BA modifying bacteria in this. This work has also offered our 
first insight into genetic regulation of BA resistance in C. difficile opening up 
several interesting avenues of future work. 
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